Note: Descriptions are shown in the official language in which they were submitted.
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
COMPOSITIONS AND METHODS RELATING TO NOVEL
COMPOUNDS AND TARGETS THEREOF
This invention was supported in part with NIH grants GM46831 and A147450. The
United States government may have rights in this invention.
FIELD OF THE INVENTION
The present invention relates to novel chemical compounds, metliods for their
discovery, and their therapeutic use. In particular, the present invention
provides
benzodiazepine derivatives and structurally and functionally related compounds
and
methods of using benzodiazepine derivatives and related compounds as
therapeutic agents
to treat a number of conditions associated with the faulty regulation of the
processes of
programmed cell death, autoimmunity, inflammation, hyperproliferation,
vascular
abnorinalities, and the like.
BACKGROUND OF THE INVENTION
Multicellular organisms exert precise control over cell nuinber. A balance
between
cell proliferation and cell death achieves this homeostasis. Cell death occurs
in nearly every
type of vertebrate cell via necrosis or through a suicidal forin of cell
death, known as
apoptosis. Apoptosis is triggered by a variety of extracellular and
intracellular signals that
engage a common, genetically programmed death mechanism.
Multicellular organisms use apoptosis to instruct damaged or unnecessary cells
to
destroy themselves for the good of the organism. Control of the apoptotic
process therefore
is very important to normal development, for example, fetal development of
fingers and toes
requires the controlled removal, by apoptosis, of excess interconnecting
tissues, as does the
formation of neural synapses within the brain. Similarly, controlled apoptosis
is responsible
for the sloughing off of the inner lining of the uterus (the endometrium) at
the start of
menstruation. While apoptosis plays an important role in tissue sculpting and
normal
cellular maintenance, it is also the primary defense against cells and
invaders (e.g., viruses)
which threaten the well being of the organism.
Not surprisingly many diseases are associated with dysregulation of the
process of
cell death. Experimental models have established a cause-effect relationship
between
aberrant apoptotic regulation and the pathenogenicity of various neoplastic,
autoimmune
1
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
and viral diseases. For instance, in the cell mediated immune response,
effector cells (e.g.,
cytotoxic T lymphocytes "CTLs") destroy virus-infected cells by inducing the
infected cells
to undergo apoptosis. The organism subsequently relies on the apoptotic
process to destroy
the effector cells when they are no longer needed. Autoimmunity is normally
prevented by
the CTLs inducing apoptosis in each other and even in themselves. Defects in
this process
are associated with a variety of autoimmune diseases such as lupus
erythematosus and
rheumatoid arthritis.
Multicellular organisms also use apoptosis to instruct cells with damaged
nucleic
acids (e.g., DNA) to destroy themselves prior to becoming cancerous. Some
cancer-causing
viruses overcome this safeguard by reprogramming infected (transformed) cells
to abort the
normal apoptotic process. For example, several human papilloma viruses (HPVs)
have
been implicated in causing cervical cancer by suppressing the apoptotic
removal of
transformed cells by producing a protein (E6) which inactivates the p53
apoptosis promoter.
Similarly, the Epstein-Barr virus (EBV), the causative agent of mononucleosis
and Burkitt's
lymphoma, reprograms infected cells to produce proteins that prevent normal
apoptotic
removal of the aberrant cells thus allowing the cancerous cells to proliferate
and to spread
throughout the organism.
Still other viruses destructively manipulate a cell's apoptotic machinery
without
directly resulting in the development of a cancer. For example, the
destruction of the
immune system in individuals infected witli the human iminunodeficiency virus
(HIV) is
thought to progress through infected CD4+ T cells (about 1 in 100,000)
instructing
uninfected sister cells to undergo apoptosis.
Some cancers that arise by non-viral means have also developed mechanisms to
escape destruction by apoptosis. Melanoma cells, for instance, avoid apoptosis
by
inhibiting the expression of the gene encoding Apaf-1. Other cancer cells,
especially lung
and colon cancer cells, secrete high levels of soluble decoy molecules that
inhibit the
initiation of CTL mediated clearance of aberrant cells. Faulty regulation of
the apoptotic
machinery has also been implicated in various degenerative conditions and
vascular
diseases.
It is apparent that the controlled regulation of the apoptotic process and its
cellular
machinery is vital to the survival of multicellular organisms. Typically, the
biochemical
changes that occur in a cell instructed to undergo apoptosis occur in an
orderly procession.
2
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
However, as shown above, flawed regulation of apoptosis can cause serious
deleterious
effects in the organism.
There have been various attempts to control and restore regulation of the
apoptotic
machinery in aberrant cells (e.g., cancer cells). For example, much work has
been done to
develop cytotoxic agents to destroy aberrant cells before they proliferate. As
such,
cytotoxic agents have widespread utility in both liuman and animal health and
represent the
first line of treatment for nearly all forms of cancer and hyperproliferative
autoimmune
disorders like lupus erythematosus and rheumatoid arthritis.
Many cytotoxic agents in clinical use exert their effect by damaging DNA
(e.g., cis-
diaminodichroplatanim(II) cross-links DNA, whereas bleomycin induces strand
cleavage).
The result of this nuclear dainage, if recognized by cellular factors like the
p53 system, is to
initiate an apoptotic cascade leading to the death of the damaged cell.
However, existing cytotoxic chemotherapeutic agents have serious drawbacks.
For
example, many known cytotoxic agents show little discrimination between
healthy and
diseased cells. This lack of specificity often results in severe side effects
that can limit
efficacy and/or result in early mortality. Moreover, prolonged administration
of many
existing cytotoxic agents results in the expression of resistance genes (e.g.,
bcl-2 family or
multi-drug resistance (MDR) proteins) that render furtller dosing either less
effective or
useless. Some cytotoxic agents induce mutations into p53 and related proteins.
Based on
these considerations, ideal cytotoxic drugs should only kill diseased cells
and not be
susceptible to chemo-resistance.
One strategy to selectively kill diseased cells or block their growth is to
develop
drugs that selectively recognize molecules expressed in diseased cells. Thus,
effective
cytotoxic chemotherapeutic agents, would recognize disease indicative
molecules and
induce (e.g., either directly or indirectly) the death of the diseased cell.
Although markers
on some types of cancer cells have been identified and targeted with
therapeutic antibodies
and small molecules, unique traits for diagnostic and therapeutic exploitation
are not known
for most cancers. Moreover, for diseases like lupus, specific molecular
targets for drug
development have not been identified.
What are needed are improved compositions and methods for regulating the
apoptotic processes in subjects afflicted with diseases and conditions
characterized by faulty
3
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
regulation of these processes (e.g., viral infections, hyperproliferative
autoimmune
disorders, chronic inflammatory conditions, and cancers).
SUMMARY
The present invention provides novel compounds that find use in treating a
number
of diseases and conditions in humans and animals and that find use in
research, compound
screening, and diagnostic applications. The present invention also provides
uses of these
novel compounds, as well as the use of known compounds, that elicit particular
biological
responses (e.g., compounds that bind to particular target molecules and/or
cause particular
cellular events). Such compounds and uses are described throughout the present
application
and represent a diverse collection of compositions and applications.
Certain preferred compositions and uses are described below. The present
invention
is not limited to these particular compositions and uses.
The present invention provides a number of useful compositions as described
throughout the present application. Certain preferred embodiments of the
present invention
include a composition comprising the following formula: _
R~
Rz-~ N
N
including both R and S enantiomeric forms and racemic mixtures;
wherein Rl comprises a chemical moiety comprising a hydrogen bonding proton
donor
(e.g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group,
an amine
group, an aniline group, a benzimidizalone group, a carbamate group, and an
imidizole
group); and R2 comprises a hydrophobic chemical moiety.
4
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In preferred embodiments, Rl is selected from the group consisting of:
Rq Rq Ra
R5 R5 R2
R2
2
R3 R3 Rs
Ril ~ 2 ~ 5 ;
Rl' Rl'
R4 R5
R2 R2
R5 R4
R3 ; and R3
wherein Rl', R2, R3 and R4 are selected from the group consisting of:
hydrogen; CH3; a
5 linear or branched, saturated or unsaturated aliphatic chain having at least
1 carbon; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and having at
least one hydroxy subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one thiol subgroup; a linear or
branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, wherein
the aliphatic
chain terminates witli an aldehyde subgroup; a linear or branched, saturated
or unsaturated
aliphatic chain having at least 2 carbons, and having at least one ketone
subgroup; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; wherein the '
aliphatic chain terminates with a carboxylic acid subgroup; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one amide
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one acyl group; a linear or branched, saturated
or unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitrogen
containing moiety;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one amine subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons, and having at least one ether subgroup; a
linear or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
5
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
halogen subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one nitronium subgroup; and R5 is OH.
In preferred embodiments, R2 is selected from group consisting of:
napthalalanine;
phenol; 1-Napthalenol; 2-Napthalenol; b~-O;
Halogen
Halogen.
\~/
OCF3; . ~ / . (CH2)nC(CH3)3
\~/
wherein n=0-5; (CH2)nCH(CH3)2 wherein n=0-5; CH2(CH2)nCH3
6
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
\I/
wherein n_-0-5; dialkyI (all regioisomers)
~nrvti.
difluoromethyl (all regioisomers) .
quinolines, and all aromatic regioisomers.
hl some preferred embodiments, R2 comprises an aryl group. In other preferred
embodiments, R2 comprises an aliphatic group.
In some preferred embodiments, R1 is selected from the group consisting of:
rvirv~, inr~ vwL
rv% I fv\j
( I I
OH OH; OH ; and OH
In some preferred embodiments, the composition comprises the following
formula:
R4
R N R3
N
JR1
R5
7
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
wherein R3 is selected from the group consisting of hydrogen, amino, a linear
or branched,
saturated or unsaturated, substituted (e.g., substituted with amines, esters,
amides or
phosphatases) or non-substituted, aliphatic chain having at least 2 carbons;
R4 is selected from the group consisting of H, a ketone, and a nitrogen; and
R5 is selected from H, a hydroxy, an alkoxy, a carboxylic acid, a carboxylic
ester, a
halogen, a nitro, a sulfonamide, an amide, a carbamate, an amino, a lower-
alkyl, a
substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-
8 carbons
and 1-20 hydrogens, a substituted aliphatic group of similar size, a
cycloaliphatic group
consisting of less than 10 carbons, a substituted cycloaliphatic group, an
aryl, a heterocyclic,
NO2; SR'; and NR'2, wherein R' is defined as a linear or branched, saturated
or unsaturated
aliphatic chain having at least one carbon; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one hydroxyl
subgroup; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and having at
least one thiol subgroup; a linear or branched, saturated or unsaturated
aliphatic chaiui
having at least 2 carbons, wherein the aliphatic chain terminates with an
aldehyde subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one ketone subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons; wherein the aliphatic chain terminates with a
carboxylic
acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least
2 carbons, and having at least one amide subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
acyl group; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one nitrogen containing moiety; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
amine
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one halogen subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
nitronium
subgroup.
In certain embodiments, the compound is selected from the group consisting of:
8
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
NH2
N
CI ~
OH
a
O
N COOH
N
N
CI
OH and
9
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
N
/N
CI
OH
In preferred embodiments, the composition is described by:
O
R
~~'~- N ( X Y
N
b\1 Z
R3
wherein R2 is selected from the group consisting of Hydrogen, alkyl,
substituted
alkyl, and (CHz)õ wherein n=1-6;
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted alkyl, carboxylic acid, amide SO2NH2, NHSO2alkyl, and NO2;
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
N
M
wherein X is selected from the group consisting of L ,
L\~\ M
L L N
L X L N
M
N
N ~ N , M M
alkyl, substituted alkyl, sulfolamide, SO2alkyl, NHSO2, CH2, CH2CH2, SOZ,
CH2SO2,
SO2CH2, OCH2CH2O, SO, CH2CH2SO, SOCH2CH2; and
wherein L, M and N are present or absent, and are selected from the group
consisting of alkyl, NOZ, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, CF3, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SO2NH2, SO2NH-alkyl, SOalkyl, NHSO2alkyl;
wherein Y is selected from the group consisting of hydrogen, alkyl,
substituted
alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO2H,
nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
zz
W W YY
I
hydrogen, SOalkyl, SO2NH2, SO2NH-alkyl, NHSOaalkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SOZNH2, SOzNH-alkyl, NHSO2alkyl; and
11
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
~nnn.
/ ~1J1l1.IL
HN HN
wherein Z is selected from the group consisting of SO2Ar N
I I
~lWL ~1~
rl"f"L ~1J""v ~ip'f"L
~ ~ I I I
HN
NH NH
O ~ 0 ~ OH OH ~ OH
v'svti' \ I
HN
HN
O
HN O
O
OZS__ NH and R5 wherein R5 is selected from
the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl,
and tri-
substituted alkyl.
In preferred embodiments, the composition is described by:
12
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
N R2
R~\
/ N
~ /
R~\
3 3
OH
wherein Rl is selected from the group consisting of methyl, hydrogen, alkyl,
and (CH2)õ-
morpholino wherein n=1-6;
BB
DDR
4
wherein R2 is selected from the group consisting of CC
~
I
\ \
R5
BB DD BB DD
CC R4 and CC R4
> >
13
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted
alkyl, carboxylic acid, amide, SO2NH2, NHSO2alkyl, and NO2; wherein BB, CC,
DD, and
R4 are present or absent, and are selected from the group consisting of
hydrogen, CF3, NO2,
alkyl, halogen, OH, 0-alkyl, nitro, OCH2CH2OH, SO2H, mono-substituted alkyl,
di-
substituted alkyl, tri-substituted alkyl, COZH, heterocycle, SO2NH2, SO2NH-
alkyl,
NHSO2alkyl, methyl ester, propyl ester, and ethyl ester; and wherein R5 is
selected from the
group consisting of NHSOz, CHaNHSO2, CHZCH2NHSO2, CH2CH2CH2NHSO2, SOZNH,
SO2NHCH2, SOZNHCH2CH2, SO2NHCH2CH2CH2, CH2, CH2CH2, CH2CH2CH2, SO2,
CH2SO, SOCH2, OCH2CH2O, SO, CH2CH2SO, and SOCH2CH2.
In preferred embodiments, the composition is selected from the group
consisting of:
14
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
cl
o
o
. I
0 H3~ H3C\
Ha \ N
N N N
cl cl cl
OH , OH , OH
SO2NHZ F
O 0 0
H3 C\ H3C\N HaO\ N I \
N N
\ / / \ \ / / \ \ / / \
cl cl cl
OH OH , OH
cl
F
o
HaC\ o
H~C, Hz~N I N N N
N
\ N / /N
\ /
cl ci a cl
~NH HN~ NH HNyNH HN' ONH
o , II , o and ~IOI'
HN l
In certain embodiments, the present invention provides a method of treating
cells,
comprising a) providing i) target cells; and ii) a coinposition comprising the
following
formula:
R,
R21%
N
N
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
including both R and S enantiomeric forms and racemic mixtures; wherein Rl
comprises a
chemical moiety comprising a hydrogen bonding proton donor (e.g., a hydroxyl
group, a
phenol group, an amide group, a sulfonamide group, an amine group, an aniline
group, a
benzimidizalone group, a carbamate group, and an imidizole group); and R2
comprises a
hydrophobic chemical moiety; and b) exposing said target cells to said
composition under
conditions such that said composition binds to said mitochondria so as to
increase.
superoxide levels or alter cellular ATP levels in said cells.
In preferred embodiments, the treating is selected from the group consisting
of
inducing cellular growth arrest in the target cells, inducing cellular death
in the target cells,
and inducing cellular apoptosis in the target cells. In preferred embodiments,
the target
cells are in a subject having, for example, an autoimmune disorder, a
hyproliferative
disorder, an epidermal hyperplasia disorder, a pigment disorder, a
cardiovascular disorder,
and/or a viral disorder.
In preferred embodiments, the composition is selected from the group
consisting of:
16
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
NH2
N
/ N
\
/
CI
~
OH
,
N COOH
N
N
CI -
OH , and
17
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
N
N
/
CI
OH
In preferred embodiments, the target cells are selected from the group
consisting of
in vitro cells, in vivo cells, and ex vivo cells. In other preferred
embodiments, the target
cells are cancer cells. In still other preferred embodiments, the target cells
are selected from
the group consisting of B cells, T cells, and granulocytes.
In preferred embodiments, Rl is selected from the group consisting of:
R5 / Ri' Rlv
Rq R R4 R R4
R2 5 / 2 /
R3 Rs R3
Rl' ; R2 ; R5
Rl' Rl'
R4 R5
R2 R2
R5 R4
Rs ; and R3
18
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
wherein Rl', R2, R3 and R4 are selected from the group consisting of:
hydrogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 1
carbon; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and having at
least one hydroxy subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one thiol subgroup; a linear or
branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, wherein
the aliphatic
chain terminates with an aldehyde subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one ketone
subgroup; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; wherein the
aliphatic chain terminates with a carboxylic acid subgroup; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one amide
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one acyl group; a linear or branched, saturated
or unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitrogen
containing moiety;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one amine subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons, and having at least one ether subgroup; a
linear or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
halogen subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one nitronium subgroup; and R5 is OH.
In preferred embodiments, R2 is selected from group consisting of:
napthalalanine;
phenol; 1-Napthalenol; 2-Napthalenol; b~-O;
a a
19
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Halogen
Halogen.
\~/
OCi'3> . (CH2)nC(CH3)3
\I~ \I/
wherein n=0-5; (CH2)nCH(CH3)2 wherein n=0-5; CH2(CH2)nCH3
\ I/ _
=0-5; dialkyl (all regioisomers) . \ /
wherein n \ / .
~nruti
difluoromethyl (all regioisomers)
quinolines, and all aromatic regioisomers.
In some preferred embodiments, R2 comprises an aryl group. In other preferred
embodiments, R2 comprises an aliphatic group.
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In some preferred embodiments, Rl is selected from the group consisting of:
I I I
~r,n, ~nrvt, rwvt,
I I I
OH OH; OH and OH
In some preferred embodiments, the composition comprises the following
formula:
R4
R3
R2-t,L
N
N
R
1
R5
wherein R3 is selected from the group consisting of hydrogen, amino, a linear
or branched,
saturated or unsaturated, substituted (e.g., substituted with amines, esters,
amides or
phosphatases) or non-substituted, aliphatic chain having at least 2 carbons;
R4 is selected
from the group consisting of H, a ketone, and a nitrogen; and R5 is selected
from H, a
hydroxy, an alkoxy, a carboxylic acid, a carboxylic ester, a halogen, a nitro,
a sulfonamide,
an amide, a carbamate, an amino, a lower-alkyl, a substituted-amino, an
acetylamino, a
hydroxyainino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a
substituted
aliphatic group of similar size, a cycloaliphatic group consisting of less
than 10 carbons, a
substituted cycloaliphatic group, an aryl, a heterocyclic, NOZ; SR'; and NR'2,
wherein R' is
defined as a linear or branched, saturated or unsaturated aliphatic chain
having at least one
carbon; a linear or branched, saturated or unsaturated aliphatic chain having
at least 2
carbons, and having at least one hydroxyl subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
thiol subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons,
wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or
branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
21
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
ketone subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one amide subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons, and having at least one acyl group; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
nitrogen containing moiety; a linear or branched, saturated or tuisaturated
aliphatic chain
having at least 2 carbons, and having at least one ainine subgroup; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
halogen subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one nitronium subgroup.
In preferred embodiments, the composition is described by:
O
R
2-1,L I X Y
N
N
R3
wherein R2 is selected from the group consisting of Hydrogen, alkyl,
substituted
alkyl, and (CHZ)õ wherein n=1-6;
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted alkyl, carboxylic acid, amide SO2NH2, NHSO2alkyl, and NOZ;
22
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
N
M
wherein X is selected from the group consisting of L ,
LM
L
L L N L N
M
N
N ~ N ~ M M
alkyl, substituted alkyl, sulfolamide, SOzalkyl, NHSO2, CH2, CH2CH2, SO2,
CH2SO2,
SO2CH2, OCH2CHZO, SO, CH2CH2SO, SOCH2CH2;
wherein L, M and N are present or absent, and are selected from the group
consisting of alkyl, NO2, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, CF3, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SO2NH2, SO2NH-alkyl, SOalkyl, NHSOZalkyl; and
wherein Y is selected from the group consisting of hydrogen, alkyl,
substituted
alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO2H,
nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
zz
WW YY
I
hydrogen, SOalkyl, SOZNH2, SO2NH-alkyl, NHSO2alkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
COzH, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SO2NH2, SO2NH-allcyl, NHSOaalkyl; and
23
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
nrvtirti
y
HN
,
wherein Z is selected from the group consisting of SO2Ar
I I
rta~ n-~
~L \ \ ~lNLIL
I I ~
HN
HN NH NH
N O 0 OH I I ~vL
I I
HN
OH OH \ ---NH
, > >
24
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
~rtn.n,
HN
HN
O
O
O
and R5 wherein R5 is selected from the group consisting
of alkyl, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl.
In preferred embodiments, the composition is described by:
0
Ri R2
N
R
3
OH
wherein Rl is selected from the group consisting of methyl, hydrogen, alkyl,
and (CH2)õ
morpholino wherein n=1-6;
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
()BB
DD"'~-I=~\Ra
wherein R2 is selected from the group consisting of CC
a
R5
BB DD BB DD
CC R4 , and CC R4
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted
alkyl, carboxylic acid, amide, SOZNHZ, NHSO2alkyl, and NO2i wherein BB, CC,
DD, and
R4 are present or absent, and are selected from the group consisting of
hydrogen, CF3, NO2,
alkyl, halogen, OH, 0-alkyl, nitro, OCH2CH2OH, SO2H, mono-substituted alkyl,
di-
substituted alkyl, tri-substituted alkyl, CO2H, heterocycle, SO2NH2, SO2NH-
alkyl,
NHSO2alkyl, methyl ester, propyl ester, and ethyl ester; and wherein R5 is
selected from the
group consisting of NHSO2, CH2NHS02, CH2CH2NHSO2a CH2CH2CH2NHSO2, SO2NH,
SO2NHCH2, SO2NHCH2CH2, SO2NHCHaCHaCH2, CH2, CH2CH2, CH2CH2CH2, SO2,
CH2SO, SOCH2, OCHZCH2O, SO, CH2CH2SO, and SOCH2CH2.
In preferred embodiments, the composition is selected from the group
consisting of:
26
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
ci o 0
O H3 H3C\
H3C~ ~N I N
N0 N N / N
\ /
CI CI ci
OH ~ OH , OH
SO2NH2 \ F
i
O O
N
HaC~N H3C~ \ H3C\
N N / N
\ / / \ \ / / \ \ / / \
ci ci ci
OH OH ~ OH
CI
H3C\ C
N H'~ ~N H' ~N
4\'N
H'
N N
/
\ /
ci CI ci
- CI
HN' ,NH HN' /NH HNyNH HNyNH
~ICI( ~I0 I( ~ o and o
In certain embodiments, the present invention provides a pharmaceutical
composition comprising an agent selected from the following group:
resveratrol,
picetannol, estrogen, lansoprazole; and a compound described by the following
formula:
R,
R2Z'Z- N
N
27
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
including botli R and S enantiomeric forms and racemic mixtures;
wherein Rl comprises a chemical moiety comprising a hydrogen bonding proton
donor
(e.g., a hydroxyl group, a phenol group, an amide group, a sulfonamide group,
an amine
group, an aniline group, a benzimidizalone group, a carbamate group, and an
imidizole
group); and R2 comprises a hydrophobic cheinical moiety.
In preferred embodiments, the compound is selected from the group consisting
of
28
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
NH2
/N
CI
OH
,
COOH
N
N
CI
OH and
29
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
N
N
CI
OH
In preferred embodiments, Rl is selected from the group consisting of:
R5 RI' Rl'
7 R4 R4 R4
R2 ~ R
R2
R3 R3 R3
Rl' ; 2 ; R5
~
Rl' Rl'
R4 R5
R2 R2
R5 R4
R3 ; and R3
5 wherein Rl', R2, R3 and R4 are selected from the group consisting of:
hydrogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 1
carbon; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and having at
least one hydroxy subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one thiol subgroup; a linear or
branched,
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
saturated or unsaturated aliphatic chain having at least 2 carbons, wherein
the aliphatic
chain terminates with an aldehyde subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one ketone
subgroup; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; wherein the
aliphatic chain terminates with a carboxylic acid subgroup; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one amide
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one acyl group; a linear or branched, saturated
or unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitrogen
containing moiety;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one amine subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons, and having at least one ether subgroup; a
linear or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
halogen subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one nitroniuin subgroup; and R5 is OH.
In preferred embodiments, R2 is selected from group consisting of:
napthalalanine;
phenol; 1-Napthalenol; 2-Napthalenol; b~-O;
31
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Halogen -
Halogen.
~- ' -
OCF3; (CH2)nC(CH3)3
\ / \ /
I I
wherein n=0-5; (CH2)nCH(CH3)2 wherein n=0-5; CH2(CH2)nCH3
\I/
dialk I re oisomers
wherein n=0-5; Y (all gi ) ; .
nnnr~,
difluoromethyl (all regioisomers) ;
quinolines, and all aromatic regioisomers.
In some preferred embodiments, R2 comprises an aryl group. In other preferred
embodiments, R2 comprises an aliphatic group.
32
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In some preferred embodiments, Rl is selected from the group consisting of:
I I I
~1f WL W VL ~1MIti
I ( I
OH ; OH; OH ; and OH
In some preferred embodiments, the composition comprises the following
formula:
R4
R3
Ra-t,L
N
N
R
,
R5
wherein R3 is selected from the group consisting of hydrogen, amino, a linear
or branched,
saturated or unsaturated, substituted (e.g., substituted with amines, esters,
amides or
phosphatases) or non-substituted, aliphatic chain having at least 2 carbons;
R4 is selected
from the group consisting of H, a ketone, and a nitrogen; and R5 is selected
from H, a
hydroxy, an alkoxy, a carboxylic acid, a carboxylic ester, a halogen, a nitro,
a sulfonainide,
an amide, a carbamate, an amino, a lower-alkyl, a substituted-amino, an
acetylamino, a
hydroxyamino, an aliphatic group having 1-8 carbons and 1-20 hydrogens, a
substituted
aliphatic group of similar size, a cycloaliphatic group consisting of less
than 10 carbons, a
substituted cycloaliphatic group, an aryl, a heterocyclic, NO2; SR'; and NR'2,
wherein R' is
defined as a linear or branched, saturated or unsaturated aliphatic chain
having at least one
carbon; a linear or branched, saturated or unsaturated aliphatic chain having
at least 2
carbons, and having at least one hydroxyl subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
thiol subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons,
wherein the aliphatic chain terminates with an aldehyde subgroup; a linear or
branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
33
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
ketone subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one amide subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons, and having at least one acyl group; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
nitrogen containing moiety; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one amine subgroup; a linear or
branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
halogen subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one nitronium subgroup.
In preferred embodiments, the coinposition is described by:
O
R
2-L'L N X Y
N
Z
R3
wherein R2 is selected from the group consisting of Hydrogen, alkyl,
substituted
alkyl, and (CH2)õ wherein n=1-6;
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted alkyl, and NOz;
34
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
N
M
wherein X is selected from the group consisting of L ,
LM
L L N
L LN
M
N
N ~ N ~ M ~ M ~ M
alkyl, substituted alkyl, sulfolamide, SO2alkyl, NHSO2, CH2, CH2CH2, SO2,
CH2SO2,
SOZCH2, OCH2CHZO, SO, CH2CH2SO, SOCH2CH2; and
wherein L, M and N are present or absent, and are selected from the group
consisting of alkyl, NO2, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, CF3, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SOZNH2, SO2NH-alkyl, SOalkyl, NHSO2alkyl; and
wherein Y is selected from the group consisting of hydrogen, alkyl,
substituted
alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, CO2H,
nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
ZZ
ww YY
hydrogen, SOalkyl, SO2NH2, SO2NH-alkyl, NHSOaalkyl, and ~(x
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SO2NH2, SO2NH-alkyl, NHSOZalkyl; and
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
nnrv~
/ nrvv~.n'
HN HN
wherein Z is selected from the group consisting of SO2Ar N
I I
v~ WVL
I
HN ~ I
NH NH //\-- 0 , O , OH OH ~ OH
I I /
HN
y
H \ O
O
_NH
O2S and R5 wherein R5 is selected from
the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl,
and tri-
substituted alkyl.
In preferred embodiments, the composition is described by:
36
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R2
R~\
' / N
~
3/
R~\
OH
wherein Rl is selected from the group consisting of methyl, hydrogen, alkyl,
and (CH2)õ-
morpholino wherein n=1-6;
BB
DDR
4
wherein R2 is selected from the group consisting of CC
X
R5
BB DD BB DD
CC R4 , and CC R4
37
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted
alkyl, carboxylic acid, amide, SO2NH2, NHSO2alkyl, and NO2, wherein BB, CC,
DD, and
R4 are present or absent, and are selected from the group consisting of
hydrogen, CF3, NO2,
alkyl, halogen, OH, 0-alkyl, nitro, OCHaCHZOH, SO2H, mono-substituted alkyl,
di-
substituted alkyl, tri-substituted alkyl, CO2H, heterocycle, SO2NH2, SO2NH-
alkyl,
NHSO2alkyl, methyl ester, propyl ester, and ethyl ester; and wherein R5 is
selected from the
group consisting of NHSOZ, CH2NHSO2, CH2CH2NHSO2, CH2CH2CH2NHSO2, SO2NH,
SO2NHCH2, SO2NHCH2CH2, SO2NHCH2CH2CHa, CH2, CH2CH2, CH2CH2CH2, SO2,
CH2SO, SOCH2, OCH2CH2O, SO, CH2CH2SO, and SOCH2CH2.1n preferred embodiments,
the composition is selected from the group consisting of:
38
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
ci
O
p H3~ H3C\
H3C\ N N
N N N N
ci ci CI
OH ~ OH , OH
SO2NH2 ~ I F
~
p pII
H3C\ N I \ H3C\N \ H3C\ 11 I \
N ~N / N
\ / / \ \ / / \ \ / / \
ci ci CI
OH OH , OH
ci
I~ I~ F ~/ I j
H3C\ 0
H3C\ N H~C~ N N H3C~
N
C1 / \ \ / \
ci CI Ol
HN' /NH HN' ,NH HNIu' /NH HNyNH
,IOI{ IuOI , OI and O
In certain embodiments, the present invention provides a method of identifying
therapeutic compositions, comprising a) providing a sample comprising
mitochondrial F1Fo-
ATPase, and molecular modeling software; b) identifying a candidate F1Fo-
ATPase
inhibitor with the molecular modeling software; c) contacting the inhibitor
with the
sample; d) measuring the kcat/Km of the mitochondrial F1Fo-ATPase; and e)
selecting the
compositions that bind predominantly a F1Fo-ATPase-substrate complex and that
do not
alter the kcat/Km ratio of the mitochondrial F1Fo ATPase upon binding of the
mitochondrial
F1Fo ATPase as therapeutic compositions.
39
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In preferred embodiments, the method further comprises the step of fl testing
the
selected compositions in an animal to identify low toxicity and ability to
treat an
autoimmune disorder.
In preferred einbodiments, the sample further comprises mitochondria. In other
preferred embodiments, the F1Fo-ATPase is a pure enzyme. In still other
preferred
embodiments, the F1Fo ATPase is located in a sub-mitochondrial particle.
In preferred embodiments, the kcat/Km ratio is measured by determining the
rate of
ATP hydrolysis or synthesis as a function of ATP concentration and inhibitor
concentration.
In other preferred embodiments, the kcat/Km ratio is calculated from Km Vmax,
and the
enzyme concentration.
In certain embodiments, the present invention provides a composition
comprising
the following formula:
O
R2\
N I
/
N
/
R
/
\ 1
0 R3
including both R and S enantiomeric forms and racemic mixtures; wherein R1 is
selected
from the group consisting of
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
HN
O
X wherein X is selected from the group consisting of heteroatom,
NH
HN
N
alkyl, and substituted alkly; SO~Ar ; H N~ 0 Z Y
0 wherein Z and Y are separately selected from the group consisting of 0, N
andS; OH ;and OH
41
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
wlierein R2 is selected from the group consisting of methyl, H, alkyl, and
(CHZ)n
morpholino wherein n=1-6; and wherein R3 is selected from the group consisting
of
hydrogen, halogen, alkyl, substituted alkyl, carboxylic acid, amide SO2NH2,
NHSOZalkyl,
and NO2. Such compounds find use in, for example, the methods and
phannaceutical
compositions of the present invention.
Certain preferred embodiments of the present invention include a composition
coinprising the following formula:
R R5
4,,
R,
~~._- N R3
R210 including both R and S enantiomeric forms and racemic mixtures; wherein
Rl is a nitrogen
atom or a carbon atom; wherein R2 is comprises a chemical moiety comprising a
heterocyclic group containing 3 or more carbon atoms; wherein R3 comprises a
chemical
moiety comprising a heterocyclic group containing 3 or more carbon atoms; and
wherein
R4 and R5 are separately selected from the group consisting of: hydrogen;
halogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; a
chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety.
In preferred embodiments, the composition comprises the formula:
R6
R R5
4,,
R,
R7
N
R2 \
R3
wherein R6 is selected from the group consisting of H and a ketone; and
wherein R7 is
selected from the group consisting of H and a ketone.
In preferred embodiments, the composition comprises the formula:
42
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
R6
Ra Re
~
R,
Rei R7
I N
R~
RRe Rs
Rs B
In such preferred embodiments, R8 is carbon or nitrogen and R9 is selected
from H, a
hydroxy, an alkoxy, a halogen, an amino, a lower-alkyl, a substituted-amino,
an
acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20
hydrogens, a
substituted aliphatic group of similar size, a cycloaliphatic group consisting
of less than 10
carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NO2;
SR'; and NR'2,
wherein R' is defined as a linear or branched, saturated or unsaturated
aliphatic chain
having at least one carbon; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one hydroxyl subgroup; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least
2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a
linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one ketone subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; wlierein the aliphatic chain terminates with a
carboxylic acid
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one amide subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
acyl group; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one nitrogen containing moiety; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
amine
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one halogen subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
nitronium
subgroup.
In preferred embodiments, the composition comprises the formula:
43
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
R6
R5
R4~
Rl
R7
S N
R3
Ry
wherein R9 is selected from H, a hydroxy, an alkoxy, a halo, an amino, a lower-
alkyl, a
substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-
8 carbons
and 1-20 hydrogens, a substituted aliphatic group of similar size, a
cycloaliphatic group
consisting of less than 10 carbons, a substituted cycloaliphatic group, an
aryl, a
heterocyclic, NO2; SR'; and NR'2, wherein R' is defined as a linear or
branched, saturated
or unsaturated aliphatic chain having at least one carbon; a linear or
branched, saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
hydroxyl
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one thiol subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic
chain terminates
with an aldehyde subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one ketone subgroup; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons; wherein
the aliphatic
chain terminates with a carboxylic acid subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
amide
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one acyl group; a linear or branched, saturated
or unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitrogen
containing
moiety; a linear or branched, saturated or unsaturated aliphatic chain having
at least 2
carbons, and having at least one amine subgroup; a linear or branched,
saturated or
tuisaturated aliphatic chain having at least 2 carbons, and having at least
one halogen
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one nitronium subgroup.
In preferred embodiments, the composition comprises the formula:
44
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
N"-N
Rio--{
' R5
1
~N
R7 R N
2 \
R3
wherein Rl O is selected from the group consisting of: hydrogen; halogen; CH3;
a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons;
a chemical
moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical
moiety
comprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical
moiety; and a
hydrophobic chemical moiety; and wherein R7 is selected from the group
consisting of H
and a ketone.
In other preferred embodiments, R3 is selected from the group consisting of:
~ R15 R15 R15
Ri i *R,,4 Riz
R12 \ / Ri q R13 /
R14 R14
R13 R13 R11
ww ~
R12
' Riz
/ R11 HN
R13 \
R11 R15 R13 \ / / R15 O H lo R14 R14 R1z SO2Ar'
PN
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
~~~"~
NH NH HN H NH
,
OH ~ OR12 ~ CN ~ F ~ CHzO, C(O)NH2, O ~ 0
I
~aww,
OH~ OH ~ and OH
wlierein R12, R13, R14 and R15 are selected from the group consisting of:
hydrogen; CH3;
a linear or branched, saturated or unsaturated aliphatic chain having at least
1 carbon; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one hydroxy subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one thiol
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
wherein the
aliphatic chain terminates wit11 an aldehyde subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ketone
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one amide subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one acyl group; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ether subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one halogen subgroup; a linear or branched, saturated or
unsaturated
46
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
aliphatic chain having at least 2 carbons, and having at least one nitronium
subgroup; and
Rl 1 is OH.
In yet other preferred embodiments, R4 or R5 are selected from group
consisting of:
A
napthalalanine; phenol; 1-Napthalenol; 2-Napthalenol;
\ Halogen
\ -~ \
I
/ Halogen;
\ +0'/
I~
oCF3(H2)nC(CH3)3
wherein n=0-5;
+ -
I
(CH2)nCH(CH3)2 wherein n=0-5; CH2(CH2)nCH3 wherein n=0-5;
dialkyl (all regioisomers) ; i iguoromethyl (all regioisomers)
Q-70
quinolines, and all aromatic regioisomers.
In other preferred embodiments, R4 or R5 is selected from the group consisting
of:
47
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
~ -~~
~ Rn Rt7
Rte I-Rts /Rts I-R\
R16=R16
Re Rts-R\ Ris /Rts=R~
R16 Rts
Rt fi I-Rts \s R~\ s \s Rt e
R17 ~ RtB Rts-Rie~ R1e Rts R+9, and
/Rt s=R16 R.n
R\\ R16
Rts (-Rts
~ Rzo~
Rzl ~ I l ao
Rao~ ~\Rzo
Rza
Rig
wherein R16 is carbon or nitrogen; wherein R17 is selected from the group
consisting of
hydrogen; halogen; CH3; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; a chemical moiety comprising a halogen; a chemical
moiety
comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical
moiety; a
hydrophilic chemical moiety; arnd a hydrophobic chemical moiety; wherein R18
is carbon or
nitrogen; wherein R19 is selected from the group consisting of hydrogen;
halogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; a
chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical '
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
X Y
-
In preferred einbodiments, R4 or R5 is wherein
N L
\ ~ \
M
I I ~
M
X is selected from the group consisting of L ~ N
48
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
LM
L L N
LN
I ~,~~ I I
N , M N, M , M , alkyl, substituted
alkyl, sulfolamide, SOZalkyl, NHSOZ, CH2, CH2CH2, SOZ, CH2SO2, SO2CH2,
OCH2CHZO,
SO, CH2CH2SO, SOCH2CH2; and wherein L, M and N are present or absent, and are
selected from the group consisting of alkyl, NOZ, halogen, OH, O-Alkyl, methyl
ester,
propyl ester, ethyl ester, CO2H, CF3, aniline, nitro, heterocycle, mono-
substituted alkyl, di-
substituted alkyl, and tri-substituted alkyl, hydrogen, SO2NH2, SOaNH-alkyl,
SOalkyl,
NHSOzalkyl; wherein Y is selected from the group consisting of hydrogen,
alkyl,
substituted alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H, nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
/ZZ
W W YY
hydrogen, SOalkyl, SO2NH2, SOZNH-alkyl, NHSO2alkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group
consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H,
aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and
tri-substituted
alkyl, hydrogen, SOaNHa, SO2NH-alkyl, NHSO2alkyl.
In preferred embodiments, the composition is selected from the group
consisting of:
o
O O H3C\
H3C\ H3 \
N N I / i /
N
/\ '
CI _ HN' ~NH
CI ~II{
OH OH , and o
49
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In certain embodiments, the present invention provides a composition
comprising
the following formula:
Rl~ R4
N/ ~(\
N
s R
3
Rz
including both R and S enantiomeric foims and racemic mixtures; wherein Rl and
R4 are
separately selected from the group consisting of: hydrogen; halogen; CH3; a
linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons;
a chemical
moiety comprising a halogen; a chemical moiety comprising Sulfur; a chemical
moiety
coinprising Nitrogen; an aromatic chemical moiety; a hydrophilic chemical
moiety; and a
hydrophobic chemical moiety; wherein R2 is selected from H, a hydroxy, an
alkoxy, a halo,
an amino, a lower-alkyl, a substituted-amino, an acetylamino, a hydroxyamino,
an aliphatic
group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic group of
similar size,
a cycloaliphatic group consisting of less than 10 carbons, a substituted
cycloaliphatic group,
an aryl, a heterocyclic, NO2; SR'; and NR'2, wherein R' is defined as a linear
or branclied,
saturated or unsaturated aliphatic chain having at least one carbon; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
hydroxyl subgroup; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one thiol subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, wherein the aliphatic
chain terminates
with an aldehyde subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one ketone subgroup; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons; wherein
the aliphatic
chain terminates with a carboxylic acid subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
amide
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one acyl group; a linear or branched, saturated
or unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitrogen
containing
moiety; a linear or branched, saturated or unsaturated aliphatic chain having
at least 2
carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
halogen
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one nitronium subgroup; and wherein R3 comprises
a chemical
moiety comprising a heterocyclic group containing 3 or more carbon atoms.
In preferred embodiments, the composition comprises the formula:
R5
R R4
N
S R
3
R2
wherein R5 is selected from the group consisting of H and ketone.
In preferred embodiments, R3 is selected from the group consisting of:
/ Ri2
R15 R75 Ri5
*R14 R12
Ri2 R11 \ / R13 R14 Rqa
R13 R13 Ri1
I ~
~"~A,
R11 HN "
*Rj
R13 R15 R13 1 R14 ~ R14 ~ R12 ~ SO2Ar' N ~
*R15
51
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
i i
vvw vw~ vw~
NH HN
iH NH NH
OH , R12 , CN CHZO , C(O)NH2, , 0
,
OH, OH , and oH
wherein R12, R13, R14 and R15 are selected from the group consisting of:
hydrogen; CH3;
a linear or branched, saturated or unsaturated aliphatic chain having at least
1 carbon; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one hydroxy subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one thiol
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
wherein the
aliphatic chain terminates with an aldehyde subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ketone
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons; wlierein the aliphatic chain terminates with a carboxylic acid
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one amide subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one acyl group; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ether subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one halogen subgroup; a linear or branched, saturated or
unsaturated
52
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
aliphatic chain having at least 2 carbons, and having at least one nitronium
subgroup; and
Rl l is OH.
In other preferred embodiments, Rl or R4 is selected from group consisting of:
-k
naptlialalanine; phenol; 1-Napthalenol; 2-Napthalenol; b--O;
\ -
Halogen
~ I \
Halogen;
\ ~ \ \ -~
I~
oCF,; (CHa)nC(CH3)3 wherein n=0-5;
_
~
I I
(CHZ)nCH(CH3)2v,herein n=0-5; CH2(CHZ)nCH3 wherein n=0-5;
ilaikYl (
(all regioisomers) fluoromethyl (all regloisomers)
KIII::c;
quinolines, and all aromatic regioisomers.
In preferred einbodiments, Rl or R4 is selected from the group consisting of:
53
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
R17 Rn
R1e-Rts Rie -Rts Rts_ RIB
~~
Rts Rts-Rts Rts Rts===Rts
Rts Rts
\\ I ~~ Rs RtC\ R18 \s R1s\ Rta
Rts Rts
R17 Rte Rta Rts Rte Rta Rts
, , , and
-~~
/Rts=Rt~ R
~ n
R16 R16
Rte 1-Rts
~ Rzo~
Rzl ~ 11 zo
Rzo,~Z \Rzo
R20
Rts
wherein R16 is carbon or nitrogen; wllerein R17 is selected from the group
consisting of
hydrogen; CH3; a linear or branched, saturated or unsaturated aliphatic chain
having at least
2 carbons; a chemical moiety comprising a halogen; a chemical moiety
comprising Sulfur; a
chemical moiety comprising Nitrogen; an aromatic chemical moiety; a
hydrophilic chemical
moiety; and a hydrophobic chemical moiety; wherein R18 is carbon or nitrogen;
wherein
R19 is selected from the group consisting of hydrogen; CH3; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons; a chemical moiety
comprising a
halogen; a chemical moiety comprising Sulfur; a chemical moiety comprising
Nitrogen; an
aromatic chemical moiety; a hydrophilic chemical moiety; and a liydrophobic
chemical
moiety; and wherein R20 is carbon or nitrogen.
X Y
In preferred embodiments, R4 or R5 is wherein
N L
\ ~ \
M
M
X is selected from the group consisting of N
54
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
L M
L L N
LN X/'
I ~~~ I I
N , M N, M , M , alkyl, substituted
alkyl, sulfolamide, SO2alkyl, NHSO2, CH2, CH2CH2, SO2, CH2SO2, SO2CHa,
OCH2CH2O,
SO, CH2CH2SO, SOCH2CH2; and wherein L, M and N are present or absent, and are
selected from the group consisting of alkyl, NOZ, halogen, OH, O-Alkyl, methyl
ester,
propyl ester, ethyl ester, CO2H, CF3, aniline, nitro, heterocycle, mono-
substituted alkyl, di-
substituted alkyl, and tri-substituted alkyl, hydrogen, SO2NH2, SOZNH-alkyl,
SOalkyl,
NHSOaalkyl; wherein Y is selected from the group consisting of hydrogen,
alkyl,
substituted alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H, nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
zz
W W YY
hydrogen, SOalkyl, SOZNH2, SO2NH-alkyl, NHSO2alkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group
consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, COZH,
aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and
tri-substituted
alkyl, hydrogen, SO2NH2, SO2NH-alkyl, NHSO2alkyl.
In certain embodiments, the present invention provides a pharmaceutical
composition comprising a compound comprising the following formula:
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
(R1)m
A
Ra
N
Rr,,. Tt/Y\N V NR
R3 R4 6
J((~~// R~)y
R 5)n
n
or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug
thereof, wherein:
Rl and R5 are attached to any available carbon atom of phenyl rings A and B,
respectively,
and at each occurrence are independently selected from alkyl, substituted
alkyl, halogen,
cyano, nitro, OR8, NR8R9, C(=0)R8, C02R8, C(=O)NR8R9, NR$C(=O)R9, NR$C(=O)OR9,
S(O) oR9, NR8SO2R9, SO2NR8R9, cycloalkyl, heterocycle, aryl, and heteroaryl,
and/or two
of Rl and/or two of R5 join together to form a fused benzo ring; R2, R3 and R4
are
independently selected from hydrogen, alkyl, and substituted alkyl, or one of
R2, R3 and R4
is a bond to R, T or Y and the other of R2, R3 and R4 is selected from
hydrogen, alkyl, and
substituted alkyl; Z and Y are independently selected from C(=0), -C02-, -SOZ-
, -CH2-, -
CH2C(=O)-, and -C(=O)C(=O) -, or Z may be absent; R and T are selected from -
CH2-, -
C(=O)-, and -CH[(CH2)p(Q)]-, wherein Q is NR10R11, OR10 or CN; R6 is selected
from
alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl,
heterocyclo, and
heteroaryl; provided that where R2 is hydrogen, Z-R6 together are not -SO2-Me
or
0
11
I O F
, R7 is selected from hydrogen, alkyl, substituted alkyl, alkenyl,
substituted alkenyl, aminoalkyl, halogen, cyano, nitro, keto (=O), hydroxy,
alkoxy,
alkylthio, C(=O)H, acyl, CO2H, alkoxycarbonyl, carbamyl, sulfonyl,
sulfonamidyl,
cycloalkyl, heterocycle, aryl, and heteroaryl; R8 and R9 are independently
selected from
hydrogen, alkyl, substituted alkyl, cycloalkyl, heterocycle, aryl, and
heteroaryl, or R8 and R9
taken together to form a heterocycle or heteroaryl, except R9 is not hydrogen
when attached
to a sulfonyl group as in SO2R9; Rlo and Rll are independently selected from
hydrogen,
56
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
alkyl, and substituted alkyl; m and n are independently selected from 0, 1, 2
and 3; o, p and
q are independently 0, 1 or 2; and r and t are 0 or 1; and comprising an
apoptotic agent.
In certain embodiments, the present invention provides a pharmaceutical
composition comprising a compound comprising the following formula:
R2 R3
N
R, OH
Me
O Me
or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug
thereof, wherein:
Rl is selected from the group consisting of H, CN and S02-piperidine; R2 is
selected from
the group consisting of H, 4-Cl-Ph, Ph, and 2-Me-imidazole; R3 is selected
from the group
consisting of H, CH2-2-iinidazole, and CH2-2-oxazole; and an apoptotic agent.
In certain embodiments, the present invention provides a pharmaceutical
composition comprising a compound comprising the following formula:
\
N
Y
I ~ X NH
R~ I
R2
or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug
thereof, wherein:
Rl is selected from the group consisting of H, 2,4-C12, 2-4-Me2, and 2,5-
(CF3)2; R2 is
selected from the group consisting of H, 4-Cl, 4-Me, 2,4-Cla, 2,4-Me2, 3-Cl; X
is selected
from the group consisting of 0 and NH; Y is selected from the group consisting
of S, 0,
NCN, CO(3-CN-Ph), CO(4-CN-Ph), CO(4-Cl-Ph), and COEt; and an apoptotic agent.
57
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
The present invention is not limited to particular apoptotic agents. In
preferred
embodiments, the present invention provides, for example, the apoptotic agents
described in
U.S. Provisional Patent Nos. 60/607,599, and 60/641,040, and U.S. Patent
Application Nos.
10/935,333, 10/886,450, 10/795,535, 10/634,114, 10/427,211, 10/427,212,
10/217,878,
09/767,283, 09/700,101, and related applications; each herein incorporated by
reference in
their entireties.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows velocity data for benzodiazepine compounds plotted versus
[ATP].
Figure 2 sliows plots of [Bz] versus V,,,a,, (Figure 2A), [Bz] versus K,,,
(Figure 2B),
and [Bz] versus V,,,aX/K,,, (Figure 2C).
DEFINITIONS
To facilitate an understanding of the present invention, a number of terms and
phrases are defined below.
As used herein, the term "benzodiazepine" refers to a seven membered non-
aromatic
heterocyclic ring fused to a phenyl ring wherein the seven-membered ring has
two nitrogen
atoms, as part of the heterocyclic ring. In some aspects, the two nitrogen
atoms are in the 1
and 4 positions or the 1 and 5 positions, as shown in the general structures
below:
N
9 9 1 8 7 6 5 4
and N .
The term "larger than benzene" refers to any chemical group containing 7 or
more
non-hydrogen atoms.
As used herein, the term "substituted aliphatic" refers to an alkane
possessing less
than 10 carbons where at least one of the aliphatic hydrogen atoms has been
replaced by a
halogen, an amino, a hydroxy, a nitro, a thio, a ketone, an aldehyde, an
ester, an amide, a
lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted
aryl, cycloaliphatic,
or substituted cycloaliphatic, etc.). Examples of such include, but are not
limited to, 1-
chloroethyl and the like.
58
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
As used herein, the term "substituted aryl" refers to an aromatic ring or
fused
aromatic ring system consisting of no more than three fused rings at least one
of which is
aromatic, and where at least one of the hydrogen atoms on a ring carbon has
been replaced
by a halogen, an amino, a hydroxy, a nitro, a thio, a ketone, an aldehyde, an
ester, an amide,
a lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted
aryl,
cycloaliphatic, or substituted cycloaliphatic). Examples of such include, but
are not limited
to, hydroxyphenyl and the like.
As used herein, the term "cycloaliphatic" refers to a cycloalkane possessing
less than
8 carbons or a fused ring system consisting of no more than three fused
cycloaliphatic rings.
Examples of such include, but are not limited to, decalin and the like.
As used herein, the term "substituted cycloaliphatic" refers to a cycloalkane
possessing less than 10 carbons or a fused ring system consisting of no more
than three
fused rings, and where at least one of the aliphatic hydrogen atoms has been
replaced by a
halogen, a nitro, a thio, an amino, a hydroxy, a ketone, an aldehyde, an
ester, an amide, a
lower aliphatic, a substituted lower aliphatic, or a ring (aryl, substituted
aryl, cycloaliphatic,
or substituted cycloaliphatic). Examples of such include, but are not limited
to, 1-
chlorodecalyl, bicyclo-heptanes, octanes, and nonanes (e.g., nonrbornyl) and
the like.
As used herein, the term "heterocyclic" refers to a cycloalkane and/or an aryl
ring
system, possessing less than 8 carbons, or a fused ring system consisting of
no more than
three fused rings, where at least one of the ring carbon atoms is replaced by
oxygen,
nitrogen or sulfur. Examples of such include, but are not limited to,
morpholino and the
like.
As used herein, the term "substituted heterocyclic" refers to a cycloalkane
and/or an
aryl ring system, possessing less than 8 carbons, or a fused ring system
consisting of no
more than three fused rings, where at least one of the ring carbon atoms is
replaced by
oxygen, nitrogen or sulfur, and where at least one of the aliphatic hydrogen
atoms has been
replaced by a halogen, hydroxy, a thio, nitro, an amino, a ketone, an
aldehyde, an ester, an
amide, a lower aliphatic, a substituted lower aliphatic, or a ring (aryl,
substituted aryl,
cycloaliphatic, or substituted cycloaliphatic). Examples of such include, but
are not limited
to 2-chloropyranyl.
As used herein, the term "linker" refers to a chain containing up to and
including
eight contiguous atoms connecting two different structural moieties where such
atoms are,
59
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
for example, carbon, nitrogen, oxygen, or sulfur. Ethylene glycol is one non-
limiting
example.
As used herein, the term "lower-alkyl-substituted-amino" refers to any alkyl
unit
containing up to and including eight carbon atoms where one of the aliphatic
hydrogen
atoms is replaced by an amino group. Examples of such include, but are not
limited to,
ethylamino and the like.
As used herein, the terin "lower-alkyl-substituted-halogen" refers to any
alkyl chain
containing up to and including eight carbon atoms where one of the aliphatic
hydrogen
atoms is replaced by a halogen. Examples of such include, but are not limited
to, chlorethyl
and the like.
As used herein, the term "acetylamino" shall mean any primary or secondary
amino
that is acetylated. Examples of such include, but are not limited to,
acetamide and the like.
The term "derivative" of a coinpound, as used herein, refers to a chemically
modified compound wherein the chemical modification takes place either at a
functional
group of the compound or on the aromatic ring. ,
The term "epidermal hyperplasia," as used herein, refers to an abnormal
multiplication or increase in the number of normal cells in normal arrangement
in epidennal
tissue. Epidermal hyperplasia is a characteristic of numerous disorders,
including but not
limited to, psoriasis.
The term "keratinocyte" as used herein, refers to a skin cell of the
keratinized layer
of the epidermis.
The term "fibroblast" as used herein, refers to mesodermally derived resident
cells
of connective tissue that secrete fibrillar procollagen, fibronectin and
collegenase.
The term "pigment disorder" as used herein, refers to disorders involving skin
pigment (e.g., melanin). Examples of pigment disorders include, but are not
limited to, all
forms of albinism, melasma, pigment loss after skin damage, and vitiligo.
The term "stent" or "drug-eluting stent," as used herein, refers to any device
which
when placed into contact with a site in the wall of a lumen to be treated,
will also place
fibrin at the lumen wall and retain it at the lumen wall. This can include
especially devices
delivered percutaneously to treat coronary artery occlusions and to seal
dissections or
aneurysms of splenic, carotid, iliac and popliteal vessels. The stent can also
have underlying
polymeric or metallic structural elements onto which the fibrin is applied or
the stent can be
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
a composite of fibrin intermixed with a polymer. For example, a deformable
metal wire
stent such as that disclosed in U.S. Pat. No.: 4,886,062, herein incorporated
by reference,
could be coated with fibrin as set forth above in one or more coats (i.e.,
polymerization of
fibrin on the metal frainework by application of a fibrinogen solution and a
solution of a
fibrinogen-coagulating protein) or provided with an attached fibrin preform
such as an
encircling film of fibrin. The stent and fibrin could then be placed onto the
balloon at a
distal end of a balloon catlieter and delivered by conventional percutaneous
means (e.g. as
in an angioplasty procedure) to the site of the restriction or closure to be
treated where it
would then be expanded into contact with the body lumen by inflating the
balloon. The
catheter can then be withdrawn, leaving the fibrin stent of the present
invention in place at
the treatment site. The stent may therefore provide both a supporting
structure for the lumen
at the site of treatment and also a structure supporting the secure placement
of fibrin at the
lumen wall. Generally, a drug-eluting stent allows for an active release of a
particular drug
at the stent, implementation site.
As used herein, the term "catheter" refers generally to a tube used for
gaining access
to a body cavity or blood vessel.
As used herein, the term "valve" or "vessel" refers to any lumen within a
mammal.
Examples include, but are not limited to, arteries, veins, capillaries, and
biological luinen.
As used herein, the term "restenosis" refers to any valve which is narrowed.
Examples include, but are not limited to, the reclosure of a peripheral or
coronary artery
following trauma to that artery caused by efforts to open a stenosed portion
of the artery,
such as, for example, by balloon dilation, ablation, atherectomy or laser
treatment of the
artery.
As used herein, "angioplasty" or "balloon therapy" or "balloon angioplasty" or
"percutaneous transluminal coronary angioplasty" refers to a method of
treating blood
vessel disorders that involves the use of a balloon catheter to enlarge the
blood vessel and
thereby improve blood flow.
As used herein, "cardiac catheterization" or "coronary angiogram" refers to a
test
used to diagnose coronary artery disease using a catheterization procedure.
Such a
procedure may involve, for example, the injection of a contrast dye into the
coronary
arteries via a catheter, permitting the visualization of a narrowed or blocked
artery.
61
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
As used herein, the term "subject" refers to organisms to be treated by the
methods
of the present invention. Such organisms preferably include, but are not
limited to,
mammals (e.g., murines, simians, equines, bovines, porcines, canines, felines,
and the like),
and most preferably includes humans. In the context of the invention, the term
"subject"
generally refers to an individual who will receive or who has received
treatment (e.g.,
administration of a compound of the present invention and optionally one or
more other
agents) for a condition characterized by the dysregulation of apoptotic
processes.
The term "diagnosed," as used herein, refers to the to recognition of a
disease by its
signs and symptoms (e.g., resistance to conventional therapies), or genetic
analysis,
pathological analysis, histological analysis, and the like.
As used herein, the terms "anticancer agent," or "conventional anticancer
agent"
refer to any chemotherapeutic compounds, radiation therapies, or surgical
interventions,
used in the treatment of cancer.
As used herein the term, "in vitro" refers to an artificial environment and to
processes or reactions that occur within an artificial environment. In vitro
environments
include, but are not limited to, test tubes and cell cultures. The term "in
vivo" refers to the
natural environment (e.g., an animal or a cell) and to processes or reaction
that occur within
a natural environment.
As used herein, the term "host cell" refers to any eukaryotic or prokaryotic
cell (e.g.,
mammalian cells, avian cells, amphibian cells, plant cells, fish cells, and
insect cells),
whether located in vitro or in vivo.
As used herein, the term "cell culture" refers to any in vitro culture of
cells. Included
within this term are continuous cell lines (e.g., with an irmnortal
phenotype), primary cell
cultures, finite cell lines (e.g., non-transformed cells), and any other cell
population
maintained in vitro, including oocytes and embryos.
In preferred embodiments, the "target cells" of the compositions and methods
of the
present invention include, refer to, but are not limited to, lymphoid cells or
cancer cells.
Lymphoid cells include B cells, T cells, and granulocytes. Granulocyctes
include
eosinophils and macrophages. In some embodiments, target cells are
continuously cultured
cells or uncultered cells obtained from patient biopsies.
Cancer cells include tumor cells, neoplastic cells, malignant cells,
metastatic cells, and
hyperplastic cells. Neoplastic cells can be benign or malignant. Neoplastic
cells are benign if
62
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
they do not invade or metastasize. A malignant cell is one that is able to
invade and/or
metastasize. Hyperplasia is a pathologic accumulation of cells in a tissue or
organ, without
significant alteration in structure or fiulction.
In one specific embodiment, the target cells exhibit pathological growth or
proliferation. As used herein, the term "pathologically proliferating or
growing cells" refers to
a localized population of proliferating cells in an animal that is not
governed by the usual
limitations of normal growth.
As used herein, the term "un-activated target cell" refers to a cell that is
either in the Go
phase or one in which a stimulus has not been applied.
As used herein, the term "activated target lymphoid cell" refers to a lymphoid
cell
that has been primed with an appropriate stiinulus to cause a signal
transduction cascade, or
alternatively, a lymphoid cell that is not in Go phase. Activated lymphoid
cells may
proliferate, undergo activation induced cell death, or produce one or more of
cytotoxins,
cytokines, and other related membrane-associated proteins characteristic of
the cell type
(e.g., CD8+ or CD4+). They are also capable of recognizing and binding any
target cell that
displays a particular antigen on its surface, and subsequently releasing its
effector
molecules.
As used herein, the term "activated cancer cell" refers to a cancer cell that
has been
primed with an appropriate stimulus to cause a signal transduction. An
activated cancer cell
may or may not be in the Go phase.
An activating agent is a stiinulus that upon interaction with a target cell
results in a
signal transduction cascade. Examples of activating stimuli include, but are
not limited to,
small molecules, radiant energy, and molecules that bind to cell activation
cell surface
receptors. Responses induced by activation stimuli can be characterized by
changes in,
among others, intracellular Ca2+, superoxide, or hydroxyl radical levels; the
activity of
enzymes like kinases or phosphatases; or the energy state of the cell. For
cancer cells,
activating agents also include transforming oncogenes.
In one aspect, the activating agent is any agent that binds to a cell surface
activation
receptor. These can be selected from the group consisting of a T cell receptor
ligand, a B cell
activating factor ("BAFF"), a TNF, a Fas ligand (FasL), a CD401igand, a
proliferation
inducing ligand ("APRIL"), a cytokine, a chemokine, a hormone, an amino acid
(e.g.,
glutamate), a steroid, a B cell receptor ligand, gamma irradiation, UV
irradiation, an agent or
63
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
condition that enhances cell stress, or an antibody that specifically
recognizes and binds a cell
surface activation receptor (e.g., anti-CD4, anti-CD8, anti-CD20, anti-TACI,
anti-BCMA, anti-
TNF receptor, anti-CD40, anti-CD3, anti-CD28, anti-B220, anti-CD38, and-CD19,
and anti-
CD21). BCMA is B cell maturation antigen receptor and TACI is transmembrane
activator and
CAML interactor. (Gross, A. et al. (2000); Laabi, Y. et al. (1992) and Madry,
C. et al. (1998)).
Antibodies include monoclonal or polyclonal or a mixture thereof.
Examples of a T cell ligand include, but are not limited to, a peptide that
binds to an
MHC molecule, a peptide MHC complex, or an antibody that recognizes components
of the T
cell receptor.
Examples of a B cell ligand include, but are not limited to, a molecule or
antibody that
binds to or recognizes components of the B cell receptor.
Examples of reagents that bind to a cell surface activation receptor include,
but are not
limited to, the natural ligands of these receptors or antibodies raised
against them (e.g., anti-
CD20). RITiJX1N (Genentecli, Inc., San Francisco, CA) is a commercially
available anti-CD
20 chimeric monoclonal antibody.
Examples of agents or conditions that enhance cell stress include heat,
radiation,
oxidative stress, or growth factor withdrawal and the like. Examples of growth
factors include,
but are not limited to serum, IL-2, platelet derived growth factor ("PDGF"),
and the like.
As used herein, the term "effective amount" refers to the amount of a compound
(e.g., a compound of the present invention) sufficient to effect beneficial or
desired results.
An effective amount can be administered in one or more administrations,
applications or
dosages and is not limited intended to be limited to a particular formulation
or
administration route.
As used herein, the term "dysregulation of the process of cell death" refers
to any
aberration in the ability of (e.g., predisposition) a cell to undergo cell
death via either
necrosis or apoptosis. Dysregulation of cell death is associated with or
induced by a variety
of conditions, including for example, autoimmune disorders (e.g., systemic
lupus
erytheinatosus, rheumatoid arthritis, graft-versus-host disease, myasthenia
gravis, Sjogren's
syndrome, etc.), chronic inflammatory conditions (e.g., psoriasis, asthma and
Crohn's
disease), hyperproliferative disorders (e.g., tumors, B cell lymphomas, T cell
lymphomas,
etc.), viral infections (e.g., herpes, papilloma, HN), and other conditions
such as
osteoarthritis and atherosclerosis.
64
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
It should be noted that when the dysregulation is induced by or associated
with a
viral infection, the viral infection may or may not be detectable at the time
dysregulation
occurs or is observed. That is, viral-induced dysregulation can occur even
after the
disappearance of symptoms of viral infection.
A "hyperproliferative disorder," as used herein refers to any condition in
which a
localized population of proliferating cells in an animal is not governed by
the usual
limitations of norinal growth. Examples of hyperproliferative disorders
include tumors,
neoplasms, lymphomas and the like. A neoplasm is said to be benign if it does
not undergo,
invasion or metastasis and malignant if it does either of these. A metastatic
cell or tissue
means that the cell can invade and destroy neighboring body structures.
Hyperplasia is a
form of cell proliferation involving an increase in cell number in a tissue or
organ, without
significant alteration in structure or function. Metaplasia is a form of
controlled cell growth
in which one type of fully differentiated cell substitutes for another type of
differentiated
cell. Metaplasia can occur in epithelial or connective tissue cells. A typical
metaplasia
involves a somewhat disorderly metaplastic epitllelium.
The pathological growth of activated lymphoid cells often results in an
autoimmune
disorder or a chronic inflammatory condition. As used herein, the term
"autoimmune
disorder" refers to any condition in which an organism produces antibodies or
iminune cells
which recognize the organism's own molecules, cells or tissues. Non-limiting
examples of
autoimmune disorders include autoimmune hemolytic anemia, autoimmune
hepatitis,
Berger's disease or IgA nephropathy, Celiac Sprue, chronic fatigue syndrome,
Crohn's
disease, dermatomyositis, fibromyalgia, graft versus host disease, Grave's
disease,
Hashimoto's thyroiditis, idiopathic thrombocytopenia purpura, lichen planus,
inultiple
sclerosis, myasthenia gravis, psoriasis, rheumatic fever, rheumatic arthritis,
scleroderma,
Sjorgren syndrome, systemic lupus erythematosus, type 1 diabetes, ulcerative
colitis,
vitiligo, tuberculosis, and the like.
As used herein, the term "chronic inflammatory condition" refers to a
condition
wherein the organism's immune cells are activated. Such a condition is
characterized by a
persistent inflammatory response with pathologic sequelae. This state is
characterized by
infiltration of mononuclear cells, proliferation of fibroblasts and small
blood vessels,
increased connective tissue, and tissue destruction. Examples of chronic
inflammatory
diseases include, but are not limited to, Crohn's disease, psoriasis, chronic
obstructive
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
pulmonary disease, inflammatory bowel disease, multiple sclerosis, and asthma.
Autoimmune diseases such as rheumatoid arthritis and systemic lupus
erythematosus can
also result in a chronic inflammatory state.
As used herein, the tenn "co-administration" refers to the administration of
at least
two agent(s) (e.g., a compound of the present invention) or therapies to a
subject. In some
embodiments, the co-administration of two or more agents/therapies is
concurrent. In other
embodiments, a first agent/therapy is administered prior to a second
agent/therapy. Those
of skill in the art understand that the formulations and/or routes of
administration of the
various agents/therapies used may vary. The appropriate dosage for co-
administration can
be readily determined by one skilled in the art. In some embodiments, when
agents/therapies are co-administered, the respective agents/tlierapies are
administered at
lower dosages than appropriate for their administration alone. Thus, co-
administration is
especially desirable in embodiments where the co-administration of the
agents/therapies
lowers the requisite dosage of a known potentially harmful (e.g., toxic)
agent(s).
As used herein, the term "toxic" refers to any detrimental or harmful effects
on a cell
or tissue as compared to the same cell or tissue prior to the administration
of the toxicant.
As used herein, the term "pharmaceutical composition" refers to the
combination of
an active agent with a carrier, inert or active, making the composition
especially suitable for
diagnostic or therapeutic use in vivo, in vivo or ex vivo.
As used herein, the term "pharmaceutically acceptable carrier" refers to any
of the
standard pharmaceutical carriers, such as a phosphate buffered saline
solution, water,
emulsions (e.g., such as an oil/water or water/oil emulsions), and various
types of wetting
agents. The compositions also can include stabilizers and preservatives. For
examples of
carriers, stabilizers and adjuvants. (See e.g., Martin, Remington's
Pharmaceutical Sciences,
15th Ed., Mack Publ. Co., Easton, PA [1975]).
As used herein, the term "pharmaceutically acceptable salt" refers to any
pharmaceutically acceptable salt (e.g., acid or base) of a compound of the
present invention
which, upon administration to a subject, is capable of providing a compound of
this
invention or an active metabolite or residue thereof. As is known to those of
skill in the art,
"salts" of the compounds of the present invention may be derived from
inorganic or organic
acids and bases. Examples of acids include, but are not limited to,
hydrochloric,
hydrobromic, sulfuric, nitric, perchloric, fumaric, maleic, phosphoric,
glycolic, lactic,
66
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric,
methanesulfonic,
ethanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic,
benzenesulfonic acid, and
the like. Other acids, such as oxalic, while not in theinselves
pharmaceutically acceptable,
may be employed in the preparation of salts useful as intermediates in
obtaining the
compounds of the invention and their pharmaceutically acceptable acid addition
salts.
Examples of bases include, but are not limited to, alkali metals (e.g.,
sodium)
hydroxides, alkaline earth metals (e.g., magnesium), hydroxides, ammonia, and
compounds
of formula NW4+, wherein W is C1_4 alkyl, and the like.
Examples of salts include, but are not limited to: acetate, adipate, alginate,
aspartate,
benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate,
camphorsulfonate,
cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate,
fumarate,
flucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate,
hydrochloride,
hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate,
methanesulfonate,
2-naphthalenesulfonate, nicotinate, oxalate, palmoate, pectinate, persulfate,
phenylpropionate, picrate, pivalate, propionate, succinate, tartrate,
thiocyanate, tosylate,
undecanoate, and the like. Other examples of salts include anions of the
compounds of the
present invention compounded with a suitable cation such as Na+, NH4+, and
NW4+
(wherein W is a C14 alkyl group), and the like.
For therapeutic use, salts of the compounds of the present invention are
contemplated as being pharmaceutically acceptable. However, salts of acids and
bases that
are non-phannaceutically acceptable may also find use, for example, in the
preparation or
purification of a pharmaceutically acceptable compound.
As used herein, the terins "solid phase supports" or "solid supports," are
used in their
broadest sense to refer to a number of supports that are available and known
to those of
ordinary skill in the art. Solid phase supports include, but are not limited
to, silica gels,
resins, derivatized plastic films, glass beads, cotton, plastic beads, alumina
gels, and the
like. As used herein, "solid supports" also include synthetic antigen-
presenting matrices,
cells, liposomes, and the like. A suitable solid phase support may be selected
on the basis
of desired end use and suitability for various protocols. For example, for
peptide synthesis,
solid phase supports may refer to resins such as polystyrene (e.g., PAM-resin
obtained from
Bachem, Inc., Peninsula Laboratories, etc.), POLYHIPE) resin (obtained from
Aminotech,
Canada), polyamide resin (obtained from Peninsula Laboratories), polystyrene
resin grafted
67
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
with polyethylene glycol (TENTAGEL, Rapp Polymere, Tubingen, Germany) or
polydimethylacrylamide resin (obtained from Milligen/Biosearch, California).
As used herein, the term "pathogen" refers a biological agent that causes a
disease
state (e.g., infection, cancer, etc.) in a host. "Pathogens" include, but are
not limited to,
viruses, bacteria, archaea, fungi, protozoans, mycoplasma, prions, and
parasitic organisms.
The terms "bacteria" and "bacterium" refer to all prokaryotic organisms,
including
those within all of the phyla in the Kingdom Procaryotae. It is intended that
the term
encompass all microorganisms considered to be bacteria including Mycoplasma,
Chlamydia, Actinomyces, Streptomyces, and Rickettsia. All forms of bacteria
are included
within this definition including cocci, bacilli, spirochetes, spheroplasts,
protoplasts, etc.
Also included within this term are prokaryotic organisms which are gram
negative or gram
positive. "Gram negative" and "gram positive" refer to staining patterns with
the
Gram-staining process which is well known in the art. (See e.g., Finegold and
Martin,
Diagnostic Microbiology, 6t11 Ed., CV Mosby St. Louis, pp. 13-15 [1982]).
"Gram positive
bacteria" are bacteria which retain the primary dye used in the Gram stain,
causing the
stained cells to appear dark blue to purple under the microscope. "Gram
negative bacteria"
do not retain the primary dye used in the Gram stain, but are stained by the
counterstain.
Thus, gram negative bacteria appear red.
As used herein, the term "microorganism" refers to any species or type of
microorganism, including but not limited to, bacteria, archaea, fungi,
protozoans,
mycoplasma, and parasitic organisms. The present invention contemplates that a
number of
microorganisms encompassed therein will also be pathogenic to a subject.
As used herein, the term "fungi" is used in reference to eukaryotic organisms
such as
the molds and yeasts, including dimorphic fungi.
As used herein, the term "virus" refers to minute infectious agents, which
with
certain exceptions, are not observable by light microscopy, lack independent
metabolism,
and are able to replicate only within a living host cell. The individual
particles (i.e., virions)
typically consist of nucleic acid and a protein shell or coat; some virions
also have a lipid
containing membrane. The term "virus" encompasses all types of viruses,
including animal,
plant, phage, and other viruses.
The term "sample" as used herein is used in its broadest sense. A sample
suspected
of indicating a condition characterized by the dysregulation of apoptotic
function may
68
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
comprise a cell, tissue, or fluids, chromosomes isolated from a cell (e.g., a
spread of
metaphase chromosomes), genomic DNA (in solution or bound to a solid support
such as
for Southern blot analysis), RNA (in solution or bound to a solid support such
as for
Northern blot analysis), cDNA (in solution or bound to a solid support) and
the like. A
sample suspected of containing a protein may comprise a cell, a portion of a
tissue, an
extract containing one or more proteins and the like.
As used herein, the terms "purified" or "to purify" refer, to the removal of
undesired
components from a sample. As used herein, the term "substantially purified"
refers to
molecules that are at least 60% free, preferably 75% free, and most preferably
90%, or
1'b more, free from other components with which they usually associated.
As used herein, the term "antigen binding protein" refers to proteins which
bind to a
specific antigen. "Antigen binding proteins" include, but are not limited to,
immunoglobulins, including polyclonal, monoclonal, chiineric, single chain,
and humanized
antibodies, Fab fragments, F(ab')2 fragments, and Fab expression libraries.
Various
procedures known in the art are used for the production of polyclonal
antibodies. For the
production of antibody, various host animals can be immunized by injection
with the
peptide corresponding to the desired epitope including but not limited to
rabbits, mice, rats,
sheep, goats, etc. In a preferred einbodiment, the peptide is conjugated to an
immunogenic
carrier (e.g., diphtheria toxoid, bovine serum albumin (BSA), or keyhole
limpet hemocyanin
[KLH]). Various adjuvants are used to increase the immunological response,
depending on
the host species, including but not limited to Freund's (complete and
incomplete), mineral
gels such as alumimun liydroxide, surface active substances such as
lysolecithin, pluronic
polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins,
dinitrophenol,
and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin)
and
Corynebacterium parvum.
For preparation of monoclonal antibodies, any technique that provides for the
production of antibody molecules by continuous cell lines in culture may be
used (See e.g.,
Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory Press,
Cold Spring Harbor, NY). These include, but are not limited to, the hybridoma
teclmique
originally developed by Kohler and Milstein (K6hler and Milstein, Nature,
256:495-497
[1975]), as well as the trioma technique, the human B-cell hybridoma technique
(See e.g.,
Kozbor et al., Inununol. Today, 4:72 [1983]), and the EBV-hybridoma technique
to produce
69
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
human monoclonal antibodies (Cole et al., in Monoclonal Antibodies and Cancer
Therapy,
Alan R. Liss, Inc., pp. 77-96 [1985]).
According to the invention, techniques described for the production of single
chain
antibodies (U.S. 4,946,778; herein incorporated by reference) can be adapted
to produce
specific single chain antibodies as desired. An additional embodiment of the
invention
utilizes the techniques known in the art for the construction of Fab
expression libraries
(Huse et al., Science, 246:1275-1281 [1989]) to allow rapid and easy
identification of
monoclonal Fab fragments with the desired specificity.
Antibody fragments that contain the idiotype (antigen binding region) of the
antibody molecule can be generated by known techniques. For example, such
fraginents
include but are not limited to: the F(ab')2 fragment that can be produced by
pepsin digestion
of an antibody molecule; the Fab' fragments that can be generated by reducing
the disulfide
bridges of an F(ab')2 fragment, and the Fab fragments that can be generated by
treating an
antibody molecule with papain and a reducing agent.
Genes encoding antigen binding proteins can be isolated by methods known in
the
art. In the production of antibodies, screening for the desired antibody can
be accomplished
by techniques known in the art (e.g., radioimmunoassay, ELISA (enzyme-linked
immunosorbant assay), "sandwich" immunoassays, immunoradiometric assays, gel
diffusion precipitin reactions, immunodiffusion assays, in situ immunoassays
(using
colloidal gold, enzyme or radioisotope labels, for example), Western Blots,
precipitation
reactions, agglutination assays (e.g., gel agglutination assays,
hemagglutination assays,
etc.), complement fixation assays, immunofluorescence assays, protein A
assays, and
immunoelectrophoresis assays, etc.) etc.
As used herein, the terin "immunoglobulin" or "antibody" refer to proteins
that bind
a specific antigen. Immunoglobulins include, but are not limited to,
polyclonal,
monoclonal, chimeric, and humanized antibodies, Fab fragments, F(ab')2
fragments, and
includes immunoglobulins of the following classes: IgG, IgA, IgM, IgD, IbE,
and secreted
immunoglobulins (sIg). Immunoglobulins generally comprise two identical heavy
chains
and two light chains. However, the terms "antibody" and "immunoglobulin" also
encompass single chain antibodies and two chain antibodies.
The term "epitope" as used herein refers to that portion of an antigen that
makes
contact with a particular immunoglobulin. When a protein or fragment of a
protein is used
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
to immunize a host animal, numerous regions of the protein may induce the
production of
antibodies which bind specifically to a given region or three-dimensional
structure on the
protein; these regions or structures are referred to as "antigenic
determinants". An antigenic
detenninant may compete with the intact antigen (i.e., the "immunogen" used to
elicit the
immune response) for binding to an antibody.
The terms "specific binding" or "specifically binding" when used in reference
to the
interaction of an antibody and a protein or peptide means that the interaction
is dependent
upon the presence of a particular structure (i.e., the antigenic determinant
or epitope) on the
protein; in other words the antibody is recognizing and binding to a specific
protein
structure rather than to proteins in general. For example, if an antibody is
specific for
epitope "A," the presence of a protein containing epitope A (or free,
unlabelled A) in a
reaction containing labeled "A" and the antibody will reduce the amount of
labeled A bound
to the antibody.
As used herein, the terms "non-specific binding" and "background binding" when
used in reference to the interaction of an antibody and a protein or peptide
refer to an
interaction that is not dependent on the presence of a particular structure
(i.e., the antibody
is binding to proteins in general rather that a particular structure such as
an epitope).
As used herein, the term "modulate" refers to the activity of a compound
(e.g., a
compound of the present invention) to affect (e.g., to promote or retard) an
aspect of cellular
function, including, but not limited to, cell growth, proliferation,
apoptosis, and the like.
As used herein, the term "competes for binding" is used in reference to a
first
molecule (e.g., a first compound of the present invention) with an activity
that binds to the
same substrate (e.g., the oligomycin sensitivity conferring protein in
mitochondrial ATP
synthase) as does a second molecule (e.g., a second compound of the present
invention or
other molecule that binds to the oligomycin sensitivity conferring protein in
mitochondrial
ATP synthase, etc.). The efficiency (e.g., kinetics or thermodynamics) of
binding by the
first molecule may be the same as, or greater than, or less than, the
efficiency of the
substrate binding to the second molecule. For example, the equilibrium binding
constant
(KD) for binding to the substrate may be different for the two molecules.
As used herein, the term "instructions for administering said
compound to a subject," and grammatical equivalents thereof, includes
instructions for
using the compositions contained in a kit for the treatment of conditions
characterized by
71
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
the dysregulation of apoptotic processes in a cell or tissue (e.g., providing
dosing, route of
administration, decision trees for treating physicians for correlating patient-
specific
characteristics with therapeutic courses of action). The term also
specifically refers to
instructions for using the compositions contained in the kit to treat
autoimmune disorders
(e.g., systemic lupus erythematosus, rheumatoid arthritis, graft-versus-host
disease,
myasthenia gravis, Sjogren's syndrome, etc.), chronic inflammatory conditions
(e.g.,
psoriasis, asthma and Crohn's disease), hyperproliferative disorders (e.g.,
tumors, B cell
lymphomas, T cell lymphomas, etc.), viral infections (e.g., herpes virus,
papilloma virus,
HIV), and other conditions such as osteoarthritis and atherosclerosis, and the
like.
The term "test compound" refers to any chemical entity, pharmaceutical, drug,
and
the like, that can be used to treat or prevent a disease, illness, sickness,
or disorder of bodily
function, or otherwise alter the physiological or cellular status of a sainple
(e.g., the level of
dysregulation of apoptosis in a cell or tissue). Test compounds comprise both
known and
potential therapeutic compounds. A test compound can be determined to be
therapeutic by
using the screening methods of the present invention. A "known therapeutic
compound"
refers to a therapeutic compound that has been shown (e.g., through animal
trials or prior
experience with administration to humans) to be effective in such treatment or
prevention.
In preferred embodiments, "test compounds" are agents that modulate apoptosis
in cells:
As used herein, the term "third party" refers to any entity engaged in
selling,
warehousing, distributing, or offering for sale a test compound contemplated
for
administered witli a compound for treating conditions characterized by the
dysregulation of
apoptotic processes.
GENERAL DESCRIPTION OF THE INVENTION
As a class of drugs, benzodiazepine compounds have been widely studied and
reported to be effective medicaments for treating a number of disease. For
example, U.S.
4,076823, 4,110,337, 4,495,101, 4,751,223 and 5,776,946, each incorporated
herein by
reference in its entirety, report that certain benzodiazepine compounds are
effective as
analgesic and anti-inflammatory agents. Similarly, U.S. 5,324,726 and U.S.
5,597,915,
each incorporated by reference in its entirety, report that certain
benzodiazepine compounds
are antagonists of cholecystokinin and gastrin and thus might be useful to
treat certain
gastrointestinal disorders.
72
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Other benzodiazepine compounds have been studied as inhibitors of human
neutrophil elastase in the treating of human neutrophil elastase-mediated
conditions such as
myocardial ischemia, septic shock syndrome, among others (See e.g., U.S.
5,861,380
incorporated herein by reference in its entirety). U.S. 5,041,438,
incorporated herein by
reference in its entirety, reports that certain benzodiazepine compounds are
useful as anti-
retroviral agents.
Despite the attention benzodiazepine compounds have drawn, it will become
apparent from the description below, that the present invention provides novel
benzodiazepine compounds and related compounds and methods of using the novel
compounds, as well as known compounds, for treating a variety of diseases.
Benzodiazepine compounds are known to bind to benzodiazepine receptors in the
central nervous systein (CNS) and thus have been used to treat various CNS
disorders
including anxiety and epilepsy. Peripheral benzodiazepine receptors have also
been
identified, which receptors may incidentally also be present in the CNS. The
present
invention demonstrates that benzodiazepines and related compounds have pro-
apoptotic and
cytotoxic properties useful in the treatment of transformed cells grown in
tissue culture.
The route of action of these compounds is not through the previously
identified
benzodiazepine receptors.
Experiments conducted during the development of the present invention have
identified novel biological targets for benzodiazepine compounds and related
compounds
(some of which are related by their ability to bind cellular target molecules
rather than their
homology to the overall chemical structure of benzodiazepine compounds). In
particular,
the present invention provides compounds that interact, directly or
indirectly, with particular
mitochondrial proteins to elicit the desired biological effects.
Thus, in some embodiments, the present invention provides a number of novel
compounds and previously known compounds directed against novel cellular
targets to
achieve desired biological results. In other embodiments, the present
invention provides
methods for using such compounds to regulate biological processes. The present
invention
also provides drug-screening methods to identify and optimize compounds. The
present
invention further provides diagnostic markers for identifying diseases and
conditions, for
monitoring treatment regimens, and/or for identifying optimal therapeutic
courses of action.
These and other research and therapeutic utilities are described below.
73
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Similar benzodiazepine related compounds, described in U.S. Patent
Applications
10/886,450, 10/795,535, 10/634,114, 10/427, 212, 10/427,211, 10/217,878,
09/767,283, and
09/700,101, and U.S. Provisional Patent Application No. 60/565,788, each
herein
incorporated by reference in their entireties, are also characterized as
modulators of cell
death. Gene expression profiles of such benzodiazepine related compounds
demonstrate a
modulation of genes directed toward apoptosis. Such benzodiazepine related
compounds
further find use within pharmaceutical compositions along with apoptotic
agents.
Additionally, such benzodiazepine related compounds find use in therapeutic
applications
(e.g., treating hyperproliferative disorders).
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides novel chemical compounds, methods for their
discovery, and their therapeutic, research, and diagnostic use. In particular,
the present
invention provides benzodiazepine derivatives and related compounds and
methods of using
benzodiazepine derivatives and related compounds as therapeutic agents to
treat a number
of conditions associated with the faulty regulation of the processes of
programmed cell
death, autoimmunity, inflammation, and hyperproliferation, and the like.
Exemplary compositions and methods of the present invention are described in
more
detail in the following sections: I. Modulators of Cell Death; II. Modulators
of Cell
Growth and Proliferation; III. Exemplary Coinpounds; IV. Pharmaceutical
compositions,
formulations, and exemplary administration routes and dosing considerations;
V. Drug
screens; VI. Therapeutic Applications; and VII. ATPase Inhibitors And Methods
For
Identifying Therapeutic Inhibitors.
The present invention herein incorporates by reference U.S. Provisional Patent
Nos.
60/607,599, and 60/641,040, and U.S. Patent Application Nos. 10/935,333,
10/886,450,
10/795,535, 10/634,114, 10/427,211, 10/427,212, 10/217,878, 09/767,283,
09/700,101, and
related applications. All compounds and uses described in the above mentioned
cases are
contemplated to be part of the present invention. Additionally, all other
known uses of
benzodiazepines may be used with the new fornnulations of the invention.
Additional
references include, but are not limited to, Otto, M.W., et al., (2005) J.
Clin. Psychiatry 66
Suppl. 2:34-38; Yoshii, M., et al., (2005) Nippon Yakurigaku Zasshi 125(1):33-
36; Yasuda,
K. (2004) Nippon Rinsho. 62 Suppl. 12:360-363; Decaudin, D. (2004) 15(8):737-
745;
Bonnot, 0., et al. (2003) Encephale. 29(6):553-559; Sugiyama, T. (2003)
Ryoikibetsu
74
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Shokogun Shirizu. 40:489-492; Lacapere, J.J., et al., (2003) Steroids. 68(7-
8):569-585;
Galiegue, S., et al., (2003) Curr. Med. Chem. 10(16):1563-1572; Papadopoulo,
V. (2003)
Ann. Pharm. Fr. 61(1):30-50; Goethals, I., et al., (2002) Eur. J. Nucl. Med.
Mol. Imaging
30(2):325-328; Castedo, M., et al., (2002) J. Exp. Med. 196(9):1121-1125;
Buffett-Jerrott,
S.E., et al., (2002) Curr. Pham. Des. 8(1):45-58; Beurdeley-Thomas, A., et
al., (2000) J.
Nuerooncol. 46(1):45-56; Smyth, W.F., et al., (1998) Electrophoresis 19(16-
17):2870-2882;
Yoshii, M., et al., (1998) Nihon Shinkei Seishin Yakurigaku Zasshi. 18(2):49-
54; Trimble,
M. and Hindmarch, I. (2000) Benzodiazepines, published by Wrighton Biomedical
Publishing; and Salamone, S.J. (2001) Benzodiazepines and GHB - Detection and
Pharmacology, published by Humana Press; each herein incorporated by reference
in their
entireties.
The practice of the present invention employs, unless otherwise indicated,
conventional techniques of orgaiiic chemistry, pharmacology, molecular biology
(including
recombinant techniques), cell biology, biochemistry, and immunology, which are
within the
skill of the art. Such techniques are explained fully in the literature, such
as, "Molecular
cloning: a laboratory manual" Second Edition (Sambrook et al., 1989);
"Oligonucleotide
synthesis" (M.J. Gait, ed., 1984); "Animal cell culture" (R.I. Freshney, ed.,
1987); the series
"Methods in enzymology" (Academic Press, Inc.); "Handbook of experimental
immunology" (D.M. Weir & C.C. Blackwell, eds.); "Gene transfer vectors for
mammalian
cells" (J.M. Miller & M.P. Calos, eds., 1987); "Current protocols in molecular
biology"
(F.M. Ausubel et al., eds., 1987, and periodic updates); "PCR: the polymerase
chain
reaction" (Mullis et al., eds., 1994); and "Current protocols in immunology"
(J.E. Coligan et
al., eds., 1991), each of which is herein incorporated by reference in its
entirety.
I. Modulators of Cell Death
In preferred einbodiments, it is contemplated that the present invention
regulates
apoptosis through the exposure of cells to compounds. The effect of compounds
can be
measured by detecting any number of cellular changes. Cell death may be
assayed as
described herein and in the art. In preferred embodiments, cell lines are
maintained under
appropriate cell culturing conditions (e.g., gas (C02), temperature and media)
for an
appropriate period of time to attain exponential proliferation without density
dependent
constraints. Cell number and or viability are measured using standard
techniques, such as
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
trypan blue exclusion/hemo-cytometry, or MTT dye conversion assay.
Alternatively, the
cell may be analyzed for the expression of genes or gene products associated
with
aberrations in apoptosis or necrosis.
In preferred einbodiments, it is contemplated that exposing the present
invention to a
cell induces apoptosis. In some embodiments, it is conteinplated that the
present invention
causes an initial increase in cellular ROS levels (e.g., 02 ). In further
embodiments, it is
contemplated that exposure of the compounds of the present invention to a cell
causes an
increase in cellular OZ levels. In still further embodiments, it is
contemplated that the
increase in cellular Oz levels resulting from the compounds of the present
invention is
detectable with a redox-sensitive agent that reacts specifically with Oa
(e.g.,
dillyroethedium (DHE)).
In other embodiments, it is contemplated that increased cellular OZ levels
resulting
from compounds of the present invention diminish after a period of time (e.g.,
10 minutes).
In other embodiments, it is contemplated that increased cellular 02 levels
resulting from the
compounds of the present invention diminish after a period of time and
increase again at a
later time (e.g., 10 hours). In furtlier einbodiments, it is contemplated that
increased cellular
OZ levels resulting from the compounds of the present invention diminish at 1
hour and
increase again after 4 hours. In preferred embodiments, it is contemplated
that an early
increase in cellular 02 levels, followed by a diminishing in cellular 02
levels, followed by
another increase in cellular 02- levels resulting from the compounds of the
present invention
is due to different cellular processes (e.g., bimodal cellular mechanisms).
In some embodiments, it is contemplated that the present invention causes a
collapse
of a cell's mitochondrial AlI',,,. In preferred embodiments, it is
contemplated that a collapse
of a cell's mitochondrial AlI',,, resulting from the present invention is
detectable with a
mitochondria-selective potentiometric probe (e.g., DiOC6). In further
embodiments, it is
contemplated that a collapse of a cell's mitochondrial AT,,, resulting from
the present
invention occurs after an initial increase in cellular 02 levels.
In some einbodiments, it is contemplated that the present invention enables
caspace
activation. In other embodiments, it is contemplated that the present
invention causes the
release of cytochrome c from mitochondria. In further embodiments, it is
contemplated that
the present invention alters cystolic cytochrome c levels. In still other
embodiments, it is
contemplated that altered cystolic cytochrome c levels resulting from the
present invention
76
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
are detectable with immunoblotting cytosolic fractions. In preferred
embodiments, it is
contemplated that diminished cystolic cytochrome c levels resulting from the
present
invention are detectable after a period of time (e.g., 10 hours). In furtlier
preferred
embodiments, it is contemplated that diminished cystolic cytochrome c levels
resulting from
the present invention are detectable after 5 hours.
In other embodiments, it is contemplated that the present invention causes the
opening of the mitochondrial PT pore. In preferred embodiments, it is
contemplated that
the cellular release of cytochrome c resulting from the present invention is
consistent witli a
collapse of mitochondrial ALI',,,. In still further preferred embodiments, it
is contemplated
that the present invention causes an increase in cellular 02- levels after a
mitochondrial ALI',,,
collapse and a release of cytochrome c. In further preferred embodiments, it
is
contemplated that a rise in cellular OZ- levels is caused by a mitochondrial
OLI',,, collapse and
release of cytochrome c resulting from the present invention.
In other embodiments, it is contemplated that the present invention causes
cellular
caspase activation. In preferred embodiments, it is contemplated that caspase
activation
resulting from the present invention is measurable with a pan-caspase
sensitive fluorescent
substrate (e.g., FAM-VAD-fink). In still further embodiments, it is
conteinplated that
caspase activation resulting from the present invention tracks with a collapse
of
mitochondrial AlI',,,. In other embodiments, it is contemplated that the
present invention
causes an appearance of hypodiploid DNA. In preferred embodiments, it is
contemplated
that an appearance of hypodiploid DNA resulting from the present invention is
slightly
delayed with respect to caspase activation.
In some embodiments, it is contemplated that the molecular target for the
present
invention is found within mitochondria. In further embodiments, it is
contemplated that the
molecular target of the present invention involves the mitochondrial ATPase.
The primary
sources of cellular ROS include redox enzymes and the mitochondrial
respiratory chain
(hereinafter MRC). In preferred embodiments, it is contemplated that
cytochrome c oxidase
(complex IV of the MRC) inhibitors (e.g., NaN3) preclude a present invention
dependent
increase in cellular ROS levels. In other preferred embodiments, it is
contemplated that the
ubiquinol-cytochrome c reductase component of MRC complex III inhibitors
(e.g., FK506)
preclude a present invention dependent increase in ROS levels.
77
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In some embodiments, it is contemplated that an increase in cellular ROS
levels
result from the binding of the compounds of the present invention to a target
within
mitochondria. In preferred embodiments, it is conteinplated that the compounds
of the
present invention oxidize 2',7'-dichlorodihydrofluorescin (hereinafter DCF)
diacetate to
DCF. DCF is a redox-active species capable of generating ROS. In further
embodiments, it
is contemplated that the rate of DCF production resulting from the present
invention
increases after a lag period.
Antimycin A generates 02 by inhibiting ubiquinol-cytochrome c reductase. In
preferred embodiments, it is contemplated that the present invention increases
the rate of
ROS production in an equivalent manner to antimycin A. In further embodiments,
it is
contemplated that the present invention increases the rate of ROS production
in an
equivalent manner to antimycin A under aerobic conditions supporting state 3
respiration.
In further embodiments, it is contemplated that the compounds of the present
invention do
not directly target the MPT pore. In additional embodiments, it is
contemplated that the
compounds of the present invention do not generate substantial ROS in the
subcellular S 15
fraction (e.g., cytosol; microsomes). In even further embodiments, it is
contemplated that
the compounds of the present invention do not stimulate ROS if mitochondria
are in state 4
respiration.
MRC complexes I - III are the primary sources of ROS within mitochondria. In
preferred embodiments, it is contemplated that the primary source of an
increase in cellular
ROS levels resulting from the dependent invention emanates from these
complexes as a
result of inhibiting the mitochondrial F1Fo-ATPase. Indeed, in still further
embodiments, it
is contemplated that the present invention inhibits mitochondrial ATPase
activity of bovine
sub-mitochondrial particles (hereinafter SMPs). In particularly preferred
embodiments, it is
contemplated that the compounds of the present invention bind to the OSCP
component of
the mitochondrial F1Fo-ATPase.
Oligomycin is a macrolide natural product that binds to the mitochondrial F1Fo-
ATPase, induces a state 3 to 4 transition, and as a result, generates ROS
(e.g., 02 ). In
preferred embodiments, the compounds of the present invention bind the OSCP
component
of the mitochondrial F1Fo-ATPase. In preferred embodiments, the compounds of
the
present invention bind the junction between the OSCP and the Fi subunit of the
mitochondrial F1Fo-ATPase. In some embodiments, the coinpounds of the present
78
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
invention bind the Fl subunit. In certain embodiments, screening assays of the
present
invention permit detection of binding partners of the OSCP, Fl, or OSCP/ Fl
junction.
OSCP is an intrinsically fluorescent protein. In certain embodiments,
titrating a solution of
test compounds of the present invention into an E. Coli sample overexpressed
with OSCP
results in quenching of the intrinsic OSCP fluorescence. In other embodiments,
fluorescent
or radioactive test compounds can be used in direct binding assays. In other
embodiments,
competition binding experiments can be conducted. In this type of assay, test
compounds
are assessed for their ability to compete with Bz-423 for binding to, for
example, the OSCP.
In some embodiments, the compounds of the present invention cause a reduced
increase in
cellular ROS levels and reduced apoptosis in cells through regulation of the
OSCP gene
(e.g., altering expression of the OSCP gene). In further embodiments, the
present invention
functions by altering the molecular motions of the ATPase motor.
II. Modulators of Cellular Proliferation and Cell Growth
In some embodiments, it is contemplated that the compounds and methods of the
present invention cause decreased cellular proliferation. In other
embodiments, it is
contemplated that the compounds and methods of the present invention cause
decreased
cellular proliferation and apoptosis.
III. Exemplary Compounds
Exeinplary compounds of the present invention are provided below.
R,
R21,L N
N
including both R and S enantiomeric forms and racemic mixtures;
wherein Rl comprises a chemical moiety comprising a hydrogen bonding proton
donor
(e.g., a hydroxyl group, a phenol group, an ainide group, a sulfonamide group,
an amine
group, an aniline group, a benziinidizalone group, a carbamate group, and an
imidizole
group); and R2 comprises a hydrophobic chemical moiety.
79
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In preferred embodiments, R1 is selected from the group consisting of:
R5 R~' R~'
7 R4 R5 R4 R R4
R2
2
R3 R3 R3
Rl' ; RZ ; R5 ;
Rl' Rl'
7 R4 R5
R2 R2
R5 R4
R3 ;and R3
wherein R1', R2, R3 and R4 are selected from the group consisting of:
hydrogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 1
carbon; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons and at least
one hydroxy subgroup; a linear or branched, saturated or unsaturated,
substituted or non-
substituted, aliphatic chain having at least 2 carbons and having at least one
thiol subgroup;
a linear or branched, saturated or unsaturated, substituted or non-
substituted, aliphatic chain
having at least 2 carbons wherein the aliphatic chain terminates with an
aldehyde subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one ketone subgroup; a linear or branched, saturated or
unsaturated,
substituted or non-substituted, aliphatic chain having at least 2 carbons;
wherein the
aliphatic chain terminates with a carboxylic acid subgroup; a linear or
branched, saturated
or unsaturated, substituted or non-substituted, aliphatic chain having at
least 2 carbons, and
having at least one amide subgroup; a linear or branched, saturated or
unsaturated,
substituted or non-substituted, aliphatic chain having at least 2 carbons, and
having at least
one acyl group; a linear or branched, saturated or unsaturated, substituted or
non-
substituted, aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated, substituted
or non-
substituted, aliphatic chain having at least 2 carbons, and having at least
one amine
subgroup; a linear or branched, saturated or unsaturated, substituted or non-
substituted,
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
aliphatic chain having at least 2 carbons, and having at least one ether
subgroup; a linear or
branched, saturated or unsaturated, substituted or non-substituted, aliphatic
chain having at
least 2 carbons, and having at least one halogen subgroup; a linear or
branched, saturated or
unsaturated, substituted or non-substituted, aliphatic chain having at least 2
carbons, and
having at least one nitronium subgroup; and R5 is OH.
In preferred embodiments, R2 is selected from group consisting of:
napthalalanine;
phenol; 1-Napthalenol; 2-Napthalenol; b~_O;
i::::::. 10 OCF3; . / / . (CH2)nC(CH3)3
81
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
\I/
wherein n=0-5; (CH2)nCH(CH3)2 wherein n=0-5; CH2(CH2)nCH3
I
dialk I re oisomers
wherein n=0-5; y (all gi ) ; =
~nrtn,
~
~
difluoromethyl (all regioisomers)
~s"\
and quinolines.
In some preferred embodiments, Rl is selected from the group consisting of:
rLrinrL vwL ~iwti
I I
OH OH; OH ; and OH
In some preferred embodiments, the composition comprises the following
formula:
82
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
R4
R3
R2-z,L
N
N
R
1
R5
wherein R3 is selected from the group consisting of Hydrogen; amino; and a
linear or
branched, saturated or unsaturated, substituted (e.g., substituted with
amines, esters, amides
or phosphatases) or non-substituted, aliphatic chain having at least 2
carbons;
R4 is selected from the group consisting of H, a ketone, and a nitrogen; and
R5 is selected from H, a hydroxy, an alkoxy, a carboxylic acid, a carboxylic
ester, a
halogen, a nitro, a sulfonamide, an amide, a carbamate, an amino, a lower-
alkyl, a
substituted-amino, an acetylamino, a hydroxyamino, an aliphatic group having 1-
8 carbons
and 1-20 hydrogens, a substituted aliphatic group of similar size, a
cycloaliphatic group
consisting of less than 10 carbons, a substituted cycloaliphatic group, an
aryl, a heterocyclic,
NOZ; SR'; and NR'2, wherein R' is defined as a linear or branched, saturated
or unsaturated
aliphatic chain having at least one carbon; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one hydroxyl
subgroup; a linear
or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and having at
least one thiol subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, wherein the aliphatic chain terminates with an
aldehyde subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one ketone subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons; wherein the aliphatic chain terminates with a
carboxylic
acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least
2 carbons, and having at least one amide subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
acyl group; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one nitrogen containing moiety; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
amine
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
83
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
carbons, and having at least one halogen subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
nitronium
subgroup.
In other preferred embodiments R2 is any chemical group that permits the
compound to bind to OSCP. In some such embodiments, R2 comprises a hydrophobic
aromatic group. In preferred embodiments R2 comprises a hydrophobic aromatic
group
larger than benzene (e.g., a benzene ring with non-hydrogen substituents, a
moiety having
two or more aromatic rings, a moiety with 7 or more carbon atoms, etc.).
The term "aliphatic" represents the groups commonly known as alkyl, alkenyl,
alkynyl, alicyclic. The term "aryl" as used herein represents a single
aromatic ring such as a
phenyl ring, or two or more aromatic rings that are connected to each other
(e.g., bisphenyl)
or fused together (e.g., naphthalene or anthracene). The aryl group can be
optionally
substituted with a lower aliphatic group (e.g., C1-C4 alkyl, alkenyl, alkynyl,
or C3-C6
alicyclic). Additionally, the aliphatic and aryl groups can be further
substituted by one or
more functional groups such as -NH2, -NHCOCH3, -OH, lower alkoxy (C1-C4), halo
(-F, -
Cl, -Br, or -I). It is preferable that Rl is primarily a nonpolar moiety.
The term "a moiety that participates in hydrogen bonding" as used herein
represents
a group that can accept or donate a proton to fonn a hydrogen bond thereby.
Some specific non-limiting examples of moieties that participate in hydrogen
bonding include a fluoro, oxygen-containing and nitrogen-containing groups
that are well-
known in the art. Some examples of oxygen-containing groups that participate
in hydrogen
bonding include: hydroxy, lower alkoxy, lower carbonyl, lower carboxyl, lower
ethers and
phenolic groups. The qualifier "lower" as used herein refers to lower
aliphatic groups (C1-
C4) to which the respective oxygen-containing functional group is attached.
Thus, for example, the term "lower carbonyl" refers to inter alia,
fonnaldehyde,
acetaldehyde.
Some nonliiniting examples of nitrogen-containing groups that participate in
hydrogen bond fonnation include amino and amido groups. Additionally, groups
containing both an oxygen and a nitrogen atom can also participate in hydrogen
bond
formation. Examples of such groups include nitro, N-hydroxy and nitrous
groups.
It is also possible that the hydrogen-bond acceptor in the present invention
can be
the 7r electrons of an aromatic ring. However, the hydrogen bond participants
of this
84
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
invention do not include those groups containing metal atoms such as boron.
Further the
hydrogen bonds formed within the scope of practicing this invention do not
include those
formed between two hydrogens, known as "dihydrogen bonds." (See, R.H.
Crabtree,
Science, 282:2000-2001 [1998], for further description of such dihydrogen
bonds).
The term "heterocyclic" represents, for example, a 3-6 membered aromatic or
nonaromatic ring containing one or more heteroatoms. The heteroatoms can be
the same or
different from each other. Preferably, at least one of the heteroatom's is
nitrogen. Other
heteroatoms that can be present on the heterocyclic ring include oxygen and
sulfur.
Aromatic and nonaromatic heterocyclic rings are well-known in the art. Some
nonlimiting exainples of aromatic heterocyclic rings include pyridine,
pyrimidine, indole,
purine, quinoline and isoquinoline. Nonlimiting exainples of nonaromatic
heterocyclic
compounds include piperidine, piperazine, morpholine, pyrrolidine and
pyrazolidine.
Examples of oxygen containing heterocyclic rings include, but not limited to
furan, oxirane,
2H-pyran, 4H-pyran, 2H-chromene, and benzofuran. Examples of sulfur-containing
heterocyclic rings include, but are not limited to, thiophene, benzothiophene,
and
parathiazine.
Examples of nitrogen containing rings include, but not limited to, pyrrole,
pyrrolidine, pyrazole, pyrazolidine, imidazole, imidazoline, imidazolidine,
pyridine,
piperidine, pyrazine, piperazine, pyrimidine, indole, purine, benzimidazole,
quinoline,
isoquinoline, triazole, and triazine.
Examples of heterocyclic rings containing two different heteroatoms include,
but are
not limited to, phenothiazine, morpholine, parathiazine, oxazine, oxazole,
thiazine, and
thiazole.
The heterocyclic ring is optionally further substituted with one or more
groups
selected from aliphatic, nitro, acetyl (i.e., -C(=O)-CH3), or aryl groups.
From the above description, it is apparent that many specific examples are
represented by the generic formulas presented above. A wide variety of sub
combinations
arising from selecting a particular group at each substituent position are
possible and all
such combinations are within the scope of this invention.
Further, it should be understood that the numerical ranges given throughout
this
disclosure should be construed as a flexible range that conteinplates any
possible subrange
within that range. For example, the description of a group having the range of
1-10 carbons
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
would also contemplate a group possessing a subrange of, for example, 1-3, 1-
5, 1-8, or 2-3,
2-5, 2-8, 3-4, 3-5, 3-7, 3-9, 3-10, etc., carbons. Thus, the range 1-10 should
be understood
to represent the outer boundaries of the range within which many possible
subranges are
clearly contemplated. Additional examples contemplating ranges in other
contexts can be
found throughout this disclosure wherein such ranges include analogous
subranges within.
Some specific examples of the compounds of the present invention include:
R2 R2
O O
N N
CH3
ci ~N ci ~N
HO HO
wherein R2 is
86
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
I I (
OH
I
N
and
N and dimethylphenyl (all isomers) and ditrifluoromethyl (all isomers).
The following exemplary compounds are also contemplated in the present
invention:
O
R2
-L%
N I X Y
N
/
z
\
R3
wherein R2 is selected from the group consisting of Hydrogen, alkyl,
substituted
alkyl, and (CH2)õ wherein n=1-6;
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted alkyl, carboxylic acid, amide SO2NH2, NHSO2alkyl, and NO2i
87
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
N
M
wherein X is selected from the group consisting of L ,
L M
L
L L N L ~\ N
\ \ \~'i \ /
M
N N M~~ N M M
> > > > >
alkyl, substituted alkyl, sulfolamide, SO2alkyl, NHSO2, CH2, CH2CH2, SO2,
CH2SO2,
SOZCH2, OCH2CH2O, SO, CH2CH2SO, SOCH2CH2; and
wherein L, M and N are present or absent, and are selected from the group
consisting of alkyl, NO2, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, CF3, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SO2NH2, SO2NH-alkyl, SOalkyl, NHSO2alkyl; and
wherein Y is selected from the group consisting of hydrogen, alkyl,
substituted
alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl ester, COZH,
nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
zz
W W YY
I
hydrogen, SOalkyl, SO2NH2, SO2NH-alkyl, NHSOaalkyl, and xx
wlierein WW, XX, YY and ZZ are present or absent, and are selected from the
group consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester,
ethyl ester,
CO2H, aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted
alkyl, and tri-
substituted alkyl, hydrogen, SO2NHZ, SO2NH-alkyl, NHSO2alkyl; and
88
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
~nnrL
/ ~rvtn'
HN HN
wherein Z is selected from the group consisting of SO2Ar N
> >
I I
\ \ l~ ~VL~'LJL WVL
I I
HN I I I
NH NH
0 ~ 0 ~ OH ~ OH ~ OH
I
~fVL
I I /
~Ji11JL \ I
I HN
HN
HN O
O
02S__ N H
and R5 wherein R5 is selected from
the group consisting of alkyl, mono-substituted alkyl, di-substituted alkyl,
and tri-
substituted alkyl.
Additional exemplary coinpounds of the present invention include, but are not
limited to,
89
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
CI
\
I
H3C\
Lg
N N
O
/ \
~~ ci
OH OH
ci
o
H3~i, \ H3C\ -1~ I \ N
N
N
ci Cl
HN\ /NH HNyNH
~LoI( , and 0
The following compound is also contemplated:
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
N
CH3
N
CI
OH
The following exemplary compounds are also contemplated in the present
invention:
O
RZ\
N
N
R
1
R3
including both R and S enantiomeric forms and racemic mixtures; wherein Rl is
selected
from the group consisting of:
91
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
HN
O
X wherein X is selected from the group consisting of heteroatom,
NH
HN
HN\, N
alkyl, and substituted alkly; SO2Ar 0
Z y
0 wherein Z and Y are separately selected from the group consisting of 0, N
and S; OH ; and OH wherein R2 is selected from the group
consisting of methyl, H, alkyl, and (CHa)õ-morpholino wherein n=1-6; and
wherein R3 is
92
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
selected from the group consisting of hydrogen, halogen, alkyl, substituted
alkyl, carboxylic
acid, amide SO2NH2, NHSO2alkyl, and NOz.
In certain embodiments, the present invention provides a composition
comprising
the following formula:
O
N RZ
Ri
/ N
~ /
R~\
3 3 / \
OH
wherein Rl is selected from the group consisting of methyl, hydrogen, alkyl,
and (CHZ)õ-
morpholino wherein n=1-6;
93
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
F~
()BB
DDR
4
wherein R2 is selected from the group consisting of CC
~
I
R5
BB DD BB DD
CC R4 , and CC Ra
wherein R3 is selected from the group consisting of hydrogen, halogen, alkyl,
substituted alkyl, carboxylic acid, amide, SOZNH2, NHSO2alkyl, and NOa;
wherein BB, CC,
DD, and R4 are present or absent, and are selected from the group consisting
of hydrogen,
CF3, NO2, allcyl, halogen, OH, 0-alkyl, nitro, OCH2CHaOH, SO2H, mono-
substituted alkyl,
di-substituted alkyl, tri-substituted allcyl, CO2H, heterocycle, SO2NH2, SO2NH-
alkyl,
NHSO2alkyl, methyl ester, propyl ester, and ethyl ester; and wherein R5 is
selected from the
group consisting of NHSO2, CH2NHSO2, CH2CH2NHSO2, CH2CH2CH2NHSO2, SO2NH,
SO2NHCH2, SO2NHCH2CH2, SO2NHCH2CH2CH2, CH2, CH2CH2, CH2CH2CH2, SO2,
CH2SO, SOCH2, OCHaCH2O, SO, CH2CH2SO, and SOCH2CH2.
The present invention,also contemplates Bz-423:
94
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
ICH3
O
N
CI N
/ \
OH
The following compounds are also contemplated:
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R5-\ R~ RI = H, alkyl, or substituted alkyl
N R3 = H, alkyl, or substituted alkyl
R4 = H, alkyl, or substituted alkyl
sterochemistry is R, S, or racemic
/ R2 is selected from hydrogen, a hydroxy, an alkoxy, a
halo, an amino, a lower-alkyl-a substituted-amino, an
/ acetylanvno, a hydroxyamino, an aliphatic group having
R 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
4 group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
R3 OH and a heterocyclic
R5 = -~ -~ -~
I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 IH2(CH2)nCH3
n=0-5 n=0-5 n = 0 - 5
-~ .
dialkyl (all regioisomers)
\I/
difluoromethyl (all regioisomers)
96
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R5-~ R~ R1 = H, alkyl, or substituted alkyl
N R3 = H, alkyl, or substituted alkyl
R4 = H, alkyl, or substituted alkyl
sterochemistry is R, S, or racemic
R2 is selected from hydrogen, a hydroxy, an alkoxy, a
halo, an aniino, a lower-alkyl-a substituted-amino, an
acetylamino, a hydroxyamino, an aliphatic group having
R 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
4 group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
R3 OH and a heterocyclic
R5 = -~ -~ -~
I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 I H2(CH2)nCH3
n=0-5 n=0-5 n = 0 - 5
-~ -
dialkyl (all regioisomers)
\~/
difluoromethyl (all regioisomers)
97
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R3 R, RI = H, alkyl, or substituted alkyl
R2 = H, alkyl, or substituted alkyl
NR2
sterochemistry is R, S, or racemic
0
R3 = - -~ -~
I I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 CH2(CH2)nCH3
n = 0 - 5 n0-5 n = 0 - 5
-~ -
dialkyl (all regioisomers)
I I
difluoromethyl (all regioisomers)
= ~
98
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R5 R, RI = H, alkyi, or substituted alkyl
N R3 = H, alkyl, or substituted alkyl
R4 = H, alkyl, or substituted alkyl
N sterochemistry ochemistry is R, S, or racemic
Ra
R2 is selected from hydrogen, hydroxy, an alkoxy, a halo,
an amino, a lower-alkyl-a substituted-amino, an
acetylamino, a hydroxyamino, an aliphatic group having
OH 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
R3 and a heterocyclic
R5 = -~ -~ -~
I I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 CH2(CH2)nCH3
n=0-5 n=0-5 n=0-5
-~ -
dialkyl (all regioisomers)
NV1,L
\~/
difluoromethyl (all regioisomers)
99
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R5-\ R, R1 = H, alkyl, or substituted alkyl
N R3 = H, alkyl, or substituted alkyl
R4 = H, alkyl, or substituted alkyl
/ sterochemistry is R, S, or racemic
/ R4
R2 is selected from hydrogen, hydroxy, an alkoxy, a halo,
\ / \ an amino, a lower-alkyl-a substituted-amino, an
acetylamino, a hydroxyamino, an aliphatic group having
OH 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
R3 and a heterocyclic
R5 = -~ -~ -
I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 IH2(CH2)nCH3
n=0-5 n=0-5 n = 0 - 5
-~ -
dialkyl (all regioisomers)
I I
difluoromethyl (all regioisomers)
100
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R4-\ R,
RI = H, alkyl, or substituted alkyl
N R3 = H, alkyl, or substituted alkyl
N
sterochemistry is R, S, or racemic
OH
R2 is selected from hydrogen, hydroxy, an alkoxy, a halo,
an amino, a lower-alkyl-a substituted-amino, an
acetylamino, a hydroxyamino, an aliphatic group having
R 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
3 group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
and a heterocyclic
R4 = -~ -~ -~
I I ~
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 CH2(CH2)nCH3
n=0-5 n = 0 - 5 n = 0 - 5
-~ -
dialkyl (all regioisomers)
\I/
difluoromethyl (all regioisomers)
101
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R4-\ R~ R1 = H, alkyl, or substituted alkyl
c_)eroc R3 = H, a lkyl, or substituted alkyl
hemistry is R, S, or racemic
OH
R2 is selected from hydrogen, hydroxy, an alkoxy, a halo,
an amino, a lower-alkyl-a substituted-amino, an
acetylamino, a hydroxyamino, an aliphatic group having
R 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
3 group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
and a heterocyclic
}
R4 = - -~ -~
I I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 CH2(CH2)nCH3
n = 0 - 5 n = 0 - 5 n=0-5
dialkyl (all regioisomers)
rvlfn
+ 01/
difluoromethyl (all regioisomers)
102
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
0
R3-\ R, R1 = H, alkyl, or substituted alkyl
N R4 = H, alkyl, or substituted alkyl
/ R I
4 sterochemistry is R, S, or racemic
/ R2 is selected from hydrogen, a hydroxy, an alkoxy, a
0 halo, an amino, a lower-alkyl-a substituted-amino, an
acetylamino, a hydroxyamino, an aliphatic group having
1-8 carbons and 1-20 hydrogens, a substituted aliphatic
group of similar size, a cycloaliphatic group consisting of
R2 < 10 carbons, a substituted cycloaliphatic group, an aryl,
and a heterocyclic
R3
I I
(CH2)nC(CH3)3 (CH2)nCH(CH3)2 IH2(CH2)nCH3
n = 0 - 5 n = 0 - 5 n=0-5
-~ -
dialkyl (all regioisomers)
+
I I
difluoromethyl (all regioisomers)
103
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Rl
~ O
N
CH3
CI N
OH
wherein Rl is selected from napthalalanine; phenol; 1-Napthalenol; 2-
Napthalenol;
Halogen
Halogen
> >
104
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
OCF3 and
quinolines.
A composition comprising the following formula:
cQ\
O
N
CH3
cl N
R,
105
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
I I
uvvti uwL
I I
wherein Rl is selected from: OH OH; CI
uv,j
~~ ~WVL
y
N3 OH ; and OCH3
The stereochemistry of all derivatives embodied in the present invention is R,
S, or racemic.
In certain embodiments, the present invention provides a composition
comprising
the following formula:
0
R R5
4\
R,
R2
R2
R R2 R3
R6 2
including both R and S enantiomeric forms and racemic mixtures. In such
preferred
embodiments, Rl is a nitrogen atom or a carbon atom; R2 is carbon or nitrogen;
R3
comprises a chemical moiety comprising a heterocyclic group containing 3 or
more carbon
atoms; R4 and R5 are separately selected from the group consisting of:
hydrogen; halogen;
CH3; a linear or branched, saturated or unsaturated aliphatic chain having at
least 2 carbons;
a chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical
106
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety; and R6 is selected from H, a hydroxy, an
alkoxy, a
halogen, an amino, a lower-alkyl, a substituted-amino, an acetylamino, a
hydroxyamino, an
aliphatic group having 1-8 carbons and 1-20 hydrogens, a substituted aliphatic
group of
similar size, a cycloaliphatic group consisting of less than 10 carbons, a
substituted
cycloaliphatic group, an aryl, a heterocyclic, NO2; SR'; and NR'z, wherein R'
is defined as
a linear or branched, saturated or unsaturated aliphatic chain having at least
one carbon; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one hydroxyl subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one thiol
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
wherein the
aliphatic chain terminates with an aldehyde subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ketone
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one amide subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one acyl group; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
halogen
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one nitronium subgroup.
In preferred embodiments, R3 is selected from the group consisting of:
107
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
/ Ri5 R15 /
R75
R i *R,,4 RiZ
R1z \ / Rql Ri3 \ /
Ria Ria
R{g R13 R
~~~~, I
R1z / vvw
R
*R,,~5 R15 R11 PN
~R~3 HN Rõ ~ " ~ R1a Ria R12 SOaAr o a > > >
vw~
I I
r~'\'v
~nnn O / vw~ ~ v n
O
HN
H H H NH
OH , ORtz , CN CH2O , C(O)NH2, O ~ 0 nr~rv~
OH, OH , and oH
wherein R12, R13, R14 and R15 are selected from the group consisting of:
hydrogen; CH3;
a linear or branched, saturated or unsaturated aliphatic chain having at least
1 carbon; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one hydroxy subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one thiol
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
wherein the
aliphatic chain terminates with an aldehyde subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ketone
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
108
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
least one amide subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one acyl group; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ether subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one halogen subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitronium
subgroup; and
Rl l is OH.
In preferred embodiments, R4 or R5 are selected from group consisting of:
naptlialalanine; phenol; 1 -Napthalenol; 2-Napthalenol;
- - / ~ Halogen
/ Halogen=
>
~ ~ -
\
I
/ OCp3; (i H2)nC(CH3)3 wherein n=0-5;
+ - 0'/
~15 (CH2)nCH(CH3)2 wherein n=0-5; CH2(CH2)nCH3 Wherein n=0-5;
CC
La(ky( (all regioisomers) I IFluoromethyl (all reglolsomers)
quinolines, and all aromatic regioisomers.
109
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In other preferred embodiments, R4 or R5 is selected from the group consisting
of:
1fi I-R\
_~~ -~~ R17 -~~ Rn
Ris R
1'-+
RiB_ -Ris ~\
/R1s-R\ R\ /R96 ==:R1B
R16 //Rts
\~ I R e Ri"~\ Q \ RtsRis\ ~jR~B
Rie -R1s ~~~
R17 Rie R e R~e R18 Rie Rls and
> >
-~~
/R1s=R~ R17
R16 R16
R1s I-R1s
~ Rzo~
Rzl ~ 11 20
Rzo~ ~\Rzo
Rzo
R1s
wherein R16 is carbon or nitrogen; wherein R17 is selected from the group
consisting of
hydrogen; halogen; CH3; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; a chemical moiety comprising a halogen; a chemical
moiety
comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical
moiety; a
hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8
is carbon or
nitrogen; wherein R19 is selected from the group consisting of hydrogen;
halogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; a
chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
X Y
In preferred embodiments, R4 or R5 is wherein
N L
\ ~ \
M
M
X is selected from the group consisting of N
110
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
L M
x L
L\~~ N LN
X/_~ I I
N , M N, M , M , alkyl, substituted
alkyl, sulfolamide, SO2alkyl, NHSO2, CH2, CH2CH2, SO2, CH2SO2, SO2CH2,
OCH2CHZO,
SO, CH2CH2SO, SOCH2CH2; and wherein L, M and N are present or absent, and are
selected from the group consisting of alkyl, NO2, halogen, OH, O-Alkyl, methyl
ester,
propyl ester, ethyl ester, CO2H, CF3, aniline, nitro, heterocycle, mono-
substituted alkyl, di-
substituted alkyl, and tri-substituted alkyl, hydrogen, S02NH2, SO2NH-alkyl,
SOalkyl,
NHSO2alkyl; wherein Y is selected from the group consisting of hydrogen,
alkyl,
substituted alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, COZH, nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
/ZZ
WW/~ yy
hydrogen, SOalkyl, SOZNH2, SO2NH-alkyl, NHSO2alkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group
consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H,
aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and
tri-substituted
alkyl, hydrogen, SO2NH2, SO2NH-alkyl, NHSOZalkyl.
In yet other preferred embodiments, the composition is:
I\
- o 0
H3~ N
H3 C\ C 0 H, ~
N \ / N I i ~ /
N \ / ~ \
ci
CI HN' ONH
CI ~II(
oH OH , and 0
111
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In certain embodiments, the present invention provides a composition
comprising
the following formula:
O
R5
R4\
R,
S N
R3
R2
including both R and S enantiomeric forms and racemic mixtures.
In such preferred embodiments, Rl is a nitrogen atom or a carbon atom; R2 is
selected from H, a hydroxy, an alkoxy, a halo, an amino, a lower-alkyl, a
substituted-amino,
an acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20
hydrogens, a substituted aliphatic group of similar size, a cycloaliphatic
group consisting of
less than 10 carbons, a substituted cycloaliphatic group, an aryl, a
heterocyclic, NO2; SR';
and NR'2, wherein R' is defmed as a linear or branched, saturated or
unsaturated aliphatic
chain having at least one carbon; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons, and having at least one hydroxyl subgroup; a
linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one thiol subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, wherein the aliphatic chain terminates with an
aldehyde subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one ketone subgroup; a linear or branched, saturated or
unsaturated aliphatic
chain having at least 2 carbons; wherein the aliphatic chain terminates with a
carboxylic
acid subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least
2 carbons, and having at least one amide subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
acyl group; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one nitrogen containing moiety; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
amine
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
112
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
carbons, and having at least one halogen subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
nitronium
subgroup; R3 comprises a chemical moiety comprising a heterocyclic group
containing 3 or
more carbon atoms; and R4 and R5 are separately selected from the group
consisting of:
hydrogen; halogen; CH3; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; a chemical moiety comprising a halogen; a chemical
moiety
comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical
moiety; a
hydrophilic chemical moiety; and a hydrophobic chemical moiety.
In preferred embodiments, R3 is selected from the group consisting of:
~ R1e Ris
Ris
R11 *R,,4 Riz
R12 \ / R11 R13 /
Riq Ria
R13 R13 R11
I i
R12 R13 R11 K:EiEII1
I .
R14 ~ R14 ~ R12 ~ SOZAr, N
v~nn.
I
O
O
HN
H i H NH NH
OH ' OR12 ~ CN CH2O , C(O)NH2, O ~ 0
nnne~ /
OH, OH , and oH
wherein R12, R13, R14 and R15 are selected from the group consisting of:
hydrogen; CH3;
a linear or branched, saturated or unsaturated aliphatic chain having at least
1 carbon; a
113
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one hydroxy subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one thiol
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
wherein the
aliphatic chain terminates with an aldehyde subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ketone
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one amide subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one acyl group; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ether subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one halogen subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one nitronium
subgroup; and
Rl l is OH.
In preferred embodiments, R4 or R5 are selected from group consisting of:
napthalalanine; phenol; 1-Napthalenol; 2-Napthalenol;
-~ ~
I \ Halogen
~ Halogen;
OCF3= s / . I
S,
(CHZ)nC(CH3)3 wherein n=0-5;
114
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
- -
~
I H nCH CH -- _ I H CH nCH -- _
~ 2~ ~ 3~~ wherein n0 5; ~( ~) 3 wherein n0 5;
La(ky((aU regioisomers) ; Luoromeiyl (all regiolsomers) quinolines, and all
aromatic regioisomers.
In other preferred embodiments, R4 or R5 is selected from the group consisting
of:
R17
R17
Ris=Ris
R1e _R18 ~R16 R~
R~~ \\R{s-Rta Ris Rae~R~
~ \ Rts
R
R1e Ri rRia \s Ri6 ~Ris
R1e I-Ris ~
R ~ Ris'Rie Rlg~ Rig Rla R9s, and
-~ \
~R1s=RJ6 R,n
R16 R16
Ris 1-R1s
R2o R20,,I I R20
Rzl \ \Rzo
R2o
;
Rig
wherein R16 is carbon or nitrogen; wherein R17 is selected from the group
consisting of
hydrogen; halogen; CH3; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; a chemical moiety comprising a halogen; a chemical
moiety
coinprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic
chemical moiety; a
hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8
is carbon or
nitrogen; wherein R19 is selected from the group consisting of hydrogen;
halogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; a
chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
i
115
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
X Y
In preferred embodiments, R4 or R5 is wherein
N L
\ \ \
M
M
X is selected from the group consisting of L , N
L\~\ M
~ L
L N L N
I ,~,~~ I I
N ~ M N, M , M , alkyl, substituted
alkyl, sulfolamide, SO2alkyl, NHSO2, CH2, CH2CH2, SO2, CH2SO2, SO2CH2,
OCH2CHZO,
SO, CH2CH2SO, SOCH2CH2; and wherein L, M and N are present or absent, and are
selected from the group consisting of alkyl, NO2, halogen, OH, O-Alkyl, methyl
ester,
propyl ester, ethyl ester, CO2H, CF3, aniline, nitro, heterocycle, mono-
substituted alkyl, di-
substituted alkyl, and tri-substituted alkyl, hydrogen, SO2NH2, SO2NH-alkyl,
SOalkyl,
NHSO2alkyl; wherein Y is selected from the group consisting of hydrogen,
alkyl,
substituted alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H, nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
ZZ
ww YY
hydrogen, SOalkyl, SOZNH2, SOzNH-alkyl, NHSO2alkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group
consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, COaH,
aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and
tri-substituted
alkyl, hydrogen, SO2NH2, SOaNH-alkyl, NHSO2alkyl.
116
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In certain embodiments, the present invention provides a composition
comprising
the following fonnula:
N-N
R5
R4
N
R1/
N
R
~ ~ / \R
RR~ R, 3
2
including both R and S enantiomeric forms and racemic mixtures.
In such preferred embodiments, Rl is carbon or nitrogen; R2 is selected from
H, a
hydroxy, an alkoxy, a halogen, an ainino, a lower-alkyl, a substituted-amino,
an
acetylamino, a hydroxyamino, an aliphatic group having 1-8 carbons and 1-20
hydrogens, a
substituted aliphatic group of similar size, a cycloaliphatic group consisting
of less than 10
carbons, a substituted cycloaliphatic group, an aryl, a heterocyclic, NOZ;
SR'; and NR'2,
wherein R' is defined as a linear or branched, saturated or unsaturated
aliphatic chain
having at least one carbon; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one hydroxyl subgroup; a linear
or branched,
saturated or unsaturated aliphatic chain having at least 2 carbons, and having
at least one
thiol subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least
2 carbons, wherein the aliphatic chain terminates with an aldehyde subgroup; a
linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one ketone subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; wherein the aliphatic chain terminates with a
carboxylic acid
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one amide subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
acyl group; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one nitrogen containing moiety; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ainine
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons, and having at least one halogen subgroup; a linear or branched,
saturated or
117
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
unsaturated aliphatic chain having at least 2 carbons, and having at least one
nitronium
subgroup; R3 comprises a chemical moiety comprising a heterocyclic group
containing 3 or
more carbon atoms; R4 is selected from the group consisting of hydrogen;
halogen; CH3; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons; a
chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety; and R5 is selected from the group
consisting of:
hydrogen; halogen; CH3; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; a chemical moiety comprising a halogen; a chemical
moiety
comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical
moiety; a
hydrophilic chemical moiety; and a hydrophobic chemical moiety.
In preferred embodiments, R3 is selected from the group consisting of:
Ris / R15 R15
R11 *Rl,4 *R,,
Ri2 \ / R11 R13 Ria R13 R13 R1i
Ri2 R 15 I / I
*Rj / ww
Ri i Rt3 R13 HN
1 Ris
~ ~
>=
R14 "N
~ Ria ~ R12 ~ SO2Ar' N
118
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
vw~. . I ~n;v, vvw
O
O\ I v ~ / ~ I I \
HN
H H H NH
OH , ORi2 , CN CH2O , C(O)NH2, O , O ~
vvv~
MM, /
OH, OH , and oH
wherein R12, R13, R14 and R15 are selected from the group consisting of:
hydrogen; CH3;
a linear or branched, saturated or unsaturated aliphatic chain having at least
1 carbon; a
linear or branched, saturated or unsaturated aliphatic chain having at least 2
carbons, and
having at least one 1lydroxy subgroup; a linear or branched, saturated or
unsaturated
aliphatic chain having at least 2 carbons, and having at least one thiol
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
wherein the
aliphatic chain terminates with an aldehyde subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ketone
subgroup; a linear or branched, saturated or unsaturated aliphatic chain
having at least 2
carbons; wherein the aliphatic chain terminates with a carboxylic acid
subgroup; a linear or
branched, saturated or unsaturated aliphatic chain having at least 2 carbons,
and having at
least one amide subgroup; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons, and having at least one acyl group; a linear or
branched, saturated
or unsaturated aliphatic chain having at least 2 carbons, and having at least
one nitrogen
containing moiety; a linear or branched, saturated or unsaturated aliphatic
chain having at
least 2 carbons, and having at least one amine subgroup; a linear or branched,
saturated or
unsaturated aliphatic chain having at least 2 carbons, and having at least one
ether subgroup;
a linear or branched, saturated or unsaturated aliphatic chain having at least
2 carbons, and
having at least one halogen subgroup; a linear or branched, saturated or
unsaturated
119
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
aliphatic chain having at least 2 carbons, and having at least one nitronium
subgroup; and
Rl l is OH.
In preferred embodiments, R4 or R5 are selected from group consisting of:
napthalalanine; phenol; 1-Napthalenol; 2-Napthalenol; i
N _
- - / ~ Halogen
Halogen;
~ -
QCF3. (I HZ)nC(CH3)3 wherein n=0-5;
+ _ -
~
I
(CH2)nCH(CH3)2 wherein n=0-5; CH2(CHa)r,CH3 wherein n=0-5;
I ialkyl (all regioisomers) ; Luoromeihyl (all regioisomers) ;
quinolines, and all aromatic regioisomers.
In other preferred embodiments, R4 or R5 is selected from the group consisting
of:
120
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
R R,7
Rie _Ris /R's RI6
/Ras=R
Rts Ris /Ris-R\ R\ /R~s~R~
)'R1. R,e R,\ g \e R's R's\\ /\8
R1s -Rie
R12 ' Rie-Rts R19 RiB Rls R19, and
-~~
/R1s=R~ R17
R16 R16
\\-I-R1s
R2s11
20 I I 20
R2s~ \R20
R2
Rly
wherein Rl6 is carbon or nitrogen; wherein R17 is selected from the group
consisting of
hydrogen; halogen; CH3; a linear or branched, saturated or unsaturated
aliphatic chain
having at least 2 carbons; a chemical moiety comprising a halogen; a chemical
moiety
comprising Sulfur; a chemical moiety comprising Nitrogen; an aromatic chemical
moiety; a
hydrophilic chemical moiety; and a hydrophobic chemical moiety; wherein Rl 8
is carbon or
nitrogen; wherein R19 is selected from the group consisting of hydrogen;
halogen; CH3; a
linear or branched,- saturated or unsaturated aliphatic chain having at least
2 carbons; a
chemical moiety comprising a halogen; a chemical moiety comprising Sulfur; a
chemical
moiety comprising Nitrogen; an aromatic chemical moiety; a hydrophilic
chemical moiety;
and a hydrophobic chemical moiety; and wherein R20 is carbon or nitrogen.
X Y
In preferred embodiments, R4 or R5 is wherein
N L
\ ~ \
M
M
X is selected from the group consisting of N
121
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
L M
L N L N
L
I ~~~ I I
N , M M , M , alkyl, substituted
alkyl, sulfolamide, SOaalkyl, NHSO2, CHZ, CH2CH2, SOa, CH2SO2, SOZCH2,
OCHZCHzO,
SO, CH2CH2SO, SOCH2CH2; and wherein L, M and N are present or absent, and are
selected from the group consisting of alkyl, NOZ, halogen, OH, O-Alkyl, methyl
ester,
propyl ester, ethyl ester, C02H, CF3, aniline, nitro, heterocycle, mono-
substituted alkyl, di-
substituted alkyl, and tri-substituted alkyl, hydrogen, SO2NH2, SO2NH-alkyl,
SOalkyl,
NHSOZalkyl; wherein Y is selected from the group consisting of hydrogen,
alkyl,
substituted alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H, nitro,
heterocycle, mono-substituted alkyl, di-substituted alkyl, and tri-substituted
alkyl,
zz
ww YY
hydrogen, SOalkyl, SO2NH2, SO2NH-alkyl, NHSO2alkyl, and xx
wherein WW, XX, YY and ZZ are present or absent, and are selected from the
group
consisting of alkyl, halogen, OH, O-Alkyl, methyl ester, propyl ester, ethyl
ester, CO2H,
aniline, nitro, heterocycle, mono-substituted alkyl, di-substituted alkyl, and
tri-substituted
alkyl, hydrogen, SO2NH2, SOzNH-alkyl, NHSO2alkyl.
From the above description, it is apparent that many specific exainples are
represented by the generic formulas presented above. A wide variety of sub
combinations
arising from selecting a particular group at each substituent position are
possible and all
such conzbinations are within the scope of this invention.
Further, it should be understood that the numerical ranges given throughout
this
disclosure should be construed as a flexible range that contemplates any
possible subrange
within that range. For example, the description of a group having the range of
1-10 carbons
would also contemplate a group possessing a subrange of, for example, 1-3, 1-
5, 1-8, or 2-3,
2-5, 2-8, 3-4, 3-5, 3-7, 3-9, 3-10, etc., carbons. Thus, the range 1-10 should
be understood
122
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
to represent the outer boundaries of the range within which many possible
subranges are
clearly contemplated. Additional examples contemplating ranges in other
contexts can be
found throughout this disclosure wherein such ranges include analogous
subranges within.
Some specific examples of the compounds of the present invention include, but
are
not limited to:
O
H3C\
N
N
CI
OH
R2 R2
O O
N N
CH3
CI N CI N
I I
HO HO
wherein R2 is
123
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
N
UOH
I I
N
and
N
and dimethylphenyl (all isomers) and ditrifluoromethyl (all isomers).
The following compound (GD-423) is also contemplated:
124
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
N
CH3
CI N
OH
In some embodiments, the compounds of the present invention have the
structure:
125
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
(R1)m
R2 I
N
Rr Tt/ N N Z
~
R3 N R4 Rs
J((/ R7)q
R 5)n n or
(R1)m
R
2 A
N
N N Z
N \
R3 H R6
O
XII((R.5n
n
or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or prodrug
thereof, wherein:
Rl and R5 are attached to any available carbon atom of phenyl rings A and B,
respectively,
and at each occurrence are independently selected from alkyl, substituted
alkyl, halogen,
cyano, nitro, OR8, NR8R9, C(=0)R8, C02R8, C(=O)NR8R9, NR$C(=O)R9, NRBC(=0)OR9,
S(O) oR9, NR8SO2R9, SO2NR8R9, cycloalkyl, heterocycle, aryl, and heteroaryl,
and/or two
126
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
of Rl and/or two of R5 join together to form a fused benzo ring; R2, R3 and R4
are
independently selected from hydrogen, alkyl, and substituted alkyl, or one of
R2, R3 and R4
is a bond to R, T or Y and the other of R2, R3 and R4 is selected from
hydrogen, alkyl, and
-
substituted alkyl; Z and Y are independently selected from C(=0), -C02-, -SO2-
, -CH2-,
CH2C(=0)-, and -C(=0)C(=0) -, or Z may be absent; R and T are selected from -
CH2-, -
C(=O)-, and -CH[(CH2)p(Q)]-, wherein Q is NR10R11, OR10 or CN; R6 is selected
from
alkyl, alkenyl, substituted alkyl, substituted alkenyl, aryl, cycloalkyl,
heterocyclo, and
heteroaryl; provided that where R2 is hydrogen, Z-R6 together are not -S02-Me
or
O
11
I I \ / F
0 ; R7 is selected from hydrogen, alkyl, substituted alkyl,
alkenyl, substituted alkenyl, aminoalkyl, halogen, cyano, nitro, keto (=0),
hydroxy, alkoxy,
alkylthio, C(=O)H, acyl, COZH, alkoxycarbonyl, carbamyl, sulfonyl,
sulfonamidyl,
cycloalkyl, heterocycle, aryl, and heteroaryl; R8 and R9 are independently
selected from
hydrogen, alkyl, substituted alkyl, cycloalkyl, heterocycle, aryl, and
heteroaryl, or R8 and R9
taken togetlier to form a heterocycle or heteroaryl, except R9 is not hydrogen
when attached
to a sulfonyl group as in S02R9; Rlo and Rll are independently selected from
hydrogen,
alkyl, and substituted alkyl; m and n are independently selected from 0, 1, 2
and 3; o, p and
q are independently 0, 1 or 2; and r and t are 0 or 1.
In further exemplary compounds, Z-R6 taken together are selected from: i.
thiophenyl optionally substituted with R14; ii. imidazolyl optionally
substituted with R14; iii.
--CH(aryl)(CO2C1_6alkyl); iv. -C02-alkyl; v. -S02-alkyl optionally substituted
with up to
three of halogen and/or phenyl; vi. -S02-alkenyl optionally substituted with
phenyl; and vii.
127
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
(R15)u (R17)v (R17)v
R16
N
(R17)v (R17)v
N N
N I or N ; wherein R15 is halogen, alkyl, nitro, cyano,
hydroxy, alkoxy, NHC(=O)alkyl, and/or two R15 groups are taken together to
form a fused
benzo ring or a five to six membered heteroaryl; R16 is selected from
hydrogen, halogen,
alkyl, nitro, cyano, hydroxy, alkoxy, NHC(=O)alkyl, and phenyloxy or benzyloxy
in turn
optionally substituted with 1 to 3 of halogen, cyano, and C1_4alkoxy; R17 is
selected from
alkyl, alkoxy, CO2C1_6alkyl, and SO2phenyl; and u and v are independently 0, 1
or 2.
Other exemplary compounds have the following structure:
(R1)m
R
2 A
N
I N N Z
N \~ \R6
R3 ~ R
7
Rq
B
(R5)n or a stereoisomer, a pharmaceutically-
acceptable salt, hydrate, or prodrug thereof, in which: Ri and R5 are attached
to any
available carbon atom of phenyl ring A and phenyl ring B, respectively, and at
each
occurrence are independently selected from C1_6alkyl, substituted C1_6alkyl,
halogen, cyano,
O(C1_6alkyl), O(phenyl), O(benzyl), NH2, NH(C1_6alkyl), N(C1_6alkyl)2, C(=O)H,
C(=O)(C1_
6alkyl), CO2H, C02(C1_6alkyl), C(=O)NHa, C(=O)NH(C1_6alkyl),
C(=O)N(C1_6alkyl)2,
128
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
NHC(=O)(C1_6alkyl), S(O)2(C1_6alkyl), NHSO2(C1_6alkyl), SO2NH2,
SO2NH(C1_6alkyl),
SO2N(C1_6alkyl)2, C3_7cycloalkyl, phenyl, five or six membered heteroaryl, or
four to seven
membered heterocyclo, and/or two of Rl and/or two of R5 join together to form
a fused
benzo ring; R2 and R3 are independently selected from hydrogen and C1_4a1ky1;
Z is -CO2-,
-SO2-, or is absent; R6 is selected from optionally-substituted alkyl,
alkenyl, aryl, and
heteroaryl; m and n are independently selected from 0, 1, and 2; and q is 0 or
1.
Other exemplary compounds have the following structure:
(R1 )m
\/ .
R
2 A
N
XJ_I__I N N N Z
-/ \ R \ R6
3 R7
Rq
J((I5~>n n , or a stereoisomer, a pharmaceutically-
acceptable salt, hydrate, or prodrug thereof, wherein: Rl and R5 are attached
to any available
carbon atom of phenyl ring A and phenyl ring B, respectively, and at each
occurrence are
independently selected from alkyl, substituted alkyl, halogen, cyano, nitro,
hydroxy, alkoxy,
alkylthio, alkylainino, C(=O)H, acyl, COaH, alkoxycarbonyl, carbamyl,
sulfonyl,
sulfonamidyl, cycloalkyl, heterocycle, aryl, and heteroaryl, and/or two of Rl
and/or two of
R5 join together to form a fused benzo ring; R2, R3 and R4 are independently
selected froin
hydrogen and alkyl; Z is -C02--, --SOa--, or is absent; R6 is selected from:
a) C1_4alkyl or
Cl_4alkenyl optionally substituted with up to three of halogen, aryl and
CO2CI_6alkyl; b)
phenyl optionally substituted with up to three R12 and/or having fused thereto
a benzo-ring
or a five to six membered heteroaryl; c) heteroaryl selected from thiophenyl,
imidazolyl,
pyrazolyl, and isoxazolyl, wherein said heteroaryl is optionally substituted
with up to two
R12, provided that where R2 is hydrogen, Z-R6 together are not -S02-Me or
129
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
11
I) \ / F
0 ; R7 is selected from hydrogen, keto (=O), C1_6alkyl,
substituted C1_6alkyl, halogen, cyano, O(C1-6alkyl), O(phenyl), O(benzyl),
NH2, NH(C1_
6alkyl), N(C1_6alkyl)2, C(=O)H, C(=0)(C1_6alkyl), COZH, C02(C1_6alkyl- ); R12
at each
occurrence is independently selected from each other R12 from the group
consisting of C1_
6alkyl, halogen, nitro, cyano, hydroxy, alkoxy, NHC(=O)alkyl, --COaalkyl, --
SO2phenyl,
five to six membered monocyclic heteroaryl, and phenyloxy or benzyloxy in turn
optionally
substituted with halogen, C1_4alkyl, and/or O(C1_4alkyl); and m and n are
independently
selected from 0, 1, or 2.
In further exemplary compounds, Z is -SO2--; R6 is selected from Cl_4alkyl,
(R15)u
R16
trifluoromethyl, benzyl, C2_3alkenyl substituted with phenyl,
(R17)v (R17)v (R17)v (R17)v
N N
~
I I ~
N S N or N ;
R15 is halogen, alkyl, nitro, cyano, hydroxy, alkoxy, NHC(=O)alkyl, and/or two
R15 groups
are taken together to form a fused benzo ring or a five to six membered
heteroaryl; R16 is
selected from hydrogen, halogen, alkyl, nitro, cyano, hydroxy, alkoxy,
NHC(=O)alkyl, and
phenyloxy or benzyloxy in turn optionally substituted with 1 to 3 of halogen,
cyano, and C1_
4alkoxy; R17 is selected from allcyl, alkoxy, C02C1_6alkyl, and SOaphenyl; and
u and v are
independently 0, 1 or 2.
Other exemplary compounds have the following formula:
130
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
R2 R3
N
RI OH
Me
O Me
or a stereoisoiner, a pharmaceutically-acceptable salt, hydrate, or prodrug
thereof, wherein:
Rl is selected from the group consisting of H, CN and S02-piperidine; R2 is
selected from
the group consisting of H, 4-Cl-Ph, Ph, and 2-Me-imidazole; R3 is selected
from the group
consisting of H, CH2-2-imidazole, and CH2-2-oxazole.
Other exemplary compounds have the following formula:
N
N
Y
I ~ ?C N H
Rl
6"i R2 10 or a stereoisomer, a pharmaceutically-acceptable salt, hydrate, or
prodrug thereof, wherein:
Rl is selected from the group consisting of H, 2,4-C12, 2-4-Me2, and 2,5-
(CF3)2; R2 is
selected from the group consisting of H, 4-Cl, 4-Me, 2,4-C12, 2,4-Me2, 3-Cl; X
is selected
from the group consisting of 0 and NH; Y is selected from the group consisting
of S, 0,
NCN, CO(3-CN-Ph), CO(4-CN-Ph), CO(4-Cl-Ph), and COEt.
Particular exemplary compounds of the present invention include, but are not
limited
to:
131
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
\
I
O
/
I / O
N N S
HN
N / \
H3C
F
O
I O
N N
CH3
N'\ NH
132
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
\
O
/
N N I I N'\ NH
F
O
N I l 0
N
N'\ /NH
133
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
\
I
/ O
N N ~0
N NH tbN
O
9
N N S ~ CI
N\ /NH
CI
134
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
N N I I~ O
~
N\ NH S /
In further embodiments, the compounds of the present invention may be provided
with benzodiazepine related compounds as described in U.S. Patent Applications
10/886,450, 10/795,535, 10/634,114, 10/427,211, 10/217,878, 09/767,283, and
09/700,101;
each herein incorporated by reference in their entireties.
In summary, a large number of compounds are presented herein. Any one or more
of these compounds can be used to treat a variety of dysregulatory disorders
related to
cellular death as described elsewhere herein. Additionally, any one or more of
these
compounds can be used to inhibit ATP Hydrolysis while not affecting cell
synthesis or cell
viability. Additionally, any one or more of these compounds can be used in
combination
with at least one other therapeutic agent (e.g., potassium channel openers,
calcium channel
blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic agents,
antiatherosclerotic
agents, anticoagulants, antithrombotic agents, prothrombolytic agents,
fibrinogen
antagonists, diuretics, antihypertensive agents, ATPase inhibitors,
mineralocorticoid
receptor antagonists, phospodiesterase inhibitors, antidiabetic agents, anti-
inflammatory
agents, antioxidants, angiogenesis modulators, antiosteoporosis agents,
hormone
replacement therapies, hormone receptor modulators, oral contraceptives,
antiobesity
agents, antidepressants, antianxiety agents, antipsychotic agents,
antiproliferative agents,
antituinor agents, antiulcer and gastroesophageal reflux disease agents,
growth hormone
agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective
agents,
antiviral agents, antibacterial agents, antifungal agents, cholesterol/lipid
lowering agents
135
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
and lipid profile therapies, and agents that inimic ischemic preconditioning
and/or
inyocardial stunning, antiatherosclerotic agents, anticoagulants,
antithrombotic agents,
antihypertensive agents, antidiabetic agents, and antihypertensive agents
selected from ACE
inhibitors, AT-1 receptor antagonists, ET receptor antagonists, dual ET/AII
receptor
antagonists, and vasopepsidase inhibitors, or an antiplatelet agent selected
from GPIIb/IIIa
blockers, P2Y1 and P2Y12 antagonists, thromboxane receptor antagonists, and
aspirin) in
along with a pharmaceutically-acceptable carrier or diluent in a
phannaceutical
composition. Additionally, any one or more of these compounds can be used to
treat a
mitochondrial F1Fo ATP hydrolase associated disorder (e.g., myocardial
infarction,
ventricular hypertrophy, coronary artery disease, non-Q wave MI, congestive
heart failure,
cardiac arrhythmias, unstable angina, chronic stable angina, Prinzmetal's
angina, high blood
pressure, intermittent claudication, peripheral occlusive arterial disease,
thrombotic or
thromboembolic symptoms of thromboembolic stroke, venous thrombosis, arterial
thrombosis, cerebral thrombosis, pulmonary einbolism, cerebral embolism,
thrombophilia,
disseminated intravascular coagulation, restenosis, atrial fibrillation,
ventricular
enlargement, atherosclerotic vascular disease, atherosclerotic plaque rupture,
atherosclerotic
plaque formation, transplant atherosclerosis, vascular reinodeling
atherosclerosis, cancer,
surgery, inflammation, systematic infection, artificial surfaces,
interventional cardiology,
immobility, medication, pregnancy and fetal loss, and diabetic complications
comprising
retinopathy, nephropathy and neuropathy) in a patient. The above-described
compounds
can also be used in drug screening assays and other diagnostic and research
methods.
IV. Pharmaceutical compositions, formulations, and exemplary administration
routes and dosing considerations
Exemplary embodiments of various contemplated medicaments and pharmaceutical
compositions are provided below.
A. Preparing Medicaments
It is contemplated that the coinpounds of the present invention are useful in
the
preparation of inedicaments to treat a variety of conditions associated with
dysregulation of
cell death, aberrant cell growth and hyperproliferation.
136
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In addition, it is conteinplated that the compounds are also useful for
preparing
medicaments for treating other disorders wherein the effectiveness of the
compounds are
known or predicted. Such disorders include, but are not limited to,
neurological (e.g.,
epilepsy) or neuromuscular disorders. The methods and techniques for preparing
medicaments of a compound of the present invention are well-known in the art.
Exemplary
pharmaceutical formulations and routes of delivery are described below.
One of skill in the art will appreciate that any one or more of the compounds
described herein, including the many specific embodiments, are prepared by
applying
standard pharmaceutical manufacturing procedures. Such medicaments can be
delivered to
the subject by using delivery methods that are well-known in the
pharmaceutical arts.
B. Exemplary pharmaceutical compositions and formulation
In some embodiments of the present invention, the compositions are
administered
alone, while in some other embodiments, the compositions are preferably
present in a
pharmaceutical formulation comprising at least one active ingredient/agent, as
defined
above, together with a solid support or alternatively, together with one or
more
pharmaceutically acceptable carriers and optionally other therapeutic agents
(e.g., a
benzodiazepine compound as described in U.S. Patent Applications 10/886,450,
10/795,535, 10/634,114, 10/427,211, 10/217,878, 09/767,283, and 09/700,101;
each herein
incorporated by reference in their entireties.). Each carrier must be
"acceptable" in the
sense that it is compatible with the other ingredients of the formulation and
not injurious to
the subject.
Contemplated formulations include those suitable oral, rectal, nasal, topical
(including transdermal, buccal and sublingual), vaginal, parenteral (including
subcutaneous,
intramuscular, intravenous and intradermal) and pulmonary administration. In
some
embodiments, formulations are conveniently presented in unit dosage form and
are prepared
by any method known in the art of pharmacy. Such methods include the step of
bringing
into association the active ingredient with the carrier which constitutes one
or more
accessory ingredients. In general, the formulations are prepared by uniformly
and
intimately bringing into association (e.g., mixing) the active ingredient with
liquid carriers
or finely divided solid carriers or both, and then if necessary shaping the
product.
137
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Formulations of the present invention suitable for oral administration may be
presented as discrete units such as capsules, cachets or tablets, wherein each
preferably
contains a predetermined amount of the active ingredient; as a powder or
granules; as a
solution or suspension in an aqueous or non-aqueous liquid; or as an oil-in-
water liquid
emulsion or a water-in-oil liquid emulsion. In other embodiments, the active
ingredient is
presented as a bolus, electuary, or paste, etc.
In some embodiments, tablets comprise at least one active ingredient and
optionally
one or more accessory agents/carriers are made by compressing or molding the
respective
agents. In preferred embodiments, compressed tablets are prepared by
compressing in a
suitable machine the active ingredient in a free-flowing form such as a powder
or granules,
optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl
cellulose),
lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch
glycolate, cross-linked
povidone, cross-linked sodium carboxymethyl cellulose)surface-active or
dispersing agent.
Molded tablets are made by molding in a suitable machine a mixture of the
powdered
compound (e.g., active ingredient) moistened with an inert liquid diluent.
Tablets may
optionally be coated or scored and may be formulated so as to provide slow or
controlled
release of the active ingredient therein using, for exainple,
hydroxypropylmethyl cellulose
in varying proportions to provide the desired release profile. Tablets may
optionally be
provided with an enteric coating, to provide release in parts of the gut other
than the
stomach.
Formulations suitable for topical administration in the mouth include lozenges
comprising the active ingredient in a flavored basis, usually sucrose and
acacia or
tragacanth; pastilles comprising the active ingredient in an inert basis such
as gelatin and
glycerin, or sucrose and acacia; and mouthwashes comprising the active
ingredient in a
suitable liquid carrier.
Pharmaceutical compositions for topical administration according to the
present
invention are optionally formulated as ointments, creams, suspensions,
lotions, powders,
solutions, pastes, gels, sprays, aerosols or oils. In alternatively
embodiments, topical
formulations comprise patches or dressings such as a bandage or adhesive
plasters
impregnated with active ingredient(s), and optionally one or more excipients
or diluents. In
preferred embodiments, the topical formulations include a compound(s) that
enhances
absorption or penetration of the active agent(s) tlirough the skin or other
affected areas.
138
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Examples of such dermal penetration enhancers include dimethylsulfoxide (DMSO)
and
related analogues.
If desired, the aqueous phase of a cream base includes, for example, at least
about
30% w/w of a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl
groups such
as propylene glycol, butane-1,3-diol, inannitol, sorbitol, glycerol and
polyethylene glycol
and mixtures thereof.
In some embodiments, oily phase emulsions of this invention are constituted
from
known ingredients in an known manner. This phase typically comprises an lone
emulsifier
(otherwise known as an emulgent), it is also desirable in some embodiments for
this phase
to further comprises a mixture of at least one emulsifier with a fat or an oil
or with both a fat
and an oil.
Preferably, a hydrophilic emulsifier is included together with a lipophilic
emulsifier
so as to act as a stabilizer. It some embodiments it is also preferable to
include both an oil
and a fat. Together, the emulsifier(s) with or without stabilizer(s) make up
the so-called
emulsifying wax, and the wax together with the oil and/or fat make up the so-
called
einulsifying ointment base which forms the oily dispersed phase of the cream
formulations.
Emulgents and emulsion stabilizers suitable for use in the formulation of the
present
invention include Tween 60, Span 80, cetostearyl alcohol, myristyl alcohol,
glyceryl
monostearate and sodium lauryl sulfate.
The choice of suitable oils or fats for the formulation is based on achieving
the
desired properties (e.g., cosmetic properties), since the solubility of the
active
compound/agent in most oils likely to be used in pharmaceutical emulsion
formulations is
very low. Thus creams should preferably be a non-greasy, non-staining and
washable
products with suitable consistency to avoid leakage from tubes or other
containers. Straight
or branched chain, mono- or dibasic alkyl esters such as di-isoadipate,
isocetyl stearate,
propylene glycol diester of coconut fatty acids, isopropyl myristate, decyl
oleate, isopropyl
palmitate, butyl stearate, 2-ethylhexyl palmitate or a blend of branched chain
esters known
as Crodamol CAP may be used, the last three being preferred esters. These may
be used
alone or in combination depending on the properties required. Alternatively,
high melting
point lipids such as white soft paraffm and/or liquid paraffm or other mineral
oils can be
used.
139
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Formulations suitable for topical administration to the eye also include eye
drops
wherein the active ingredient is dissolved or suspended in a suitable carrier,
especially an
aqueous solvent for the agent.
Formulations for rectal administration may be presented as a suppository with
suitable base comprising, for example, cocoa butter or a salicylate.
Formulations suitable for vaginal administration may be presented as
pessaries,
creams, gels, pastes, foams or spray formulations containing in addition to
the agent, such
carriers as are known in the art to be appropriate.
Formulations suitable for nasal administration, wherein the carrier is a
solid, include
coarse powders having a particle size, for example, in the range of about 20
to about 500
microns which are administered in the manner in which snuff is taken, i.e., by
rapid
inhalation (e.g., forced) through the nasal passage from a container of the
powder held close
up to the nose. Other suitable formulations wherein the carrier is a liquid
for administration
include, but are not limited to, nasal sprays, drops, or aerosols by
nebulizer, an include
aqueous or oily solutions of the agents.
Formulations suitable for parenteral administration include aqueous and non-
aqueous isotonic sterile injection solutions which may contain antioxidants,
buffers,
bacteriostats and solutes which render the formulation isotonic with the blood
of the
intended recipient; and aqueous and non-aqueous sterile suspensions which may
include
suspending agents and thickening agents, and liposomes or other
microparticulate systems
which are designed to target the compound to blood components or one or more
organs. In
some embodiments, the formulations are presented/formulated in unit-dose or
inulti-dose
sealed containers, for example, ampoules and vials, and may be stored in a
freeze-dried
(lyophilized) condition requiring only the addition of the sterile liquid
carrier, for example
water for injections, iminediately prior to use. Extemporaneous injection
solutions and
suspensions may be prepared from sterile powders, granules and tablets of the
kind
previously described.
Preferred unit dosage formulations are those containing a daily dose or unit,
daily
subdose, as herein above-recited, or an appropriate fraction thereof, of an
agent.
It should be understood that in addition to the ingredients particularly
mentioned
above, the formulations of this invention may include other agents
conventional in the art
having regard to the type of formulation in question, for example, those
suitable for oral
140
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
administration may include such further agents as sweeteners, thickeners and
flavoring
agents. It also is intended that the agents, coinpositions and methods of this
invention be
combined with other suitable compositions and therapies. Still other
formulations
optionally include food additives (suitable sweeteners, flavorings, colorings,
etc.),
phytonutrients (e.g., flax seed oil), minerals (e.g., Ca, Fe, K, etc.),
vitamins, and other
acceptable compositions (e.g., conjugated linoelic acid), extenders, and
stabilizers, etc.
In some embodiments, the compounds of the present invention are provided in
unsolvated form or are in non-aqueous solutions (e.g., ethanol). The compounds
may be
generated to allow such formulations through the production of specific
crystalline
polymorphs compatible with the fonnulations. Such compositions and methods are
described in U.S. Provisional Patent Application Serial No. 60/686,348, filed
June 1, 2005,
and herein incorporated by reference in its entirety.
C. Exemplary administration routes and dosing considerations
Various delivery systems are known and can be used to administer therapeutic
agents (e.g., exemplary compounds as described in Section III above) of the
present
invention, e.g., encapsulation in liposomes, microparticles, microcapsules,
receptor-
mediated endocytosis, and the like. Methods of delivery include, but are not
limited to,
intra-arterial, intra-muscular, intravenous, intranasal, and oral routes. In
specific
embodiments, it may be desirable to administer the pharmaceutical compositions
of the
invention locally to the area in need of treatment; this may be achieved by,
for example, and
not by way of limitation, local infusion during surgery, injection, or by
means of a catheter.
It is conteinplated that the agents identified can be administered to subjects
or
individuals susceptible to or at risk of developing pathological growth of
target cells and
correlated conditions. When the agent is administered to a subject such as a
mouse, a rat or
a human patient, the agent can be added to a pharmaceutically acceptable
carrier and
systemically or topically administered to the subject. To determine patients
that can be
beneficially treated, a tissue sample is removed from the patient and the
cells are assayed
for sensitivity to the agent.
Therapeutic amounts are empirically determined and vary with the pathology
being
treated, the subject being treated and the efficacy and toxicity of the agent.
When delivered
to an animal, the method is useful to further confirm efficacy of the agent.
One example of
141
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
an animal model is MLR/MpJ-lpr/lpr ("MLR-lpr") (available from Jackson
Laboratories,
Bal Harbor, Maine). MLR-lpf mice develop systemic autoimmune disease.
Alternatively,
other animal models can be developed by inducing tumor growth, for example, by
subcutaneously inoculating nude mice with about 105 to about 109
hyperproliferative,
cancer or target cells as defined herein. When the tumor is established, the
compounds
described herein are administered, for example, by subcutaneous injection
around the
tumor. Tumor measurements to determine reduction of tumor size are made in two
dimensions using venier calipers twice a week. Other animal models may also be
employed
as appropriate. Such animal models for the above-described diseases and
conditions are
well-known in the art.
In some embodiments, in vivo administration is effected in one dose,
continuously or
intermittently throughout the course of treatment. Methods of determining the
most
effective means and dosage of administration are well known to those of skill
in the art and
vary witll the composition used for therapy, the purpose of the therapy, the
target cell being
treated, and the subject being treated. Single or multiple administrations are
carried out
with the dose level and pattern being selected by the treating physician.
Suitable dosage formulations and methods of adininistering the agents are
readily
determined by those of skill in the art. Preferably, the compounds are
administered at about
0.01 mg/kg to about 200 mg/kg, more preferably at about 0.1 mg/kg to about 100
mg/kg,
even more preferably at about 0.5 mg/kg to about 50 mg/kg. When the compounds
described herein are co-administered with another agent (e.g., as sensitizing
agents), the
effective amount may be less than when the agent is used alone.
The pharmaceutical compositions can be administered orally, intranasally,
parenterally or by inhalation therapy, and may take the form of tablets,
lozenges, granules,
capsules, pills, ainpoules, suppositories or aerosol form. They may also take
the form of
suspensions, solutions and emulsions of the active ingredient in aqueous or
nonaqueous
diluents, syrups, granulates or powders. In addition to an agent of the
present invention, the
pharmaceutical compositions can also contain other pharmaceutically active
compounds or
a plurality of compounds of the invention.
More particularly, an agent of the present invention also referred to herein
as the
active ingredient, may be administered for therapy by any suitable route
including, but not
limited to, oral, rectal, nasal, topical (including, but not limited to,
transdermal, aerosol,
142
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
buccal and sublingual), vaginal, parental (including, but not limited to,
subcutaneous,
intramuscular, intravenous and intradermal) and pulmonary. It is also
appreciated that the
preferred route varies with the condition and age of the recipient, and the
disease being
treated.
Ideally, the agent should be administered to achieve peak concentrations of
the
active compound at sites of disease. This may be achieved, for example, by the
intravenous
injection of the agent, optionally in saline, or orally administered, for
example, as a tablet,
capsule or syrup containing the active ingredient.
Desirable blood levels of the agent may be maintained by a continuous infusion
to
provide a therapeutic amount of the active ingredient within disease tissue.
The use of
operative combinations is contemplated to provide therapeutic combinations
requiring a
lower total dosage of each component antiviral agent than may be required when
each
individual therapeutic coinpound or drug is used alone, thereby reducing
adverse effects.
D. Exemplary co-administration routes and dosing considerations
The present invention also includes methods involving co-administration of the
compounds described herein with one or more additional active agents. Indeed,
it is a
further aspect of this invention to provide methods for enhancing prior art
therapies and/or
pharmaceutical compositions by co-administering a compound of this invention.
In co-
administration procedures, the agents may be administered concurrently or
sequentially. In
one embodiment, the compounds described herein are administered prior to the
other active
agent(s). The pharmaceutical formulations and modes of administration may be
any of
those described above. In addition, the two or more co-administered chemical
agents,
biological agents or radiation may each be administered using different modes
or different
formulations.
The agent or agents to be co-administered depends on the type of condition
being
treated. For example, when the condition being treated is cancer, the
additional agent can
be a chemotherapeutic agent or radiation. When the condition being treated is
an
autoimmune disorder, the additional agent can be an immunosuppressant or an
anti-
inflammatory agent. When the condition being treated is chronic
infla.inmation, the
additional agent can be an anti-inflammatory agent. The additional agents to
be co-
administered, such as anticancer, immunosuppressant, anti-inflammatory, and
can be any of
143
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
the well-known agents in the art, including, but not limited to, those that
are currently in
clinical use. The determination of appropriate type and dosage of radiation
treatment is also
within the skill in the art or can be determined with relative ease.
Treatment of the various conditions associated with abnormal apoptosis is
generally
limited by the following two major factors: (1) the development of drug
resistance and (2)
the toxicity of known therapeutic agents. In certain cancers, for example,
resistance to
chemicals and radiation therapy has been shown to be associated with
inhibition of
apoptosis. Some therapeutic agents have deleterious side effects, including
non-specific
lymphotoxicity, renal and bone marrow toxicity.
The methods described herein address both these problems. It is contemplated
that
drug resistance, where increasing dosages are required to achieve therapeutic
benefit, is
overcome by co-administering the compounds described herein with the known
agent. It is
contemplated that the compounds described herein sensitize target cells to
known agents
(and vice versa) and, accordingly, less of these agents are needed to achieve
a therapeutic
benefit.
It is contemplated that the sensitizing function of the claimed compounds also
address the problems associated with toxic effects of known therapeutics. In
instances
where the known agent is toxic, it is desirable to limit the dosages
administered in all cases,
and particularly in those cases were drug resistance has increased the
requisite dosage. It is
contemplated that when the claimed compounds are co-administered with the
known agent,
they reduce the dosage required which, in turn, reduces the deleterious
effects. Further,
because the claimed compounds are contemplated to be both effective and non-
toxic in
large doses, co-administration of proportionally more of these compounds than
known toxic
therapeutics will achieve the desired effects while minimizing toxic effects.
V. Drug screens
In preferred embodiments of the present invention, the compounds of the
present
invention, and other potentially useful compounds, are screened for their
binding affinity to
the oligomycin sensitivity conferring protein (OSCP) portion of the
mitochondrial ATP
synthase complex. In particularly preferred embodiments, compounds are
selected for use
in the methods of the present invention by measuring their biding affinity to
recombinant
OSCP protein. A number of suitable screens for measuring the binding affinity
of drugs
144
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
and other small molecules to receptors are known in the art. In some
embodiments, binding
affinity screens are conducted in in vitro systems. In other embodiments,
these screens are
conducted in in vivo or ex vivo systems. While in some embodiments quantifying
the
intracellular level of ATP following administration of the compounds of the
present
invention provides an indication of the efficacy of the methods, preferred
embodiments of
the present invention do not require intracellular ATP or pH level
quantification.
Additional embodiments are directed to measuring levels (e.g., intracellular)
of
superoxide in cells and/or tissues to measure the effectiveness of particular
contemplated
methods and compounds of the present invention. In this regard, those skilled
in the art will
appreciate and be able to provide a number of assays and methods useful for
measuring
superoxide levels in cells and/or tissues.
In some embodiments, structure-based virtual screening methodologies are
contemplated for predicting the binding affinity of compounds of the present
invention with
OSCP. In some preferred embodiments, coinpound structures are predicted from a
molecular modeling software (e.g., MacroModel).
Any suitable assay that allows for a measurement of the rate of binding or the
affinity of an exemplary compound of the present invention to the OSCP may be
utilized.
Examples include, but are not limited to, competition binding using an
exemplary
compound, surface plasma resonance (SPR) and radio-immunopreciptiation assays
(Lowman et al., J. Biol.Chem. 266:10982 [1991]). Surface Plasmon Resonance
techniques
involve a surface coated with a thin film of a conductive metal, such as gold,
silver, chrome
or aluminum, in which electromagnetic waves, called Surface Plasmons, can be
induced by
a beam of light incident on the metal glass interface at a specific angle
called the Surface
Plasmon Resonance angle. Modulation of the refractive index of the interfacial
region
between the solution and the metal surface following binding of the captured
macromolecules causes a change in the SPR angle which can either be measured
directly or
which causes the amount of light reflected from the underside of the metal
surface to
change. Such changes can be directly related to the mass and other optical
properties of the
molecules binding to the SPR device surface. Several biosensor systems based
on such
principles have been disclosed (See e.g., WO 90/05305). There are also several
commercially available SPR biosensors (e.g., BiaCore, Uppsala, Sweden).
145
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In some embodiments, copmpounds are screened in cell culture or in vivo (e.g.,
non-
human or human maminals) for an ability to modulate mitochondrial ATP synthase
activity.
Any suitable assay may be utilized, including, but not limited to, cell
proliferation assays
(Commercially available from, e.g., Promega, Madison, WI and Stratagene, La
Jolla, CA)
and cell based dimerization assays. (See e.g., Fuh et al., Science, 256:1677
[1992]; Colosi
et al., J. Biol. Chem., 268:12617 [1993]). Additional assay formats that find
use with the
present invention include, but are not limited to, assays for measuring
cellular ATP levels,
and cellular superoxide levels.
The present invention also provides methods of modifying and derivatizing the
compositions of the present invention to increase desirable properties (e.g.,
binding affinity,
activity, and the like), or to minimize undesirable properties (e.g.,
nonspecific reactivity,
toxicity, and the like). The principles of chemical derivatization are well
understood. In
some embodiments, iterative design and chemical synthesis approaches are used
to produce
a library of derivatized child compounds from a parent compound. In other
embodiments,
rational design methods are used to predict and model in silico liga.nd-
receptor interactions
prior to confirming results by routine experimentation.
VI. Therapeutic Application
A. General Therapeutic Application
In particularly preferred embodiments, the compositions of the present
invention are
contemplated to provide therapeutic benefits to patients suffering from any
one or more of a
number of conditions (e.g., diseases characterized by dysregulation of
necrosis and/or
apoptosis processes in a cell or tissue, disease characterized by aberrant
cell growth and/or
liyperproliferation, etc.) by modulating (e.g., inhibiting or promoting) the
activity of the
mitochondrial ATP synthase (as referred to as mitochondrial FoFI ATPase)
complexes in
affected cells or tissues. In further preferred embodiments, it is
contemplated that the
compositions of the present invention are used to treat autoimmune/chronic
inflammatory
conditions (e.g., psoriasis). In even further embodiments, it is contemplated
that the
compositions of the present invention are used in conjunction with stenosis
therapy to treat
compromised (e.g., occluded) vessels.
In particularly preferred embodiments, it is contemplated that the
compositions of
the present invention inhibit the activity of mitochondrial ATP synthase
complex by binding
146
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
to a specific subunit of this multi-subunit protein complex. While the present
invention is
not limited to any particular mechanism, nor to any understanding of the
action of the
agents being administered, in some embodiments, it is contemplated that the
compositions
of the present invention bind to the oligomycin sensitivity conferring protein
(OSCP)
portion of the mitochondrial ATP synthase complex, to the OSCP/F1 junction, or
to the Fl
subunit. Likewise, it is further contemplated that when the compositions of
the present
invention bind to the OSCP the initial affect is overall inhibition of the
mitochondrial ATP
synthase complex, and that the downstream consequence of binding is a change
in ATP or
pH level and the production of reactive oxygen species (e.g., 02-). In still
other preferred
embodiments, while the present invention is not limited to any particular
mechanism, nor to
any understanding of the action of the agents being administered, it is
contemplated that the
generation of free radicals ultimately results in cell killing. In yet other
embodiments, while
the present invention is not limited to any particular mechanism, nor to any
understanding
of the action of the agents being administered, it is contemplated that the
inhibiting
mitochondrial ATP synthase complex using the compositions and methods of the
present
invention provides therapeutically useful inhibition of cell proliferation.
Accordingly, it is contemplated that preferred methods embodied in the present
invention, provide therapeutic benefits to patients by providing compounds of
the present
invention that modulate (e.g., inhibiting or promoting) the activity of the
mitochondrial
ATP synthase complexes in affected cells or tissues via binding to the
oligomycin
sensitivity conferring protein (OSCP) portion of the mitochondrial ATP
synthase complex.
Importantly, by itself the OSCP, the OSCP/F1 junction, or the Fl subunit has
no biological
activity.
Thus, in one broad sense, it is conteinplated that preferred embodiments of
the
present invention are directed to the discovery that many diseases
characterized by
dysregulation of necrosis and/or apoptosis processes in a cell or tissue, or
diseases
characterized by aberrant cell growth and/or hyperproliferation, etc., can be
treated by
modulating the activity of the mitochondrial ATP synthase complex including,
but not
limited to, by binding to the oligomycin sensitivity conferring protein (OSCP)
component
thereof. The present invention is not intended to be limited, however, to the
practice of the
compositions and methods explicitly described herein. Indeed, those skilled in
the art will
appreciate that a number of additional compounds not specifically recited
herein are suitable
147
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
for use in the methods disclosed herein of modulating the activity of
mitochondrial ATP
synthase.
The present invention thus specifically contemplates that any number of
suitable
compounds presently known in the art, or developed later, can optionally find
use in the
methods of the present invention. For example, compounds including, but not
limited to,
oligoinycin, ossamycin, cytovaricin, apoptolidin, bafilomyxcin, resveratrol,
piceatannol, and
dicyclohexylcarbodiimide (DCCD), and the like, find use in the methods of the
present
invention. The present invention is not intended, however, to be limited to
the methods or
compounds specified above. In one embodiment, that conipounds potentially
useful in the
methods of the present invention may be selected from those suitable as
described in the
scientific literature. (See e.g., K.B. Wallace and A.A. Starkov, Annu. Rev.
Pharmacol.
Toxicol., 40:353-388 [2000]; A.R. Solomon et al., Proc. Nat. Acad. Sci.
U.S.A.,
97(26):14766-14771 [2000]).
In some einbodiments, compounds potentially useful in metllods of the present
invention are screened against the National Cancer Institute's (NCI-60) cancer
cell lines for
efficacy. (See e.g., A. Monks et al., J. Natl. Cancer Inst., 83:757-766
[1991]; and K.D.
Paull et al., J. Natl. Cancer Inst., 81:1088-1092 [1989]). Additional screens
suitable screens
(e.g., autoimmunity disease models, etc.) are within the skill in the art.
In one aspect, derivatives (e.g., pharmaceutically acceptable salts, analogs,
stereoisomers, and the like) of the exemplary compounds or other suitable
compounds are
also contemplated as being useful in the methods of the present invention.
In other preferred embodiments, it is contemplated that the compositions of
the
present invention are used to treat drug sensitive and/or drug resistant
mycobacterium
tuberculosis.
In other preferred embodiments, it is contemplated that the compositions of
the
present invention are used in the treatment of angiogenesis.
In other preferred embodiments, it is contemplated that the compositions of
the
present invention are used in the treatment of cardiovascular disease.
In other preferred embodiments, it is contemplated that the compositions of
the
present invention are used in conjunction with stenosis therapy to treat
compromised (e.g.,
occluded) vessels. In further embodiments, it is contemplated that the
compositions of the
148
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
present invention are used in conjunction with stenosis therapy to treat
compromised
cardiac vessels.
Vessel stenosis is a condition that develops when a vessel (e.g., aortic
valve)
becomes narrowed. For example, aortic valve stenosis is a heart condition that
develops
when the valve between the lower left chamber (left ventricle) of the heart
and the major
blood vessel called the aorta becomes narrowed. This narrowing (e.g.,
stenosis) creates too
small a space for the blood to flow to the body. Normally the left ventricle
pumps oxygen-
rich blood to the body through the aorta, which branches into a system of
arteries
throughout the body. When the heart pumps, the 3 flaps, or leaflets, of the
aortic valve open
one way to allow blood to flow from the ventricle into the aorta. Between
heartbeats, the
flaps close to form a tight seal so that blood does not leak backward through
the valve. If the
aortic valve is damaged, it may become narrowed (stenosed) and blood flow may
be
reduced to organs in the body, including the heart itself. The long-term
outlook for people
with aortic valve stenosis is poor once symptoms develop. People with
untreated aortic
valve stenosis who develop symptoms of heart failure usually have a life
expectancy of 3
years or less.
Several types of treatment exist for treating compromised valves (e.g.,
balloon
dilation, ablation, atherectomy or laser treatment). One type of treatment for
compromised
cardiac valves is angioplasty. Angioplasty involves inserting a balloon-tipped
tube, or
catheter, into a narrow or blocked artery in an attempt to open it. By
inflating and deflating
the balloon several times, physicians usually are able to widen the artery.
A common limitation of angioplasty or valve expansion procedures is
restenosis.
Restenosis is the reclosure of a peripheral or coronary artery following
trauma to that artery
caused by efforts to open a stenosed portion of the artery, such as, for
example, by balloon
dilation, ablation, atherectomy or laser treatment of the artery. For these
angioplasty
procedures, restenosis occurs at a rate of about 20-50% depending on the
definition, vessel
location, lesion length and a number of other morphological and clinical
variables.
Restenosis is believed to be a natural healing reaction to the injury of the
arterial wall that is
caused by angioplasty procedures. The healing reaction begins with the
thrombotic
mechanism at the site of the injury. The final result of the complex steps of
the healing
process can be intimal hyperplasia, the uncontrolled migration and
proliferation of medial
149
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
smooth muscle cells, combined with their extracellular matrix production,
until the artery is
again stenosed or occluded.
lii an attempt to prevent restenosis, metallic intravascular stents have been
permanently implanted in coronary or peripheral vessels. The stent is
typically inserted by
catheter into a vascular lumen told expanded into contact with the diseased
portion of the
arterial wall, thereby providing mechanical support for the lumen. However, it
has been
found that restenosis can still occur with such stents in place. Also, the
stent itself can cause
undesirable local thrombosis. To address the problem of thrombosis, persons
receiving
stents also receive extensive systemic treatment with anticoagulant and
antiplatelet drugs.
To address the restenosis problem, it has been proposed to provide stents
which are
seeded with endothelial cells (Dichek, D. A. et al; Circulation 1989; 80: 1347-
1353). In that
experiment, sheep endothelial cells that had undergone retrovirus-mediated
gene transfer for
either bacterial beta-galactosidase or human tissue-type plasminogen activator
were seeded
onto stainless steel stents and grown until the stents were covered. The cells
were therefore
able to be delivered to the vascular wall where they could provide therapeutic
proteins.
Other methods of providing therapeutic substances to the vascular wall by
means of stents
have also been proposed (see, e.g., International Patent Applications WO
91/12779, and
WO 90/13332; each herein incorporated by reference in their entirities). In
those
applications, it is suggested that antiplatelet agents, anticoagulant agents,
antimicrobial
agents, anti-inflammatory agents, antimetabolic agents and other drugs could
be supplied in
stents to reduce the incidence of restenosis. Further, other vasoreactive
agents such as nitric
oxide releasing agents could also be used.
An additional cause of restenosis is the over-proliferation of treated tissue.
In
preferred embodiments, it is contemplated that the anti-proliferative
properties of the
present invention inhibit restenosis. Drug-eluting stents are well known in
the art (see, e.g.,
U.S. Patent No.: 5,697,967; U.S. Patent No.: 5,599,352; and U.S. Patent No.:
5,591,227;
each of which are herein incorporated by reference). In preferred embodiments,
the
coinpositions of the present invention are eluted from drug-eluting stents in
the treatment of
compromised (e.g., occluded) vessels. In further embodiments, the compositions
of the
present invention are eluted from drug-eluting stents in the treatment of
compromised
cardiac vessels.
150
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Those skilled in the art of preparing pharmaceutical compounds and
formulations
will appreciate that when selecting optional compounds for use in the methods
disclosed
herein, that suitability considerations include, but are not limited to, the
toxicity, safety,
efficacy, availability, and cost of the particular compounds.
In preferred embodiments, pharmaceutical coinpositions comprise compounds of
the
invention and, for example, therapeutic agents (e.g., antiatherosclerotic
agents,
anticoagulants, antithrombotic agents, antihypertensive agents, potassium
channel openers,
calcium channel blockers, sodium hydrogen exchanger inhibitors, antiarrhythmic
agents,
prothrombolytic agents, fibrinogen antagonists, diuretics, ATPase inhibitors,
mineralocorticoid receptor antagonists, phospodiesterase inhibitors, anti-
inflammatory
agents, antioxidants, angiogenesis modulators, antiosteoporosis agents,
honnone
replacement therapies, hormone receptor modulators, oral contraceptives,
antiobesity
agents, antidepressants, antianxiety agents, antipsychotic agents,
antiproliferative agents,
antitumor agents, antiulcer and gastroesophageal reflux disease agents, growth
hormone
agents and/or growth hormone secretagogues, thyroid mimetics, anti-infective
agents,
antiviral agents, antibacterial agents, antifungal agents, cholesterol/lipid
lowering agents
and lipid profile therapies, and agents that mimic ischeinic preconditioning
and/or
myocardial stunning, and antidiabetic agents). Antihypertensive agents
include, but are not
limited to, ACE inhibitors, AT-1 receptor antagonists, ET receptor
antagonists, dual ET/AII
receptor antagonists, and vasopepsidase inhibitors, or an antiplatelet agent
selected from
GPIIb/IIIa blockers, P2Y1 and P2Y12 antagonists, thromboxane receptor
antagonists, and
aspirin.
In preferred embodiments, the compounds of the present invention are useful in
treating a mitochondrial F1Fo ATP hydrolase associated disorder (e.g.,
myocardial
infarction, ventricular hypertrophy, coronary artery disease, non-Q wave MI,
congestive
heart failure, cardiac arrhythmias, unstable angina, chronic stable angina,
Prinzmetal's
angina, high blood pressure, intermittent claudication, peripheral occlusive
arterial disease,
thrombotic or thromboembolic symptoms of thromboembolic stroke, venous
thrombosis,
arterial thrombosis, cerebral thrombosis, pulmonary embolism, cerebral
embolism,
thrombophilia, disseminated intravascular coagulation, restenosis, atrial
fibrillation,
ventricular enlargement, atherosclerotic vascular disease, atherosclerotic
plaque rupture,
atherosclerotic plaque formation, transplant atherosclerosis, vascular
remodeling
151
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
atherosclerosis, cancer, surgery, inflammation, systematic infection,
artificial surfaces,
interventional cardiology, iminobility, medication, pregnancy and fetal loss,
and diabetic
complications comprising retinopathy, nephropathy and neuropathy) in a
patient.
B. Autoimmune Disorder and Chronic Inflammatory Disorder Therapeutic
Application
Autoimmune disorders and chronic inflammatory disorders often result from
dysfunctional cellular proliferation regulation and/or cellular apoptosis
regulation.
Mitochondria perform a key role in the control and execution of cellular
apoptosis. The
mitochondrial permeability transition pore (MPTP) is a pore that spans the
inner and outer
mitochondrial membrandes and functions in the regulation of proapoptotic
particles.
Transient MPTP opening results in the release of cytochrome c and the
apoptosis inducing
factor from the mitochondrial intermembrane space, resulting in cellular
apoptosis.
The oligomycin sensitivity conferring protein (OSCP) is a subunit of the FoFI
mitochondrial ATP synthase/ATPase and functions in the coupling of a proton
gradient
across the Fo sector of the enzyme in the mitochondrial meinbrane. In
preferred
embodiments, it is conteinplated that compounds of the present invention bind
the OSCP,
the OSCP / Fl junction, or the Fl subunit, increases superoxide and cytochrome
c levels,
increases cellular apoptosis, and inhibits cellular proliferation. The adenine
nucleotide
translocator (ANT) is a 30kDa protein that spans the inner mitochondrial
membrane and is
central to the mitochondrial permeability transition pore (MPTP). Thiol
oxidizing or
alkylating agents are powerful activators of the MPTP that act by modifying
one or more of
three unpaired cysteines in the matrix side of the ANT. 4-(N-(S-
glutathionylacetyl)amino)
phenylarsenoxide, inhibits the ANT.
C. Treatment of Epidermal Hyperplasia
Epidermal hyperplasia (e.g., excessive keratinocyte proliferation) leading to
a
significant thickening of the epidermis in association with shedding of the
thickened
epidermis, is a feature of diseases such as psoriasis (see, e.g., Krueger GC,
et al., (1984) J.
Am. Acad. Dermatol. 11: 937-947; Fry L. (1988), Brit. J. Dermatol. 119:445-
461; each
herein incorporated by reference in their entireties) and also occurs under
physiological
conditions (e.g., during wound-healing).
152
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Topical treatment of the skin with all-trans retinoic acid (RA) or its
precursor, all-
trans retinol (ROL) also results in epidermal hyperplasia (see, e.g., Varani
J, et al., (2001) J.
Invest. Dermatol, 117:1335-1341; herein incorporated by reference in its
entirety). While
the underlying etiologies are different, all of these hyperplasias have in
common the
activation of the epidermal growth factor (EGF) receptor in the proliferating
keratinocytes
(see, e.g., Varani J, et al., (2001) J. Invest. Dermato1117:1335-1341; Baker
BS, et al.,
(1992) Brit. J. Dermatol. 126:105-110; Gottlieb AB, et al., (1988) J. Exp.
Med. 167:670-
675; Elder JT, et al., (1989) Science 243:811-814; Piepkorn M, et al., (1998)
J Invest
Dermato1111:715-721; Piepkom M, et al., (2003) Arch Dermatol Res 27:27; Cook
PW, et
al., (1992) Cancer Res 52:3224-3227; each herein incorporated by reference in
their
entireties). Normal epidermal growth does not appear to be as dependent on EGF
receptor
function as hyperplastic growth (see, e.g., Varani J, et al., (2001) J.
Invest. Dermatol
117:1335-1341; Varani J, et al., (1998) Pathobiology 66:253-259; each herein
incorporated
by reference in their entireties). Likewise, function of the dermis in intact
skin does not
depend on EGF receptor function (see, e.g., Varani J, et al., (2001) J.
Invest. Dermatol
117:1335-1341; herein incorporated by reference in its entirety).
The central role of the EGF receptor in regulating hyperplastic epithelial
growth
makes the EGF receptor tyrosine kinase a target for antiproliferative agents.
Likewise, the
series of signaling molecules engaged downstream of this receptor are
additional points at
which keratinocyte growth can be interrupted. The mitogen activated protein
kinase
(MAPK) cascade is activated by the EGF receptor (see, e.g., Marques, S. A., et
al., (2002) J
Pharinacol Exp Ther 300, 1026-1035; herein incorporated by reference in its
entirety). In
hyperproliferative epidermis, but not in normal epidermis, extracellular
signal-regulated
kinases 1/2 (Erk 1/2) are activated in basal and suprabasal keratinocytes and
contribute to
epidermal hyperproliferation (see, e.g., Haase, I., et al., (2001) J Clin
Invest 108, 527-536;
Takahashi, H., et al., (2002) J Dermatol Sci 30, 94-99; each herein
incorporated by
reference in their entireties). In culture models, keratinocyte growth
regulation through the
EGF receptor results in increased MAPK activity. In keratinocytes, growth
factor-
stimulated MAPK activity is also dependent on integrin engagement and
extracellular
matrix molecules that bind integrins are capable of independently activating
MAPKs and
increasing keratinocyte proliferation (see, e.g., Haase, I., et al., (2001) J
Clin Invest 108,
527-536; herein incorporated by reference in its entirety). The proliferation
of other skin
153
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
cells, including fibroblasts, is less dependent on Erk 1/2 activity, making
Erk inhibition a
potentially useful characteristic to evaluate lead compounds for potential
utility against
epidermal hyperplasia.
In preferred embodiments, it is contemplated that compounds of the present
invention are useful for treating epidermal hyperplasias.
In preferred embodiments, it is contemplated that compounds of the present
invention (e.g., Bz-423) are useful in treating psoriasis. Psoriasis is common
and chronic
epidermal hyperplasia. Plaque psoriasis is the most common type of psoriasis
and is
characterized by red skin covered with silvery scales and inflammation.
Patches of circular
to oval shaped red plaques that itch or burn are typical of plaque psoriasis.
The patches are
usually found on the arins, legs, trunk, or scalp but may be found on any part
of the skin.
The most typical areas are the knees and elbows. Psoriasis is not contagious
and can be
inherited. Environmental factors, such as smoking, sun exposure, alcoholism,
and HIV
infection, may affect how often the psoriasis occurs and how long the flares
up last.
Treatment of psoriasis includes topical steroids, coal tar, keratolytic
agents, vitamin
D-3 analogs, and topical retinoids. Topical steroids are agents used to reduce
plaque
formation. Topical steroid agents have anti-inflammatory effects and may cause
profound
and varied metabolic activities. In addition, topical steroid agents modify
the body's
immune response to diverse stimuli. Examples of topical steroids include, but
are not
limited to, triamcinolone acetonide (Artistocort, Kenalog) 0.1% cream, and
betamethasone
diproprionate (Diprolene, Diprosone) 0.05% cream. Coal tar is an inexpensive
treatment
available over the counter in shampoos or lotions for use in widespread areas
of
involvement. Coal tar is particularly useful in hair-bearing areas. An example
of coal tar is
coal tar 2-10% (DHS Tar, Doctar, Theraplex T) - antipruitic. Keratolytic
agents are used to
remove scale, smooth the skin, and to treat hyperkeratosis. An example of a
keratolytic
agent is anthralin 0.1-1% (Drithocreme, Anthra-Derm). Vitamin D-3 analogs are
used in
patients with lesions resistant to older therapy or with lesions on the face
or exposed areas
where thinning of the skin would pose cosmetic problems. An example of a
vitamin D-3
analog is calcipotriene (Dovonex). Topical retinoids are agents that decrease
the
cohesiveness of follicular epithelial cells and stimulate mitotic activity,
resulting in an
increase in turnover of follicular epithelial cells. Examples of topical
retinoids include, but
are not limited to, tretinoin (Retin-A, Avita), and tazarotene (Tazorac).
154
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Approximately 1-2% of people in the United States, or about 5.5 million, have
plaque psoriasis. Up to 30% of people with plaque psoriasis also have
psoriatic arthritis.
Individuals with psoriatic arthritis have inflammation in their joints and may
have other
artliritis symptoms. Sometimes plaque psoriasis can evolve into more severe
disease, such
as pustular psoriasis or erythrodermic psoriasis. In pustular psoriasis, the
red areas on the
skin contain blisters with pus. In erythrodermic psoriasis, a wide area of red
and scaling
skin is typical, and it may be itchy and painful. The present invention is
useful in treating
additional types of psoriasis, including but not limited to, guttate
psoriasis, nail psoriasis,
inverse psoriasis, and scalp psoriasis.
In some embodiments, the compounds of the present invention are useful in
treating
pigmentation disorders (e.g., albinism, melasma, and vitiligo). The present
invention is not
limited to a particular mechanism for treating pigment disorders. In preferred
embodiments,
pigment disorders are treated through targeting of the F1Fo ATPase by the
compounds of the
present invention. In further embodiments, pigment disorders are treated
through the rerouting
of tyrosinase by the compounds of the present invention. In further
embodiments, pigment
disorders are treated through targeting of prohibitin by the compounds of the
present invention.
VII. ATPase Inhibitors And Methods For Identifying Therapeutic Inhibitors
The present invention provides coinpounds that are contemplated to target the
F1Fo
ATPase. In addition, the present invention provides compounds that are
contemplated to
target the F1Fo ATPase as a treatment for autoimmune disorders, and in
particular,
compounds with low toxicity. The present invention further provides methods of
identifying compounds that are contemplated to target the F1Fo ATPase.
Additionally, the
present invention provides therapeutic applications for compounds contemplated
to target
the F1Fo ATPase.
A majority of ATP within eukaryotic cells is synthesized by the mitochondrial
F1Fo
ATPase (see, e.g.,C.T. Gregory et al., J. Immunol., 139:313-318 [1987]; J.P.
Portanova et
al., Mol. Immunol., 32:117-135 [1987]; M.J. Shlomchik et al., Nat. Rev.
Immunol., 1:147-
153 [2001]; each herein incorporated by reference in their entireties).
Although the F1Fo
ATPase synthesizes and hydrolyzes ATP, during normal physiologic conditions,
the F1Fo-
ATPase only synthesizes ATP (see, e.g., Nagyvary J, et al., Biochem. Educ.
1999; 27:193-
99; herein incorporated by reference in its entirety). The mitochondrial F1Fo
ATPase is
155
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
composed of three major domains: Fo, F1 and the peripheral stator. Fl is the
portion of the
enzyme that contains the catalytic sites and it is located in the matrix (see,
e.g., Boyer, PD,
Annu Rev Biochem. 1997; 66:717-49; herein incorporated by reference in its
entirety). This
domain is highly conserved and has the subunit composition a3(33y8E. The
landmark X-ray
structure of bovine Fl revealed that a43 forms a hexagonal cylinder with the y
subunit in
the center of the cylinder. Fo is located within the inner mitochondrial
membrane and
contains a proton channel. Translocation of protons from the inner-membrane
space into
the matrix provides the energy to drive ATP synthesis. The peripheral stator
is composed of
several proteins that physically and functionally link Fo with Fl. The stator
transmits
conformational changes from Fo into in the catalytic domain that regulate ATP
synthesis
(see, e.g., Cross RL, Biochim Biophys Acta 2000; 1458:270-75; herein
incorporated by
reference in its entirety).
Mitochondrial F1Fo ATPase inhibitors are invaluable tools for mechanistic
studies of
the F1Fo ATPase (see, e.g., James AM, et al., J Bioined Sci 2002; 9:475-87;
herein
incorporated by reference in its entirety). Because F1Fo ATPase inhibitors are
often
cytotoxic, they have been explored as drugs for cancer and other
hyperproliferative
disorders. Macrolides (e.g., oligomycin and apoptolidin) are non-competitive
inhibitors of
the F1Fo ATPase (see, e.g., Salomon AR, et al., PNAS 2000; 97:14766-71;
Salomon AR, et
al., Chem Bio12001; 8:71-80; herein incorporated by reference in its
entirety). Macrolides
bind to Fo which blocks proton flow through the channel resulting in
inhibition of the F1F0-
ATPase. Macrolides are potent (e.g., the IC50 for oligomycin = 10 nM) and lead
to large
decreases in [ATP]. As such, macrolides have an unacceptably narrow
therapeutic index
and are highly toxic (e.g., the LD50 for oligomycin in rodents is two daily
doses at 0.5
mg/kg) (see, e.g., Kramar R, et al., Agents & Actions 1984, 15:660-63; herein
incorporated
by reference in its entirety). It is contemplated that inhibitors of F1Fo
ATPase include the
compounds of the present invention.
In cells that are actively respiring (known as state 3 respiration),
inhibiting F1Fo
ATPase blocks respiration and places the mitochondria in a resting state
(known as state 4).
In state 4, the MRC is reduced relative to state 3, which favors reduction of
02 to 02- at
complex III (see, e.g., N. Zamzami et al., J. Exp. Med., 181:1661-1672 [1995];
herein
incorporated by reference in its entirety). For example, treating cells with
either oligomycin
or, it is contemplated, coinpounds of the present invention, leads to a rise
of intracellular 02-
156
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
as a consequence of inhibiting complex V. In the case of oligomycin,
supplementing cells
with ATP protects against death whereas antioxidants do not, indicating that
cell death
results from the drop in ATP (see, e.g., Zhang JG, et al., Arch Biochem
Biophys 2001;
393:87-96; McConkey DJ, et al., The ATP switch in apoptosis. In: Nieminen La,
ed.
Mitochondria in pathogenesis. New York: Plenum, 2001:265-77; each herein
incorporated
by reference in their entireties). Cell death induced by compounds of the
present invention,
it is contemplated, is blocked by antioxidants and is not affected by
supplementing cells
with ATP, suggesting that compounds of the present invention engage an ROS-
dependent
death response (see, e.g., N.B. Blatt, et al., J. Clin. Invest., 2002, 110,
1123; herein
incorporated by reference in its entirety). As such, F1Fo ATPase inhibitors
are either toxic
(e.g., oligomycin) or, it is contemplated, therapeutic (e.g., compounds of the
present
invention).
The present invention provides a method of distinguishing toxic F1Fo ATPase
inhibitors from therapeutic FIFo ATPase inhibitors. F1Fo ATPase inlzibitors
with
therapeutic potential (e.g., compounds of the present invention) present a
novel mode of
inhibition. Specifically, it is contemplated that F1Fo ATPase iiihibitors with
beneficial
properties (e.g., compounds of the present invention) are uncompetitive
inhibitors that only
bind enzyme-substrate complexes at high substrate concentration and do not
alter the
kcat/K,,, ratio. This knowledge forms the basis to identify and distinguish
FiFo ATPase
inhibitors with therapeutic potential from toxic compounds.
The present invention provides compounds that are contemplated to target the
F1Fo-
ATPase as an autoimmune disorder treatment. In particular, the present
invention provides
methods of identifying compounds that target the F1Fo ATPase while not
altering the
kcat/K,,, ratio. Additionally, the present invention provides therapeutic
applications for
compounds targeting the FiFo ATPase.
A. ATPase Inhibiting Compounds
The present invention provides compounds that are contemplated to inhibit the
F1F0,-
ATPase. In some embodiments, it is contemplated that the compounds do not bind
free F1Fo
ATPase, but rather bind to an F1Fo ATPase-substrate complex. It is
contemplated that the
compounds show maximum activity at high substrate concentration and minimal
activity (e.g.,
F1Fo-ATPase inhibiting) at low substrate concentration. In preferred
embodiments, it is
157
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
contemplated that the compounds do not alter the kcat/K,,, ratio of the F1Fo-
ATPase. It is
contemplated that the properties of the FiFo ATPase inhibitors of the present
invention are
in contrast with oligomycin, which is a F1Fo ATPase inhibitor that is acutely
toxic and
lethal. Oligomycin is a noncompetitive inhibitor, which binds to both free
F1Fo-ATPase and
F1Fo ATPase-substrate complexes and alters the kcat/K,,, ratio.
It is contemplated that he compounds of the present invention that inhibit
F1Fo
ATPase while not altering the kcat/Km ratio, in some embodiments, have the
structure
described elsewhere herein. However, compounds of other structures that are
identified as
therapeutic inhibitors by the methods of the present invention are also
encompassed by the
present invention.
B. Identifying ATPase Inhibitors
The present invention provides methods of identifying (e.g., screening)
compounds
useful in treating autoimmune disorders. The present invention is not limited
to a particular
type compound. In preferred embodiments, compounds of the present invention
include, but
are not limited to, pharmaceutical compositions, small molecules, antibodies,
large molecules,
synthetic molecules, synthetic polypeptides, synthetic polynucleotides,
synthetic nucleic acids,
aptamers, polypeptides, nucleic acids, and polynucleotides. The present
invention is not
limited to a particular method of identifying compounds useful in treating
autoimmune
disorders. In preferred enibodiments, compounds useful in treating autoimmune
disorders are
identified as possessing an ability to inhibit an F1Fo ATPase while not
altering the kcat/.K,,, ratio.
C. Therapeutic Applications With F1Fo ATPase Inhibitors
The present invention provides methods for treating disorders (e.g.,
neurodegenerative
diseases, Alzheimers, ischemia reprofusion injury, neuromotor disorders, non-
Hodgkin's
lymphoma, lymphocytic leukemia, cutaneous T cell leukemia, an autoimmune
disorder, cancer,
solid tumors, lymphomas, leukemias, and tuberculosis). The present invention
is not limited to
a particular form of treatment. In preferred embodiments, treatment includes,
but is not limited
to, symptom amelioration, symptom prevention, disorder prevention, and
disorder
amelioration. The present invention provides methods of treating autoimmune
disorders
applicable within in vivo, in vitro, and/or ex vivo settings.
158
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
In some embodiments, the present invention treats autoimmune disorders through
inhibiting of target cells. The present invention is not limited to a
particular form of cell
inliibition. In preferred embodiments, cell inhibition includes, but, is not
limited to, cell growth
prevention, cell proliferation prevention, and cell death. Jii preferred
embodiments, inhibition
of a target cell is accomplished through contacting a target cell with a
compound contemplated
to inhibit the F1Fo ATPase. In further embodiments, target cell inhibition is
accomplished
through targeting of the F1Fo-ATPase with a compound contemplated to inhibit
the F1Fo
ATPase. The present invention is not liunited to a particular F1Fo ATPase
inhibitor. In
preferred embodiments, the F1Fo ATPase inhibitor is contemplated to possess an
ability to
inhibit an F1Fo-ATPase while not altering the k,at/K,,, ratio.
The present invention further provides methods for selectively inhibiting the
pathology of target cells in a subject in need of therapy. The present
invention is not limited
to a particular method of inhibition target cell pathology. In preferred
einbodiments, it is
contemplated that target cell pathology is inhibited through administration of
an effective
amount of a compound of the invention. The present invention is not limited to
a particular
compound. In preferred embodiments, it is contemplated that the compound is an
F1Fo
ATPase inhibitor. In further preferred embodiments, it is contemplated that
the compound
inhibits the F1Fo ATPase while not altering the kcat/K,,, ratio.
EXAMPLES
Example 1. Detection of Cell Death
Jurkat T cells were exposed to the following compound:
159
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
O
R
N
)'-
/N
CI
OH
wherein R was H, NH2, or nicotinic. Each compound resulted in cellular death
for the
Jurkat T cells. In particular, R = H resulted in 90% cell death; R = NH2
resulted in 90% cell
death; and R= nicotinic resulted in 50% cell death. Cells in log-phase growth
were
collected by centrifugation (300 g, 5 inin), exchanged into fresh media
(containing 1% or
0.2% FBS), and diluted to a concentration between 100,000 and 300,000
cells/mL. Drugs
were added from 50x stocks, and the cells cultured (37 C, 5% C02) for 24 h
prior to
analysis. Cells were analyzed by the MTT dye conversion assay to determine
relative cell
nuinber/viability, and by flow cytometry to enumerate cell viability.
Example II. Kinetics Assay
The mechanism of inhibition for ATP hydrolysis induced by Bz-423 and
derivatives
of Bz-423 was assayed using an NADH-coupled assay. The ATP hydrolytic activity
of the
sub-mitochondrial particles (hereinafter SMPs) was measured by coupling the
production of
ADP to the oxidation of NADH via the pyruvate kinase and lactate dehydrogenase
reaction.
Briefly, ATP hydrolysis SMPs (0.8 mg; 7.14 g/well) were added to hydrolysis
buffer (100
mM Tris-HCI, pH 8.0 at 25 C, 4 mM MgCIZ, 50 mM EDTA, 0.2 mM EDTA) and
vortexed.
125 L of this suspension was added to each well of a 96-well plate containing
50x drug or
DMSO vehicle control (1% DMSO, final). The 96-well plate was then placed at 30
C in a
Molecular Devices Versamax tunable microplate reader and allowed to incubate
for 5 min.
160
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
During this 5 min, a substrate-coupling mixture was prepared (containing X mM
ATP, 0.2
mM NADH, 1 mM phosphoenolpyruvate (PEP), 2 U/mL pyruvate kinase (PK), and 2
U/mL
lactate dehydrogenase (LDH) in hydrolysis buffer). The rate of hydrolysis was
assayed
over a range of ATP concentrations (0.1- 4.0 mM) at each [Bz]. 125 L of the
substrate-
coupling mixture was added to each well, and the rate of NADH oxidation was
monitored
for 10 min at 340 nm, 30 C. The measured decrease in absorbance over time (in
OD/min)
was converted to mol ATP hydrolyzed/min/mg SMP (s= 6220). The velocity data
was
plotted versus [ATP] for each concentration of [Bz] (e.g., 1-8 M) (see, e.g.,
Figure 1) and
then fit to the Michaelis-Menten equation:
ml*m0 / (1+m /m2)
where ml = Vmax / Km and m2 = Km
The apparent kinetic parameters for each [Bz] were obtained from these curve
fits to
generate secondary plots of [Bz] versus Vmax, [Bz] versus K,,,, and [Bz]
versus V,,,ax/Km (see,
e.g., Figure 2). The o-tert-Butyl derivative, shown below,
CH,
O
CI N
O
OH
decreased both V,,,ax and K,,,, while Vmax/Km remained unchanged, indicative
of an
uncompetitive mechanism of inhibition. In contrast, derivatives of Bz that
also decreased
V,,,ax/K,,, were indicative of a mixed type inhibition. To obtain K; values
and confirm that an
uncompetitive model of inhibition was the best fit for the data, three-
dimensional fits of the
velocity, [ATP], and [Bz] were performed to solve for Vmax, Km, K;, and K;*
[where K;
indicates Bz binding to the ATPase with the third catalytic site empty (mixed-
type
inhibition only), and K;* indicates binding when all three sites have
substrate bound
(uncompetitive and mixed-type inhibition)]. The following equations were used:
161
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
Competitive Inhibition:
V. = VmaX [S] / ((1+ [I] / K)Km + [S])
Uncompetitive Inhibition:
V. = VmaX [S] I((1+ [I] / Ki*) [S] + Km)
Mixed or Noncompetitive Inhibition:
V. = Vmax [S] / ((1+ [I]/Ki)Km + (1+ [I]Ki*)[S])
The results for the o-tert-Butyl derivative of Bz-423 are shown in Table 1 and
confirm that
this derivative binds the ATPase with an iuicompetitive binding mechanism,
similar to Bz-
423.
Table 1.
Competitive Inhibition
Bz Km Vmax Ki
Bz-423 0.40 + 0.1 2.62 ~: 0.9 13.32 ~ 0.1
o-tert-Butyl 0.25 +.02 1.25 +.01 9.35 ~ 2.4
.Uncompetitive Inhibition
Bz Km Vmax Ki*
Bz-423 0.68 0.1 3.34 ~ 1.3 19.03 5.8
o-tert-Butyl 0.39 :h 0.3 1.53 ~ 0.03 12.68 1.1
Non- Inhibition
competitive
Bz Km Vmax Ki Ki
Bz-423 0.68 0.1 3.37~1.4 no fit 18.9~6.3
o-tert-Butyl 0.39 .02 1.53 .03 no fit 12.68 ~ 1.1
162
CA 02579567 2007-03-06
WO 2006/029245 PCT/US2005/031942
All publications and patents mentioned in the above specification are herein
incorporated by reference. Although the invention has been described in
connection with
specific preferred embodiments, it should be understood that the invention as
claimed
should not be unduly limited to such specific embodiments. Indeed, various
modifications
of the described modes for carrying out the invention that are obvious to
those skilled in the
relevant fields are intended to be within the scope of the following claims.
163
